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Summary 
The yeast Saccharomyces cerevisiae is well a characterized microorganism and widely used as 
eukaryotic model organism as well as a key cell factory for bioproduction of various products. The 
latter comprise a large variety of scientifically and industrially relevant products such as low-value 
bulk chemicals and biofuels, food additives, high-value chemicals and recombinant proteins. 
Despite the recent achievements in the fields of systems biology and metabolic engineering 
together with availability of broad genetic engineering toolbox, the full potential of S. cerevisiae as 
a cell factory is not yet exploited. This will require additional insights into functionality of the 
production system and improved genetic engineering strategies for efficient cell factory design. The 
aim of this project was to develop novel genetic engineering tools that allow for rapid and efficient 
assembly of metabolic pathways and controlled expression/overexpression of genes of interest. De 
novo biosynthetic pathway for vanillin-β-glucoside production was employed as a model system for 
several case studies in this project. 
In order to construct yeast cell factories fulfilling current demands of industrial biotechnology, 
methods allowing for the introduction of large and complex metabolic pathways need to be added 
to the existing repertoire. To reduce the number of gene engineering steps required for cell factory 
construction, a new set of integrative “EasyClone” vectors have been developed in this study. This 
platform enables simultaneous integration of multiple genes with an option of recycling selection 
markers. Moreover, EasyClone vectors combine the advantage of efficient uracil-excision reaction 
based cloning that allows integration of one or two genes per plasmid and Cre-LoxP mediated 
marker recycling system. As a proof of concept, it was demonstrated that using EasyClone system 
it is possible to simultaneously integrate three DNA fragments carrying genes encoding for either 
yellow, cyan or red fluorescent proteins. In addition, all genetic markers were successfully removed 
using Cre-mediated recombination without compromising production levels of all three fluorescent 
proteins.  
Assembly of multi-enzyme pathways into yeast does not guarantee high production levels per se. 
Moreover, pathway engineering requires precise control over the genes of interest.  In this work, a 
novel gene amplification system was designed for fast, controlled and efficient gene overexpression 
in a manner that is based on targeted integration of multiple gene copies into defined loci in the 
yeast genome. For a proof of concept two genes encoding red and cyan fluorescent proteins were 
successfully amplified up to ten copies using the developed method. Linear correlation between 
gene copy number and mean fluorescence intensity for both reporter proteins was observed. The 
system was compared to multi-copy plasmids based systems and parameters such as expression 
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stability and homogeneity were assessed. Moreover, the gene amplification method was further 
applied for balancing vanillin-β-glucoside production in S. cerevisiae. It was previously 
demonstrated that de novo biosynthetic pathway is not capable to efficiently convert its precursor 
metabolite into vanillin-β-glucoside, which resulted in significant accumulation of several 
intermediates. Here, the gene amplification system was used to systematically overexpress 
individual genes or gene combinations of the biosynthetic pathway. Using this strategy, metabolic 
bottlenecks were identified and the production yield of vanillin-β-glucoside was 6-fold improved. 
Several S. cerevisiae strains are commonly used by the yeast community. Among those, the S288c 
and CEN.PK strain backgrounds have been most frequently applied for metabolic engineering 
experiments. As a result, these strains have been subjected to extensive comparison studies with 
respect to genotype and phenotype differences. In this study, it was investigated how strain genetic 
background affects heterologous production of a given product. For that reason vanillin-β-glucoside 
biosynthetic pathway was identically reconstructed in S288c and CEN.PK strains. Comparison of two 
producer strains revealed that genetic background has a large impact on the vanillin-β-glucoside 
yield. 
In summary, this work contributes with novel insights, genetic engineering tools and methodologies 
for improved yeast cell factory construction and metabolic engineering strategies. 
. 
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Dansk resumé  
Gæren Saccharomyces cerevisiae er en velkarakteriseret mikroorganisme, der i vid udstrækning 
anvendes som eukaryot model organisme, og som  en central celle fabrik til bioproduktion af 
forskellige produkter. Sidstnævnte omfatter et stort udvalg af videnskabeligt og industrielt 
relevante produkter såsom lav værdi bulk- kemikalier og biobrændstoffer, tilsætningsstoffer og høj 
værdi kemikalier og rekombinante proteiner. Trods de seneste resultater inden for systembiologi 
og metabolic engineering, sammen med tilgængeligheden til en bred genteknologiskværktøjskasse, 
er det fulde potentiale af S. cerevisiae som en cellefabrik, endnu ikke udnyttet. Dette vil kræve 
yderligere indsigt i funktionalitet af det produktive system og forbedrede genetiske strategier til 
effektive cellefabrik design. Formålet med dette projekt var at udvikle nye genteknologiske 
værktøjer, der giver mulighed for hurtig og effektiv samling af metaboliske veje og kontrolleret 
udtryk af gener af interesse. De novo biosyntesevejen for vanillin-β-glucosid produktion blev fastsat 
som model for en række eksampler i dette projekt. 
For at konstruere cellefabrikker i gær, der opfylder de nuværende industrielle bioteknologiske krav, 
nye metoder som giver mulighed for indførelse af store og komplekse metaboliske veje skal føjes 
til det eksisterende repertoire. For at reducere antallet af gen-engineering trin, der kræves for 
cellefabrik konstruering, er et nyt sæt af integrative "EasyClone" vektorer blevet udviklet i 
forbindelse med dette projekt. EasyClone giver mulighed for simultan integration af flere gener 
med mulighed for genbrug af selektionsmarkører. Desuden kombinerer EasyClone vektorer 
fordelen ved effektiv uracil - excision reaktion baseret kloning, der tillader integration af en eller to 
gener pr. plasmid, med det Cre-LoxP medieret markør genbrugssystem. Som et proof of concept, 
blev det påvist at ved brug af EasyClone systemet, er det muligt samtidig at integrere tre DNA-
fragmenter, der bærer gener kodende for enten gul, cyan eller røde fluorescerende proteiner. 
Desuden blev alle genetiske markører  fjernet under anvendelse af Cre-medieret rekombination 
uden at kompromittere produktionen af alle tre fluorescerende proteiner. 
Montering af multi-enzymveje i gær garanterer i sig selv ikke et højt produktionsniveau. Desuden 
kræver pathway engineering præcis kontrol over generne af interesse. I dette arbejde blev et nyt 
genamplifikationssystem designet til hurtig, kontrolleret og effektiv genoverekspression. Systemet 
blev baseret på målrettet integration af flere genkopier ind i et defineret loci i gærgenomet. Som 
proof of concept blev to gener, der koder for røde og cyan fluorescerende proteiner forstærket op 
til ti kopier ved hjælp af den udviklede metode. Lineær korrelation mellem genkopitallet og 
gennemsnitlig fluorescens for begge reporter -proteiners intensitet blev iagttaget. Systemet blev 
sammenlignet med multi-kopi plasmid baserede systemer og parametre udtryk-stabilitet og 
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homogenitet blev vurderet. Desuden blev denne genamplifikation metode yderligere anvendt til 
balancering af vanillin- β-glucosid produktion i S. cerevisiae. Det er tidligere blevet vist, at de novo 
biosyntesevejen ikke er i stand til effektivt at omdanne forløber metabolitten til vanillin-β-glucosid, 
hvilket resulterede i signifikant akkumulering af flere mellemprodukter. I dette arbejde blev 
genamplifikationssystemet anvendt til systematisk at overudtrykke enkelte gener eller gen-
kombinationer af biosyntesevejen. Under anvendelse af denne strategi blev de metaboliske 
flaskehalse identificeret og produktionsudbyttet af vanillin-β-glucosid blev forøget 6 gange. 
Adskillige S. cerevisiae-stammer er almindeligt anvendt i gærforskningssamfundet. Blandt disse har 
baggrundsstammerne S288c og CEN.PK været de mest anvendte i metabolic engineering 
eksperimenter. Som et resultat af dette, har disse stammer været underkastet omfattende 
sammenligninger med hensyn til genotype og fænotype forskelle.I dette studie blev det undersøgt, 
hvordan stammens genetiske baggrund påvirker heterolog produktion af et givet produkt. Derfor 
blev vanillin-β-glucosid biosyntesevejen rekonstrueret identisk i S288C og CEN.PK stammerne. 
Sammenligning af to produktions stammer viste, at den genetiske baggrund havde en stor 
indflydelse på vanillin-β-glucosid udbyttet. 
Sammenfattende bidrager dette arbejde med nye indsigter, genetisk engineering værktøjer og 
metoder til forbedret konstruktion af gærcellefabrikker og metabolic engineering strategier. 
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Chapter 1 
1. Introduction and Outline 
 
Nature offers a great spectrum of chemical variety with extremely diverse properties and broad 
fields of application, resembling food additives, cosmetics, pharmaceuticals and etc. Several ways 
can be (or are) used to acquire these products; i.e., by extraction from natural sources or by 
chemical synthesis, using crude starting materials. However, isolation of structurally complex 
compounds from their natural habitats in most cases is low yielding and time consuming, and 
chemical synthesis of these products is often extremely difficult or not possible [1]. Alternatively, 
these products can be produced by employing the bio-synthetic capacity of microorganisms. 
Microbial fermentations have a long association with human activities such as production of 
alcoholic beverages and fermented foods. As early as in the 1920s the first large-scale microbial 
production of citric acid by filamentous fungi was introduced. The success of the latter paved the 
way for industrial scale microbial synthesis of range of other products (the most notable example - 
penicillin). However, the variety of early products was restricted to metabolites that were naturally 
synthesized (and in sufficient amounts) by the microorganisms applied. Introduction of the genetic 
engineering tools in the 1970s opened the possibility for production of the compounds which were 
not native to the microbial hosts which led to the establishment of what today is called 
biotechnological industry. The advent of metabolic engineering [2], [3], synthetic biology [4] and 
systems biology [5] approaches as the tools for engineering of microbes with enhanced and 
desirable properties has further accelerated development on industrial biotechnology. Today, 
biosynthesis of desired products is usually achieved by transferring genes or entire metabolic 
pathways from rare or genetically intractable organisms to well-characterized, safe and industrially 
relevant hosts also called “microbial cell factories”. 
The yeast Saccharomyces cerevisiae is an attractive production host which is rigorously explored 
and already used as a platform for biofuel production, commodity chemical biosynthesis and 
production of pharmaceuticals [6]–[8]. In order to construct a yeast cell factory that would fulfill 
the current demand of industrial biotechnology, large and complex metabolic pathways have to be 
manipulated which involves multiple rounds of genetic engineering. Despite a broadly available 
metabolic engineering toolbox, strain construction and optimization steps are still time consuming 
and represent major bottlenecks in development of efficient and cost competitive production hosts 
Introduction and Outline 
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(see Figure 1.1). Therefore, in addition to the well-established genetic engineering tools for yeast, 
there is a need for novel technologies that can be used for improved yeast strain construction and 
metabolic engineering strategies. 
 
The aim of this study 
The potential of S. cerevisiae as a cell factory is far from being fully exploited. This will require 
additional insights into how the production system works and additional genetic tools for better or 
faster cell factory design.  The main aim of my project was therefore to expand the genetic 
engineering toolbox that allows for rapid construction of cell factories as that can be used to provide 
insights into the functionality of the production system. In this work several key points in yeast cell 
factory engineering were addressed, these included i) assembly of a heterologous pathway, ii) 
control of heterologous gene expression levels and iii) choice of the optimal yeast strain background 
for heterologous production of a given product. Therefore the main goals for this project were (also 
see Figure 1.1): 
i. To improve an available gene integration platform for efficient transfer of complex multi-
gene metabolic pathways into yeast genome (Chapter 3). 
ii. To develop and test a novel system for stable gene amplification that allows overexpressing 
gene/s of interest in a controlled manner for improved yield and identification of 
bottlenecks in a defined pathway (Chapters 4 and 5).  
iii. To benchmark production capacities of two commonly used S. cerevisiae strains for 
heterologous production of vanillin-β-glucoside (Chapter 6). 
To achieve the aforementioned goals two commonly used S. cerevisiae laboratory strain 
backgrounds S288c and CEN.PK were chosen as platform cell factories and were also used for 
benchmarking experiments towards heterologous production. The industrially relevant de novo 
vanillin-β-glucoside biosynthetic pathway was employed as a model system for several case studies 
in this project (Chapters 5 and 6). 
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Figure 1.1. The development of a yeast cell factory for production of a given product. Production 
capacity refers to yields, titer or productivity. With currently available metabolic engineering tools it 
usually takes three to six years to improve a proof of concept strain to the final industrially compatible 
strain [8]. 
 
 
Outline  
The thesis contains a literature overview (Chapter 2) that will introduce concepts of microbial cell 
factories and metabolic engineering of yeast. This chapter is followed by descriptions of the 
experimental work and results that I have obtained during my PhD project (Chapters 3 – 6). These 
chapters can be read independently, but it is recommended to understand the technique explained 
in the Chapter 4 before reading Chapter 5. Lastly, Chapter 7 concludes the thesis and provides 
future perspectives. The content of these chapters are briefly outlined below. 
Chapter 2 provides with a general background to microbial cell factories and their role in modern 
industrial biotechnology with the emphasis to yeast Saccharomyces cerevisiae as a production host. 
Moreover, the available biological toolbox used for design and construction of yeast based cell 
factories is discussed. 
Chapter 3 describes the construction and validation of a new set of “EasyClone” vectors, which can 
serve as a platform for fast, efficient, and stable multiple gene integration into S. cerevisiae genome. 
Development of yeast strains for production of chemicals and pharmaceuticals requires iterative 
rounds of genetic engineering. The EasyClone set was designed in a way that allows for 
simultaneous genomic integration of multiple genes with a marker recycling option. In this study, a 
vector set was tested by simultaneous integration of genes encoding cyan, yellow and red 
fluorescent proteins (CFP, YFP and RFP, respectively) into separate vectors and analyzing for co-
expression of proteins by flow cytometry. 
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In Chapter 4, a novel Gene Amplification (GA) system in S. cerevisiae is presented. When building 
cell factories, balanced gene expression levels play a major role in successful production of a given 
metabolite. Generally, biosynthesis is hampered by low activity of heterologous enzymes in the 
host cell. The GA was designed for fast, controlled and efficient gene amplification in a manner that 
is based on targeted integration of multiple copies into defined loci in the yeast genome by a system 
inspired by the mechanism of homing endonuclease gene transfer. As a proof of concept, 
overexpression of genes encoding for red and cyan fluorescent proteins (RFP and CFP, respectively) 
was performed. Moreover, the system was compared to multi-copy plasmids based systems and 
parameters such as expression stability and homogeneity were assessed. 
Chapter 5 is a continuation of the work presented in Chapter 4 and it demonstrates one of many 
possible applications of the GA system. Previously, a multi-step synthetic pathway for production 
of vanillin-β-glucoside in S. cerevisiae has been analyzed in detail [9]. In this study it was shown that 
several intermediates towards vanillin-β-glucoside accumulate, as substrate entering the pathway 
cannot efficiently be converted into the final product. To eliminate possible metabolic bottlenecks, 
I therefore used GA system as a tool to improve production of heterologous vanillin-β-glucoside by 
overexpressing individual genes or gene combinations of the biosynthetic pathway. Using this 
strategy, the production yield was significantly improved. 
In Chapter 6, I have compared two commonly used S. cerevisiae laboratory strains for production 
of vanillin-β-glucoside. Several S. cerevisiae strains are commonly used by the yeast community. 
Among those, the S288c and CEN.PK strain backgrounds have been most frequently applied for 
metabolic engineering experiments. By comparing production of vanillin-β-glucoside in S288c and 
CEN.PK, I demonstrate that genetic background has a large impact on the vanillin-β-glucoside yield.  
Chapter 7 provides with conclusions and future perspectives. 
NOTE TO READER! Chapters 4 to 6 are intended to be published in peer-reviewed international 
journals and are written in a manuscript format, therefore, minor redundancies might appear in 
the text of this thesis. 
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Chapter 2 
2. General Background 
 
Importance of industrial biotechnology 
The concept of biotechnology integrates a wide range of methods and processes for exploiting and 
modifying of living organisms for production of useful goods and has been used by humankind for 
thousands of years mainly for food production and agricultural purposes. Definition of this concept 
has changed over the years and today it is closely associated with microbial biotechnology 
accompanied with genetic engineering and microbial fermentation technologies. When 
biotechnology is applied for purposes of different industrial sectors by use of microbes as cell 
factories it is commonly defined as industrial biotechnology (in Europe known as white 
biotechnology). The major progress of modern biotech industry started after discovery of genetic 
engineering techniques which made possible production of recombinant proteins in microbial cell 
factories. In 1982 human insulin produced by engineered Escherichia coli was the first recombinant 
DNA drug to appear on the market [10]. Since then several other microorganisms have been 
successfully adopted for microbial bioproduction of heterologous products of which 
pharmaceutical proteins were primary targets due to their demand and high price in the market 
[11]. 
Availability of genetic engineering tools made it also possible to synthesize chemical industry 
related products in microbial hosts, however not in a cost-efficient or cost-competitive manner 
compared to traditional methods (e.g., chemical synthesis routes using petrochemicals as raw 
materials). This, however, has changed dramatically within last two decades. Substantial 
advancements in technology and scientific areas such as multidisciplinary field of metabolic 
engineering and systems biology greatly expanded the palette of products that can be synthesized 
via microbial cells. Today it is conceivable to design and develop a cell factory for the production of 
virtually any relevant organic molecule [12]. The huge variety of biotechnology related products 
can be roughly grouped in two categories: low-value (fuels, bulk chemicals) and high-value (fine 
chemicals, pharmaceutics).Recent progress in production of above mentioned products via various 
microbial cell factories is summarized in a review [12]. 
One needs to add that industrial biotechnology related processes offer several advantages such as 
reduced pollution and energy consumption compared to classical methods i.e., chemical synthesis. 
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Moreover, the ability of microorganisms to utilize renewable biomass based materials offers 
sustainable alternatives for petrochemical based industry. Dwindling resources of fossil fuels, 
increase in CO2 emissions and overall environmental concern has turned industrial biotechnology 
into a key technology for future development of biosustainable production [13]. It is therefore 
predicted that microbial based production will substitute up to 20% of products of chemical 
industry by year 2020 [11]. In a recent reviews [14], [15] it is also anticipated that future production 
of biofuels and other desired chemicals will take place in so called “biorefineries”, where different 
types of biomass will be processed into sugars and subsequently converted into the desired 
products through microbial fermentation [15]. 
To this end, the future and success of industrial biotechnology greatly depends on a constant 
improvement of technologies allowing fast construction and optimization of microbial cell factories 
that can cost efficiently convert the sugar-based raw materials into products of interest [11]. 
Depending on the desired product and its further applications different types of microbial cells can 
be used for biosynthesis, commonly these are several variants of bacteria, yeast and filamentous 
fungi. The yeast Saccharomyces cerevisiae has a tremendous application potential in biotech 
industry, moreover, it is forecasted to become a key cell factory for production of biosustainable 
chemicals in the near future [15]. 
 
Saccharomyces cerevisiae 
From beer brewing to eukaryotic model organism 
Saccharomyces cerevisiae also known as baker’s yeast represents one of the most studied and 
characterized species out of about 1000 known yeast species in a vast kingdom of Fungi. It has 
earned a title of “the oldest domesticated microorganism” due to its millennia-long association with 
human activities in wine and beer brewing as well as bread baking [16]. This microorganism 
however was not discovered until the 19th century after pioneering studies of Louis Pasteur and 
others [17]. The name of the species reflects its ability to ferment sugar and produce ethanol – 
word Saccharomyces means sugar mold and cerevisiae means beer [18]. Taxonomically, S. 
cerevisiae is defined as a eukaryotic single-cell (ovoid shaped 5 to 10μm in diameter) microorganism 
that propagates (vegetatively) by a process called budding [19]. The life cycle of S. cerevisiae can 
alternate between two phases – haploid and diploid either of which can exist in stable cultures. 
Research activities focusing on S. cerevisiae have resulted in accumulation of comprehensive 
knowledge concerning genetics, physiology and biochemistry as well as genetic engineering and 
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fermentation technologies. Pioneering discoveries in molecular biology (recombinant DNA 
technology) and introduction of highly efficient transformation methods in S. cerevisiae [20], [21] 
has opened new possibilities for basic as well as applied research areas. In 1996, full genome 
sequence of S. cerevisiae became available for scientific community [22] marking the beginning of 
“revolutionary” era of genomics. Right after, a comprehensive genome characterization study to 
refine the number and location OFRs present in the S. cerevisiae was done via bioinformatics [23]. 
The latter also made it possible to study yeast gene expression profiles by microarray hybridization 
[24], [25]. Moreover, availability of genome sequence in combination with gene engineering tools 
made particular yeast a workhorse for high throughput systematic studies using various “omics” 
approaches [26]. Increasing interest in the particular yeast resulted in several global scale analysis; 
i.e., functional profiling was done by constructing single gene deletion library of nearly all annotated 
(approx. 6000) OFRs of S. cerevisiae [27], moreover, a comprehensive study of cellular protein 
localization was done by assembling the library of green fluorescent tagged proteins [28]. Recently, 
genetic interactions with regards to phenotype was studied by assembling a double gene deletion 
library in yeast [29], [30]. To this end, constantly increasing amounts of information resulted in an 
assembly of the most comprehensive yeast genome database – Saccharomyces genome database 
(SGD) [31]. 
Due to its substantial role in science, it is not surprising that the yeast S. cerevisiae has become a 
widely applied model organism to study fundamental biological processes such as cell aging [32], 
mRNA transport [33] or cell cycle [34] and other processes [18]. More importantly, as a 
representative of eukaryotic organism S. cerevisiae served as a model for studying human diseases 
such as cancer [35], [36], neurological disorders such as Alzheimer’s  and Parkinson’s [18] and other 
important syndromes [37].  
Sub-species variation 
Since the isolation of the first yeast culture by Hansen in 1900s the number of isolated/developed 
S. cerevisiae strains has increased dramatically. Today a broad collection of S. cerevisiae strains are 
available for both commercial and academic purposes. However, not until appearance of high-
throughput and cheap Next-Generation DNA sequencing we could discover the extraordinary 
variation within a single yeast species. Large-scale genome sequencing of mainly commercial S. 
cerevisiae strains revealed existence of at least four separate lineages with a considerable genetic 
variation between and within these lineages [16]. Detailed analysis of DNA sequences revealed 
extensive cross hybridization, genomic mosaicism [16] and gene copy number variation, which is 
most likely a result of an artificial selection for preferred traits [38]. 
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For academic purposes several laboratory S. cerevisiae strains have been developed such as FL100, 
BY series (S288c derivative), Sigma1278b, W303 and CEN.PK series. The variety of laboratory strains 
was as result of diverse research activities within different disciplines such as genetics, physiology 
and biochemistry. Recent genome sequencing projects have covered most of the laboratory strains 
(reviewed in [39]), revealing their genetic variations and relation to various S. cerevisiae strains 
(Figure 2.1). Genome comparison analyses have shown significant differences within laboratory 
yeast strains, represented by different gene copy numbers, insertions, deletions, and an extensive 
number of single nucleotide polymorphisms affecting thousands of genes [39]. As laboratory strains 
are widely used for development of industrially related processes further systems-level comparison 
studies have been pursued in order to address the phenotype to genotype relations of these strains. 
In particular, differences of the two commonly used strains for cell factory development (S288c [40] 
and CEN.PK [41]) have been studied extensively [42]–[44]. These differences are also addressed in 
Chapter 6 of this thesis. 
 
 
Figure 2.1. Phylogenetic three based on whole genomic distances as calculated by Nijkamp et al. [44]. 
The names marked in green represent laboratory strains of S. cerevisiae, the unmarked ones are 
commercial yeast strains mainly used for industrial production of beer, wine and bioethanol. The graph 
is modified from [39]. 
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S. cerevisiae as a cell factory 
In addition to the fact of being a well-established eukaryotic model organism [37], S. cerevisiae also 
plays a major role in applied research due to its fast growth, robustness and substantial tolerance 
towards a harsh industrial conditions. Without a doubt, brewing and baking represent the oldest 
applications of S. cerevisiae for industrial purposes. As a result, well-established fermentation 
technology and its long association with food production earned S. cerevisiae a GRAS (Generally 
Regarded as Safe) status that further increased interest in the particular yeast as a platform for bio-
production. In addition, S. cerevisiae presents a range of advantages for industrial applications: i.e., 
tolerance to relatively low pH (3~5), high sugar and ethanol concentrations, thereby minimizing the 
risk of bacterial contamination; ability to grow in aerobic and anaerobic conditions, fast utilization 
of wide range of sugars; fair resistance to inhibitors found in the hydrolysates of cellulosic biomass 
[6].  
The advent of genetic engineering tools allowed modifying the genetic landscape of yeast and 
transforming it into a cell factory that can produce nonnative yeast products. Since then, numerous 
works aimed to construct a yeast cell factory that can convert sugar-based substrates into different 
types of products ranging from bioethanol and low-value chemicals to therapeutic proteins and 
high-value chemicals (see Figure 2.2) [6]–[8]. Table 2.1 lists the recent achievements/attempts in 
engineering of the S. cerevisiae for production of valuable products. Several native yeast 
metabolites such as succinic acid and fumaric acid can be produced as bulk chemicals. 
Bioproduction of biofuels is of extensive interest, in fact, S. cerevisiae is currently used for the 
world’s largest industrial production of bioethanol [45]. Attempts to produce fine chemicals in yeast 
is highly represented by increasing number of research projects focusing on production of the 
particular class of compounds [6]–[8]. These are chemically diverse and structurally complex 
molecules, usually found in secondary metabolism of, bacteria, fungi or plants, and can be applied 
in food, perfume or pharmaceutical industries. An extensive list of the chemicals belong to several 
classes of secondary metabolites: i.e., isoprenoids (carotenoids, sesquiterpenes and diterpenoids), 
phenolics (flavonoids, stilbenoids), polyketides and alkaloids [46]. 
Most prominent among yeast cell factories producing secondary metabolites are those which 
synthesize precursors to the antimalarial drug – artemisinin [47]. Artemisinin is a sesquiterpene 
that is naturally isolated from the plant Artemisia annua. An alternative for natural extraction was 
recently proposed by Westfall and coworkers [48], here yeast strain was engineered to produce 
high titers of amorpha-4,11-diene. By combining microbial production of amorphadiene and 
developed methods for its subsequent conversion to the final product, industrially feasible 
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production of semisynthetic artemisinin was achieved [49]. In fact, it was estimated that the 
antimalarial treatments produced via particular technology will have lower than the current 
average prices, making it more accessible to the developing world. 
 
 
Figure 2.2. Concept of a yeast cell factory and input of various scientific disciplines to its development. 
 
Microbial production of most of the products mentioned in this section would not be possible 
without multiple rounds of genetic manipulations, phenotype characterization and strain 
optimization. This is done through metabolic engineering strategies which are discussed in the 
following section. 
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Table 2.1. Examples of the products produced in S. cerevisiae. The table is based on [8]. 
Category Product Year Strain  Reference 
Biofuels Ethanol 2007  
2010 
2010 
D452-2 
CEN.PK,   
YPH499 
[50]  
[51] 
[52] 
 Isobutanol 2008 
2011 
BY4742  
CEN.PK 
[53] 
[54] 
 Bisabolene 2011 BY4742 [55] 
 Biodiesels 2012  
2013 
YPH499  
YS58 
[56]  
[57] 
Bulk chemicals Glycerol 2002 CEN.PK [58] 
 Pyruvic acid  2004 CEN.PK [59] 
 Polyhydroxyalkanoates (PHA) 2006 BY4743 [60] 
 D-ribose and ribitol  2010 CEN.PK [61] 
 Succinic acid 2010 AH22 [62] 
 L-lactic acid 2011 CEN.PK [63] 
 Polyhydroxybutyrate (PHB) 2013 CEN.PK [64] 
Fine chemicals Resveratrol1 2003 FY23 [65] 
 Farnesol2 2003 FL100 [66] 
 L-ascorbic acid1 2004 W303 [67] 
 Artemisinic acid1 2006 S288c [47] 
 β-carotene3 2007 CEN.PK [68] 
 Vanillin2,3 2009 S288c [69] 
 Non-ribosomal peptides (NRPs)1 2010 CEN.PK [70] 
 Casbene1 2010 BY4742 [71] 
 Patchoulol2 2011 CEN.PK [72] 
 Eicosapentaenoic acid (EPA)1 2011 CEN.PK [73] 
 β-amyril 2011 CEN.PK [42] 
 Naringenin1 2012 CEN.PK [74] 
 Amorphadiene1  2012 CEN.PK [48] 
 Cubebol3 2009  
2010 
CEN.PK 
CEN.PK 
[75]  
[76] 
 Vanillin-β-glucoside2,3 2010  
2013 
S288c   
S288c 
[9]  
[77] 
1- pharmaceutic, 2- fragrance, 3- food additive 
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Metabolic engineering of yeast cell factories 
Since the discovery of the yeast S. cerevisiae, there has been increasing interest to develop yeast 
strains with improved characteristics that could be exploited in industrial processes. 
Conventionally, strain improvement was done by classical genetic methods (i.e., sexual cross) or by 
random mutagenesis (using radiation or DNA damaging substances) followed by a subsequent 
selection for desired phenotype. Despite the great success, these approaches were time consuming 
as a high number of mutants had to be screened. Moreover, in addition to the desired traits, 
generated mutations were leading to accumulation of unwanted characteristics. As an alternative 
to the classical strain improvement methods a new concept, namely Metabolic Engineering has 
emerged. 
Briefing on Metabolic Engineering 
The concept of metabolic engineering was simultaneously proposed in two independent 
publications in 1991 [2], [3]. Bailey defined metabolic engineering as “the improvement of cellular 
activities by manipulations of enzymatic, transport and regulatory functions of the cell with the use 
of recombinant DNA technology” [3]. In other words, the main aim of the metabolic engineering is 
a rational construction of microorganisms with desired phenotypes through the targeted genetic 
engineering. The fact that S. cerevisiae is extremely well characterized and tractable to genetic 
modifications made this particular microorganism one of the main workhorses for industrially 
driven metabolic engineering applications (Table 2.1). Depending on the overall aim, metabolic 
engineering is used to increase yields of the desired products, improve metabolic fluxes through 
desired pathways or remove unwanted or competing reactions. In addition, the heterologous 
properties can be introduced by transferring foreign genes or all metabolic pathways into the yeast 
S. cerevisiae. However, introduction of heterologous pathway does not imply high levels of desired 
product production [78]. To solve this, several knowledge-based approaches such as local and/or 
global metabolic engineering can be applied. The first strategy involves manipulation of native or 
heterologous metabolic pathway responsible for biosynthesis of a given [47]. An example of the 
particular strategy is described in Chapter 5 of this thesis. On the other hand, global metabolic 
engineering aims to reshape the overall metabolic network of the yeast in order to improve 
precursor metabolites and cofactor supply [9], up-regulate the genes involved in product export 
routes, or redesign native (competing) metabolic pathways so that competing reactions are 
alleviated [72]. 
Metabolic engineering is a constantly developing discipline that relies on advancing tools for genetic 
modifications and systems-level analytical and computational techniques (Figure 2.2 and Table 
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2.2). In general construction of novel cell factories is done in an iterative manner following the three 
principles of metabolic engineering: design, construction and analysis. Each of these steps have a 
specific function during cell factory development process (reviewed in [7]). A brief explanation of 
each step in metabolic engineering cycle is described below. 
For the design step, several key decision points have to be considered: i.e., choice of the product 
and production host and identification of target genes to be manipulated. The design step also 
involves computational strategies such as use of genome scale models in order to predict cellular 
responses or identify new targets for genetic engineering [79]. With regards to the choice of 
production host, it has been shown that S. cerevisiae displays a significant sub-species variation, 
thus is highly likely that production yields of a given metabolite might vary depending on the cells 
genetic background. The latter is addressed in the Chapter 6. 
The construction step implements the designed strategies and mainly relies on the genetic 
engineering and synthetic biology tools. Here native, heterologous or synthetic genes can be 
integrated, genes can be overexpressed, deleted or mutated. Moreover, the ability to control 
expression levels of genes involved in the biosynthetic pathway of interest is of high importance. 
The gene expression levels can be manipulated in several ways. The simplest method is to control 
gene copy number which can be achieved by using yeast shuttle vectors or by genomic integration 
of the gene of interest (see page 17) [80]. Alternatively, gene expression can be controlled at the 
transcription level (i.e., by using native yeast promoters of various strength [81], [82] or synthetic 
promoters [83]–[85]) or translation level (i.e., by RNA regulators [86] or codon optimization). 
Lastly, in the analysis step the constructed cell factory is characterized using various analytical 
methods. Technological and computational advances resulted in a development of high-throughput 
analysis tools also known as “omics” technologies, i.e., genomics, transcriptomics, metabolomics 
and etc. [7]. These approaches made it possible to analyze the effects of genetic manipulation on 
the cell in a global scale and provide with better understanding of the mechanisms underlying 
advantageous phenotypes of the constructed cell factories. 
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Table 2.2. Metabolic engineering with respect to other disciplines. The following strategies are 
described in recent reviews [5], [7]. 
Metabolic Engineering 
Redesign or import metabolic pathways 
Systems biology Synthetic biology 
High-throughput analysis New parts and functions 
 Genomics 
 Proteomics 
 Transcriptomics 
 Metabolomics 
 Fluxomics 
 Synthetic genes (codon 
optimization) 
 Protein engineering 
 Unnatural metabolic 
pathways and new regulatory 
circuits 
 Assembling synthetic 
organisms 
Computational tools 
 Genome-scale models 
 
Biosynthetic pathway engineering 
Biosynthetic (metabolic) pathway can be defined as a sequence of enzymatically catalyzed reactions 
that convert source (S) metabolites into a product (P) [87]. Nature has provided a great array of 
metabolic pathways represented by diversity of existent (micro)organisms, however, these 
pathways often need to be reshaped or most commonly transplanted from the original organism 
to the well-developed production platform (in this case S. cerevisiae). In general, engineering of 
metabolic pathways in yeast (as well as in other microbial hosts) can be done in several ways (Figure 
2.3). In some cases, the host’s native biosynthetic pathway can be re-designed in order to eliminate, 
bypass or to direct fluxes towards a given product metabolite. This is typically done by deleting, 
overexpressing or mutating genes of the metabolic pathway of interest.  In other cases, a fraction 
or a whole natural biosynthetic pathway originating from one organism can be transferred into 
another more suitable production host, e.g., metabolic pathway found in plants is transferred into 
S. cerevisiae. Recent examples of successful integration of heterologous pathways into S. cerevisiae 
includes production of artemisinic acid [47] and amorphadiene [48] – precursor metabolites for 
well-known antimalarial drug artemisinin; or introduction of seven-step pathway from Arabidopsis 
thaliana for indolylglucosinolate production [88]. Moreover, multiple genes resembling fractions of 
biosynthetic pathways of several different organisms might be assembled to form a hybrid 
metabolic pathway in heterologous microorganism. In this manner, synthetic pathways can be 
constructed to produce novel and structurally non-natural molecules [89]. The last, and perhaps 
the most challenging design strategy, namely de novo pathway engineering, involves assembly of 
biosynthetic pathways using a combination of unrelated genes originating from discrete organisms 
to create novel metabolic routes towards compounds of interest. De novo metabolic pathways 
represent possibly the most promising strategy to exploit and expand synthetic capacity of 
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microbial systems making it possible to produce un-natural or natural chemicals for which original 
biosynthetic pathways are not known. One of the first examples of the latter is the de novo multi-
step biosynthetic pathway for production of aroma compounds vanillin and vanillin-glucoside in 
baker’s and fission yeast [69] and more recent example demonstrates production of key 
intermediate for flavonoids – naringenin [74]. Today, the de novo pathway design is much easier 
due to availability of numerous computational based tools (reviewed in [87]). 
It is important to emphasize that all the above mentioned pathway engineering strategies can in 
theory be applied to expand host’s capability to utilize new substrates, e.g., cellulose, starch, 
lactose, xylose, arabinose and etc. [8].  
 
Figure 2.3. Strategies for biosynthetic pathway design.A) Parts of a native pathway can be modified in 
order to redirect or eliminate flux towards a given product.  B) Parts or whole metabolic pathways can 
be transferred from one organism to another. C) Each part of a metabolic pathway is proposed 
individually and usually originates from different sources. S – substrate, P – product; the color of the 
arrows represent metabolic enzymes originating from the same organism. 
 
 
Genetic engineering tools for S. cerevisiae 
The construction step in metabolic engineering cycle is always based on genetic engineering. Due 
to extensive research efforts within yeast genetics, a vast number of genetic engineering tools have 
been developed. In general, a gene(s) can be introduced into S. cerevisiae in two ways; by using 
plasmid vectors or by genomic integration (Figure 2.4). Depending on the overall goal both methods 
have their advantages and disadvantages and were routinely applied for metabolic engineering 
purposes [80]. These methods are briefly explained in the following text. 
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Figure 2.4. Introduction of genes into yeast S. cerevisiae. A) Simplified representation of different types 
of yeast plasmid vectors; YIp – integrative, YCp – centromeric, YEp – multicopy episomal vector. B) 
Genomic integration by homologous recombination. YFG – your favorite gene, UP and DW targeting 
sequences for homologous recombination.  
 
Plasmid based expression 
There are several types of extra-chromosomally replicating plasmids of which YEp and YCp are 
commonly used ones. Both types are S. cerevisiae/E. coli vectors (can propagate in both 
microorganisms) which contain a selection marker and typically a multi cloning site (MCS) for 
insertion of DNA fragments of interest. These vectors are widely used and proven effective for 
various applications [80]. The YCp plasmids carry an origin of replication and centromere sequence 
(CEN/ARS) that provides stable segregation during cell division maintaining 1-2 copies per cell [90]. 
Another type is YEp (or episomal) vectors, these contain a native 2μ sequence and are reported to 
be maintained at 10 to 40 copies per cell under selective conditions [91], [92]. The latter plasmids 
are usually used when high gene overexpression level is needed. 
Today, an extensive YCp and YEp (and YIp – integrative plasmids discussed later) vector collection 
carrying various properties and modifications are available for yeast community (see Table 2.3). 
First generation plasmids were relatively simple in design and were constructed in several versions 
that differed in selection markers and origins of replication [93], [94]. The pRS series developed by 
Sikorski and Hieter [95] were constantly updated with additional selection markers [96]–[98] and 
were widely used for gene expression in yeast. Several new variants (mainly derivatives of pRS 
series) were constructed to contain a range of various constitutive and inducible promoters [99]–
[101]. With increasing interest in metabolic engineering there was need to express more than one 
gene simultaneously, therefore, series of vectors (YCp and YEp) equipped with bidirectional 
promoters were assembled [81], [102]. Commercially available multicopy pESC vectors (Agilent 
A B 
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Technologies) with bidirectional promoters are the ones commonly used for metabolic engineering 
purposes [103], [104]. 
Table 2.3. Yeast vector series for gene expression in yeast. 
Name Type Marker Promoter Ref. 
YCp4XX, YEp4XX YCp, YEp URA3, TRP1, LEU2, LYS2, HIS3 ― [93] 
YCplac, YEplac, 
YIplac 
YCp, YEp, 
YIp, 
URA3, TRP1, LEU2 ― [94] 
pRS series  YCp, YEp URA3, TRP1, HIS3, LEU2, KanMX, 
ADE2, MET15 , hphNT1, natNT2 
― [95]–[98] 
p4XX YIp, YCp, 
YEp 
URA3, TRP1, HIS3, LEU2 CYC1, ADH1, TEF1, GPD1, 
MET25, GAL1, GALS, GALL 
[99], [100] 
pCMXXX series YCp, YEp URA3, TRP1 tetO-CYC1 [101] 
pBEVY, pBEVY-G YEp URA3, TRP1, LEU2, ADE2 TDH3-ADH1, GAL1-GAL10 [102] 
pISXXX YIp URA3 TEF1, GAL1, STE12 [105] 
pAG (Gateway™) YIp, YCp, 
YEp 
URA3, TRP1, HIS3, LEU2 TDH3, GAL1 [106] 
pY2x-GAL(1/10)-
GPD 
YEp URA3, TRP1, HIS3, LEU2 GAL1-TDH3, GAL10 -TDH3 [107] 
pSP-G1, pSP-G2 YEp URA3 TEF1-PGK1 [81] 
pXP series (Cre-
LoxP) 
YIp ,YCp, 
YEp 
URA3, TRP1, HIS3, LEU2, ADE2, 
MET15 (recyclable) 
PGK1, TEF1, HXT7-391 , 
ADH2, GAL1, CUP1 
[108] 
[109] 
pX, pXI, pXII 
series (USER™) 
YIp URA3 (recyclable) Uni- or bidirectional [88] 
pCfB series (Cre-
LoxP, USER™) 
YIp URA3, HIS3, LEU2,LYS5, KanMX 
(recyclable) 
Uni- or bidirectional [110] 
Commercial vectors 
pYC, pYES YCp, YEp URA3, TRP1 GAL1 Invitrogen 
pESC set YEp URA3, TRP1, HIS3, LEU2 GAL1-GAL10 Agilent 
 
Both YCp and YEp type vectors are ideal for expression of one/two genes from a single plasmid in a 
fast and convenient manner. However, in order to construct a yeast cell factory for production of 
high value heterologous products large and complex metabolic pathways (can exceed more than 
ten genes) have to be expressed. Moreover, precise control of heterologous gene expression levels 
is crucial for balanced biosynthesis of a given metabolite. The latter would be very difficult to 
achieve using plasmids; first, because there is a limited number of genetic markers available, and 
second, it is difficult to stably maintain two or more different vectors in a single cell even if a strong 
selection is applied [108], [111], [112]. Non nonhomogeneous gene expression patterns when using 
two or three plasmids were demonstrated in the following Chapters 3 and 4. In addition, it has been 
recently shown that plasmid copy number can significantly vary depending on the promoter and 
selection marker used for expression of the gene of interest [113]. Chromosomal gene integration 
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is an alternative method for gene expression that offers precise control on copy number and 
segregation stability. 
Chromosomal integration 
Highly efficient homologous recombination machinery of S. cerevisiae [114] allows controlled 
integration of biosynthetic pathway genes. Gene integration (or deletion) can be done by 
transforming yeast cells with a linear DNA fragment(s) that contain homologous targeting 
sequences (UP and DW), gene(s) of interest and selection marker (see Figure 2.4B). The UP and DW 
sequences can be as short as 50 bp, however, routinely 200-500 bp long sequences are used to 
ensure a precise gene targeting.  Once integrated, the DNA fragment of interest will stably 
segregate during cell division (assuming that no unstable structures are introduced i.e., direct or 
inverted repeats) without an additional selective pressure. Moreover, recyclable marker systems 
(e.g., Cre-LoxP based [115] or direct repeat recombination based systems using URA3 or TRP1 
markers) allow iterative integrations/deletions of many genes of interest.  
There are two basic methods to construct a DNA substrate for genomic integration; i.e., by using 
integrative vector (YIp) based or PCR based methods. YIp vectors contain the same basic structural 
elements as extra-chromosomal plasmids apart the replication sequence. These vectors cannot be 
retained in the yeast cell unless integrated. Several series of integrative vectors with the specific 
targeting sequences were developed over the years (Table 2.3). Standard YIp vectors were designed 
to target the auxotrophic marker regions [94], [95], [105], [106], [116]. The insertion of large 
metabolic pathways requires multiple targeting sites.  Recently, YIp series were developed to target 
a number of specific genomic regions that exhibit various gene expression levels [117] or stable 
(high) expression levels [88]. 
PCR generated DNA targeting substrates have been/are widely used for gene integration and gene 
deletions [30], [115], [118]. PCR-based gene targeting substrates can be assembled in vitro by 
fusion-PCR [119] or in vivo by exploiting yeast homologous recombination [120]–[122]. To facilitate 
construction of PCR based integration fragments various “template plasmids” have been 
developed. These contain readily constructed cassettes suitable for different purposes (i.e., 
deletion, promoter swap or tagging) that can be PCR amplified and fused to UP and DW targeting 
sequences of interest. To this end, low oligonucleotide price and availability of High fidelity DNA 
polymerases makes, in many cases, PCR based integration methods preferably for high-throughput 
metabolic engineering purposes [80]. 
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Available DNA cloning techniques 
Conventionally, restriction-ligation methods were used to clone expression cassettes into above 
mentioned plasmids. Today, a wide array of different high-throughput cloning methods are 
available which over time have proven to be of great importance, e.g., GatewayTM cloning 
(Invitrogen) [123], Gibson Assembly® cloning (New England Biolabs) [124], Golden Gate cloning 
[125], Infusion cloning (Clontech) and DNA assembler [122]. For a recent review on available cloning 
and pathway assembling techniques refer to [126]. In this PhD project a uracil-specific excision 
reaction (USER)-based cloning [127] and USER fusion [128] techniques were extensively applied. 
USER cloning is a restriction-ligation free in vitro assembly method allowing to combine multiple 
DNA fragments. The technique is described in [129] and its application for yeast based systems is 
explained in Chapter 3. Moreover, the gene expression platform [88] described in the following 
section was designed to be compatible with USER cloning technique. 
Yeast gene expression platform 
As outlined previously, to fulfill the current demands of industrial biotechnology large and complex 
metabolic pathways have to be manipulated. Moreover, to obtain a stable yeast factory 
heterologous genes have to be integrated genomically in a fast and simple manner. To fulfill this, 
several methods allowing assembly and transfer of multi-gene metabolic pathways have been 
recently proposed [130], [131].  
In my PhD project all yeast strains were constructed by implementing the gene integration platform 
(Figure 2.5) previously developed at our center. The platform contains a collection of custom made 
vectors carrying unique recombination sequences (UP) and (DW) that target designated locations 
on three chromosomes X, XI and XII [88]. Moreover, integration sites are grouped in clusters in 
order to facilitate construction of multi-gene pathways by strategies that involve sexual crossings. 
The main benefit of the platform is that all integration sites are separated by genetic elements that 
are essential for sustaining wild type growth rates (e.g., essential genes). The latter is a built-in 
safety system that prevents strains from propagating if they lose genes through direct repeat 
recombination – the spontaneous event that can occur if repetitive elements (i.e., promoters, 
terminators or genes) are used. Moreover, each vector in the set contains a USER cloning friendly 
cassette AsiSI/Nb.BsmI [132] flanked by two S. cerevisiae terminators ADH1 and CYC1. By applying 
USER cloning and fusion [129] techniques it is possible to simultaneously assemble and clone one 
or two genes together with uni- or bidirectional promoter into a vector of choice. The success of 
the platform was demonstrated by reconstruction of indolylglucosinolate metabolic pathway from 
Arabidopsis thaliana [88] and de novo vanillin-glucoside pathway (Chapters 5 and 6) in to S. 
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cerevisiae. Recently, the integration sites of the particular platform were used for development of 
a novel Gene Amplification (GA) system described in Chapter 4.  
Unfortunately, all integrative plasmids contain the same genetic marker which is URA3 gene of 
Kluyveromyces lactis. This means that DNA fragments (containing one or two genes of interest) 
need to be integrated in an iterative manner, i.e., prior to the next round of transformation URA3 
marker has to be counter-selected. This can become time consuming when larger pathways need 
to be engineered. In this PhD project the integrative vectors have been updated to contain an 
expanded genetic marker repertoire (see Chapter 3 or [110]). Using an updated vector set it was 
possible to simultaneously integrate three DNA fragments (or up to six genes) and successfully 
recycle all genetic markers through Cre-LoxP system [115] without compromising the expression 
levels of integrated genes. 
 
Figure 2.5. Overview of the gene integration platform for yeast Saccharomyces cerevisiae. P1, P2 – 
promoters of interest, T1, T2 – terminators of ADH1 and CYC1, respectively. UP (upstream) and DW 
(downstream) homology sequences targeting the specific integration sites. 
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Abstract 
Development of strains for efficient production of chemicals and pharmaceuticals requires multiple 
rounds of genetic engineering. In this study we describe construction and characterization of 
EasyClone vector set for baker’s yeast Saccharomyces cerevisiae, which enables simultaneous 
expression of multiple genes with an option of recycling selection markers. The vectors combine 
the advantage of efficient uracil-excision reaction based cloning and Cre-Lox mediated marker 
recycling system. The episomal and integrative vector sets were tested by inserting genes encoding 
cyan, yellow and red fluorescent proteins into separate vectors and analyzing for co-expression of 
proteins by flow cytometry. Cells expressing genes encoding for the three fluorescent proteins from 
three integrations exhibited a much higher level of simultaneous expression than cells producing 
fluorescent proteins encoded on episomal plasmids, where correspondingly 95% and 6% of the cells 
were within a fluorescence interval of Log10 mean ± 15% for all three colors. We demonstrate that 
selective markers can be simultaneously removed using Cre-mediated recombination and all the 
integrated heterologous genes remain in the chromosome and show unchanged expression levels. 
Hence this system is suitable for metabolic engineering in yeast where multiple rounds of gene 
introduction and marker recycling can be carried out. 
  
PhD Thesis, Tomas Strucko 
35 
 
Introduction 
Baker’s yeast S. cerevisiae is an attractive cell factory for industrial biotechnology [1]. It is used for 
the production of food and beverages and for chemicals, enzymes and pharmaceuticals. Due to 
extensive efforts within yeast genetic research, a vast number of genetic and molecular tools have 
been developed (for reviews see [2]–[4]. Among these tools high- and low- copy as well as 
integrative plasmids have found extensive use in gene function studies and in metabolic 
engineering [5]. There are strengths and weaknesses for each type of plasmids and eventually the 
choice depends on the overall goal. When it comes to metabolic engineering of yeast to obtain a 
process with high titer, rate and yield, multiple rounds of strain engineering are commonly required. 
To cut down the costs it is important that the turnaround time of the metabolic engineering cycle 
is as short as possible. At the same time it is critical that the cycle is at the highest possible standard 
e.g. in terms of stability of expression of the genes introduced and that expression levels can be 
controlled in a reliable way either by inducible promoters or constitutive promoters of various 
strengths (see [2] for references and details). Another important consideration for pathway 
engineering is the ability to co-express the introduced genes and at the desired levels in each and 
every cell of the yeast population. This is a problem as the copy number for both the high- and low 
copy-number plasmids fluctuates in the cell population [6], [7]. The stability issue can be overcome 
by using integration plasmids, where the expression cassettes are integrated in the genome. Several 
integration vector series have been developed over time [8]–[11]. Despite the stable nature of 
chromosomal integrations when compared to e.g. high copy episomal plasmids, instability can 
occur if the introduced fragments share a high degree of sequence homology or if insertions are 
multiple tandem insertions. If the latter is the case, there is a high risk of chromosomal 
rearrangements including loss of the introduced genes due to direct repeat recombination [12], 
[13].  
Another crucial step for the turnaround time of a metabolic engineering cycle is the cloning phase. 
Several high-throughput cloning methods developed over time have proven to be of great 
importance, e.g. GatewayTM cloning (Invitrogen) [14], Gibson Assembly® cloning (New England 
Biolabs) [15], Golden Gate cloning [16] and Infusion cloning from Clontech. Another method is the 
uracil-specific excision reaction (USER)-based cloning technique [17].This cloning technique was the 
basic technique for the plasmid set developed by [18], which allows stable integration into 15 
individual integration sites, where each site was validated for growth impairment and production 
of β-galactosidase. Furthermore, the insertion sites on each chromosome are interspaced by 
essential genetic elements preventing loop out of the inserted fragments by homologous 
recombination. As an example of their system’s applicability the authors showed successful 
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expression of a complex eight gene indole glucosinolate biosynthetic pathway in S. cerevisiae. One 
limitation of this plasmid set is the fact that it is based on only one selectable marker, Kluyveromyces 
lactis URA3, which needs to be recycled during sequential integration steps in a process mediated 
by direct repeat recombination and 5-fluoroorotic acid selection.  Hence, introduction of multi-gen 
pathways will be time consuming as it will require many rounds of strain transformation and marker 
elimination. 
Our intention has been to create a method that allows repeated cycles of genetic engineering, in 
which multiple genes are simultaneously stably integrated into the genome of S. cerevisiae. We 
describe integrative vector set EasyClone with a wide repertoire of LoxP-flanked selection markers, 
developed on the basis of [18] vectors. As proof of concept, we simultaneously integrate three 
different gene targeting cassettes containing genes encoding three different fluorescent proteins 
and then loop-out the markers without losing fluorescent proteins genes. We also evaluate the 
heterogeneity in the population of cells expressing multiple proteins from the integrative EasyClone 
vectors and from 2µ-based episomal plasmids.  
Materials and Methods 
Strains and media 
Saccharomyces cerevisiae CEN.PK102-5B (MATa ura3-52 his31 leu2-3/112 MAL2-8c SUC2) strain 
was obtained from Verena Siewers (Chalmers University). Yeast transformants were selected on 
synthetic complete (SC) drop out media lacking the amino acids matching the auxotrophic markers 
on the plasmids used. These SC plates were made from pre-mixed drop-out powders from Sigma-
Aldrich. When yeast was grown in liquid media it was either in SC, Delft or standard yeast peptone 
dextrose (YPD) media. Delft contained per liter: 7.5 g (NH4)2SO4, 14.4g KH2PO4, 0.5 g MgSO4·7H2O, 
22 g dextrose, 2 mL trace metals solution, and 1 mL vitamins. The pH of Delft medium was adjusted 
to 6 prior to autoclavation. Vitamin solution was added to Delft medium after autoclavation. The 
trace metals solution contained per liter: 4.5 g CaCl2·2H2O, 4.5 g ZnSO4·7H2O, 3 g FeSO4·7H2O, 1 g 
H3BO3, 1 g MnCl2·4H2O, 0.4 g Na2MoO4·2H2O, 0.3 g CoCl2·6H2O, 0.1 g CuSO4·5H2O, 0.1 g KI, 15 g 
EDTA. The trace metals solution was prepared by dissolving all the components except EDTA in 900 
mL ultra-pure water at pH 6. The solution was then gently heated and EDTA was added. In the end, 
the pH was adjusted to 4, and the solution volume was adjusted to 1L and autoclaved (121oC in 20 
min). This solution was stored at +4oC. The vitamins solution had per liter: 50 mg biotin, 200 mg p-
aminobenzoic acid, 1 g nicotinic acid, 1 g Ca-pantotenate, 1 g pyridoxine-HCl, 1 g thiamine-HCl, 25 
g myo-inositol. Biotin was dissolved in 20 mL 0.1 M NaOH and 900 mL water is added. pH was 
adjusted to 6.5 with HCl and the rest of the vitamins was added. pH was re-adjusted to 6.5 just 
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before and after adding m-inositol. The final volume was adjusted to 1 L and sterile-filtered before 
storage at +4oC. 
All standard cloning was carried out using Escherichia coli strain DH5α, which was grown in standard 
Lysogeny broth (LB) medium containing 100 µg mL-1 of ampicillin. For the cloning of plasmid carrying 
the ccdB gene and chloramphenicol cassette, E. coli ccdB strain was used as a host strain and 
transformants were selected on LB medium containing 100 µg mL-1 ampicillin and 25 µg mL-1 
chloramphenicol. 
Plasmid and strain construction 
The episomal plasmids were generated as follows: the 1.8-kb fragment carrying the USER cassette, 
ccdB gene and chloramphenicol marker was generated by PCR amplification using primers 
pESC_U_ccdB_fw and pESC_U_ccdB_rv and plasmid pCfB49 (pXII-1-ccdB) as a template. The PCR 
fragment was digested with SacI and XhoI, gel-purified and then ligated into plasmid pESC-URA or 
pESC-HIS, which were digested with the same enzyme pair. The final plasmids were designated as 
pCfB54 (pESC-URA-ccdB-USER) and pCfB55 (pESC-HIS-ccdB-USER), respectively. Finally, the pCfB54 
and pCfB55 plasmids were digested with FastDigest® AsiSI to remove the ccdB gene including the 
chloramphenicol marker and re-ligated to generate the final plasmids pCfB132 (pESC-URA-USER) 
and pCfB291 (pESC-HIS-USER). 
To construct pCfB220 (pESC-LEU-USER), the 36 bp fragment carrying the USER cassette was excised 
from the plasmid pCfB132 (pESC-URA-USER) using SacI and XhoI, gel-purified and then ligated into 
plasmid pESC-LEU, which was digested with the same enzyme pair. 
The integration plasmids were made from the plasmid set previously described in [18] by replacing 
the directed repeats (DR) flanking K. lactis URA3 selection marker with different selection markers 
flanked with LoxP sites [19]. The selection marker exchange was accomplished by uracil-specific 
excision reaction (USER) [17], where the parent plasmids and the different LoxP flanked selection 
marker fragments were PCR amplified by PfuX7 polymerase [20] using oligos listed in Table 3.1. The 
integration plasmids listed in Table 3.2. using the following protocol: 3 µL of gel purified plasmid 
PCR product was mixed with 5 µL of gel purified selection marker PCR fragment together with 1 µL 
Taq polymerase buffer, and 1 µL USER enzyme (EB). The mix was incubated at 37°C for 25 min, at 
25°C for 25 min and transformed into chemically competent E. coli DH5α cells. The clones with 
correct inserts were identified by colony PCR and the plasmids were isolated from overnight E. coli 
cultures and confirmed by sequencing. This way the following plasmids were obtained: pCfB255, 
pCfB257, pCfB258, pCfB259, pCfB260, pCfB261, pCfB262, pCfB353, pCfB388, pCfB389, pCfB390, 
pCfB391. 
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Plasmids expressing genes of fluorescent protein were constructed using USER-cloning as 
previously described in [21]. Prior cloning, episomal and integrative vectors containing USER 
cassettes were digested with AsiSI and subsequently with the nicking endonuclease Nb.BsmI Figure 
3.1. Each batch of USER vector prepared for USER cloning (SI Figure S 3.1) was tested for number 
of background transformants, i.e. the number of transformants growing on selective plates but that 
do not carry a vector with the insert. This experiment was carried as follows. A defined amount of 
prepared USER vector (~30 ng) was mixed with a PCR product bearing the green fluorescent protein 
encoding gene under the control of an E. coli promoter. This PCR product was generated by using 
primers ID1493 and ID1494 and pCfB774 as template. Prepared USER vector and PCR product were 
mixed in a 1:3 vector to insert molar ratio. After USER reaction and transformation of chemically 
competent E. coli cells, cells were spread on LBAMP and incubated for approximately 18h at 37⁰C. 
The plate was directly analyzed under blue light excitation (bench top blue light table): the number 
of white colonies corresponds to the number of “background” transformants, while the fluorescent 
colonies are the “positive” transformants. Routinely at least 80-90% of the colonies were 
fluorescent. 
The coding sequences of the genes encoding for the three different fluorescence proteins and TEF1 
promoter were amplified by PCR using PfuX7 polymerase and primers listed in Table 3.1. CFP, RFP 
and YFP were obtained from appropriate plasmid templates pWJ1163, pWJ1350 and pWJ1165, 
respectively, and the promoter TEF1 from genomic DNA of the CEN.PK113-11C strain. The promoter 
TEF1 and cDNAs were cloned into previously linearized and tested expression vectors. A total of six 
constructs were produced: three designed to integrate on chromosome X and three to be expressed 
episomally. All constructed plasmids were validated by sequencing. 
Yeast strain CEN.PK102-5B was transformed with different combinations of either episomal 
plasmids or linearized fragments for chromosomal integration by the lithium acetate 
transformation protocol [22]. Prior transformation, integrative plasmids were digested with NotI 
and the fragment containing the sequences for integration was purified from agarose gel. For each 
integrative fragment we used 300-700 ng DNA for each transformation. For episomal plasmids 200-
400 ng DNA was used per transformation. The integration of the plasmids was verified by PCR 
analysis on yeast gDNA purified by the ZR Fungal/Bacterial DNA MiniPrepTM kit from Zymo Research 
using primers listed in Table 3.1. 
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Table 3.1. List of the primers used for vector construction and strain verification. USER-specific 
overhangs are marked in bold, translational enhancer (Kozak) sequence is underlined (Cavener & Ray, 
1991; Nakagawa, Niimura, Gojobori, Tanaka, & Miura, 2008) 
Name Sequence (5’ to 3’) Application 
pESC_U_ccdB_fw AAAAGAGCTCGAATGCGTGCGATCGCAG Amplification of USER 
cassette, ccdB gene 
and chloramphenicol 
cassette 
pESC_U_ccdB_rv AAAACTCGAGGAATGCACGCGATCGCTG 
ID399USERrev ATTGGGUGCATAGGCCACTAGTGGATCTG Amplification of LoxP 
flanked selection 
marker cassettes ID400USERfwd ATCGCGUCAGCTGAAGCTTCGTACGC 
ID401pIntFwdU ACCCAAUTCGCCCTATAGTGAGTCG Amplification of 
integrative plasmid 
backbone ID402pintRevU ACGCGAUCTTCGAGCGTCCCAAAACC 
ID1493 CGTGCGAUCCGCATAGGGAGTGTAAATTTATC Positive GFP control 
fragment for USER 
plasmid  ID1494 CACGCGAUAGTGAAAGGAAGGCCCATGAG  
PTEF1_fw ACCTGCACUTTGTAATTAAAACTTAG Amplification of TEF1 
promoter 
PTEF1_rv CACGCGAUGCACACACCATAGCTTC 
YFP/CFP_F+ AGTGCAGGUAAAACAATGAGTAAAGGAGAAGAACTTTTCAC Amplification of YFP 
and CFP genes 
YFP/CFP_R+ CGTGCGAUTCATTTGTATAGTTCATCCATGCCATG 
RFP_F+ AGTGCAGGUAAAACAATGGCCTCCTCCGAGGACGTCATC Amplification of RFP 
gene 
RFP_R+ CGTGCGAUTCAGGCGCCGGTGGAGTGGCGG 
ID901 X-2-up-out TGCGACAGAAGAAAGGGAAG PCR with ID339 
verifies insertion in X-
2-UP 
ID902-X-2-down-
out 
GAGAACGAGAGGACCCAACAT PCR with ID401 
verifies insertion in X-
2-DW 
ID903-X-3-up-out TGACGAATCGTTAGGCACAG PCR with ID339 
verifies insertion in X-
3-UP 
ID904-X-3-down-
out 
CCGTGCAATACCAAAATCG PCR with ID401 
verifies insertion in X-
3-DW 
ID905-X-4-up-out CTCACAAAGGGACGAATCCT PCR with ID339 
verifies insertion in X-
4-UP 
ID906-X-4-down-
out 
GACGGTACGTTGACCAGAG PCR with ID401 
verifies insertion in X-
4-DW 
ID339-TEF1_test_rv GCTCATTAGAAAGAAAGCATAGC Verification of 
insertion of constructs 
containing TEF1 
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Table 3.2. List of plasmids used in this study. 
Name Description Reference 
Integrative plasmid set with URA3 selection marker flanked with direct repeats 
pCfB126 pX-2-USER-URA3-DR [18] 
pCfB127 pX-3-USER-URA3-DR [18] 
pCfB128 pX-4-USER-URA3-DR [18] 
pCfB383 pXI-1-USER-URA3-DR [18] 
pCfB384 pXI-2-USER-URA3-DR [18] 
pCfB385 pXI-3-USER-URA3-DR [18] 
pCfB387 pXI-5-USER-URA3-DR [18] 
pCfB129 pXII-1-USER-URA3-DR [18] 
pCfB120 pXII-2-USER-URA3-DR [18] 
pCfB130 pXII-4-USER-URA3-DR [18] 
pCfB131 pXII-5-USER-URA3-DR [18] 
pCfB49 pXII-1-ccdB-USER-URA3-DR [18] 
Plasmids that contain LoxP-flanked selection marker cassettes 
pUG6  LoxP-KanMX [19] 
pUG27 LoxP-SpHIS5 [19] 
pUG72 LoxP-KlURA3 [19] 
pUG73 LoxP-KlLEU2 [19] 
pSA40 LoxP-CaLYS5 [23] 
Episomal replication vectors with USER cassette (derived from pESC, Agilent) 
pCfB54 pESC-URA-ccdB-USER This study 
pCfB55 pESC-HIS-ccdB-USER This study 
pCfB132 pESC-URA-USER This study 
pCfB291 pESC-HIS-USER This study 
pCfB220 pESC-LEU-USER This study 
EasyClone integrative vector set with loxP-flanked selection markers 
pCfB255 pX-2-LoxP-KlURA3 This study 
pCfB353 pX-2-LoxP-KanMX This study 
pCfB257 pX-3-LoxP-KlLEU2 This study 
pCfB258 pX-4-LoxP-SpHiS5 This study 
pCfB388 pXI-1-LoxP-KlLEU2 This study 
pCfB389 pXI-2-LoxP-KlURA3 This study 
pCfB390 pXI-3-LoxP-KlURA3 This study 
pCfB391 pXI-5-LoxP-SpHIS5 This study 
pCfB259 pXII-1-LoxP-KlLEU2 This study 
pCfB260 pXII-2-LoxP-CaLYS5 This study 
pCfB262 pXII-4-LoxP-SpHIS5 This study 
pCfB261 pXII-5-LoxP-SpHIS5 This study 
Plasmids containing genes encoding fluorescent proteins 
pWJ1163 CFP [24] 
pWJ1165 YFP [24] 
pWJ1350 RFP [25] 
EasyClone vectors for expression of genes for fluorescent proteins in S. cerevisiae 
pCfB393 pX-2-LoxP-KlURA3-TEF1::CFP This study 
pCfB394 pX-3-LoxP-KlLEU2-TEF1::RFP This study 
pCfB395 pX-4- LoxP-SpHiS5-TEF1::YFP This study 
Episomal vectors for expression of genes for fluorescent proteins in S. cerevisiae 
pCfB396 pESC-URA-USER-TEF1::CFP This study 
pCfB397 pESC-LEU-USER-TEF1::RFP This study 
pCfB398 pESC-HIS-USER-TEF1::YFP This study 
Plasmid contains a cassette for expression of GFP in E. coli (for positive control in USER cloning) 
pCfB774 pmExpCtrl Dr. Hao Lao, DTU 
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Flow cytometry analysis 
Transformants were grown O/N in SC-His-Leu-Ura and 50 µL were used to inoculate 3 mL Delft 
medium in 24 deep well plates, where the cells were grown at 30oC with 300 rpm agitation. When 
the cultures had reached mid exponential phase they were harvested and fixed with 
paraformaldehyde according to the following protocol. Samples (1.5 mL) were taken and 
immediately cooled in ice-water bath and subsequently centrifuged at 4oC, 2000 x g for 2 min. 
Supernatant was removed and pellet was resuspended in 200 µL of 2 % paraformaldehyde. The mix 
was incubated on ice for 1 hour and subsequently centrifuged at 4oC, 2000 x g for 2 min. Finally, the 
paraformaldehyde was removed and pellet was resuspended in 200 µl PBS buffer. The fixed cells 
were stored at 4oC until FACS analysis (max 1-2 days). 
Cells were analyzed on a BD FACSAria equipped with three solid state diode lasers: air-cooled 
CoherentTM SapphireTM solid-state diode laser (488 nm, 100 mW), air-cooled CoherentTM Yellow 
Green laser (561 nm, 100 mW), and an air-cooled CoherentTM Deep Blue laser (445 nm, 50 mW). 
The following filters were used: FITC-A, PE-Cy5-A and mCFP-A for analysis of emission from YFP, RFP 
and CFP, respectively. Compensation was performed according to manufacturer’s protocol (BD 
FACSAria II User’s Guide). 
Flow cytometry data sets were analyzed and interpreted by software packages derived from the 
open source platform of Bioconductor [26].Outliers were removed by pre-gating on FSC and SSC 
data sets with the rule for outliers set at 90% quantile region. Cells were analyzed for their mean 
values, extracted as vectors and plotted by the scatterplot3d function (Ligges & Maechler). 
Cre-Lox mediated selection marker loop out 
Strains were transformed with pSH65 (EUROSCARF) harboring the cre gene under control of the 
GAL10 promoter, and transformants were selected on YPD containing 10 µg mL-1 phleomycin 
(InvivoGen). Single colonies were picked and grown in YPD for 4-6 hours, harvested by 
centrifugation and resuspended in YPGal, where they were subsequently grown for another 12-16 
hours. Dilutions of the culture were then plated on YPD plates and the emerging colonies were 
replica-plated on YPD, SC-Ura, SC-His and SC-Leu to verify that all three markers had been looped 
out. Strains showing successful triple selection marker loop-out were analyzed by flow cytometry 
as described above using SC-complete media as growth media. 
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Figure 3.1. Overview of the procedure for cloning genes into EasyClone vectors. Detailed protocol can 
be found as supplementary material (Figure S 3.1). 
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Results and discussion 
In order to decrease the turnaround time in the metabolic engineering cycle, two sets of plasmids, 
one episomal and one integrative were created (Figure 3.2). The episomal set was derived from a 
subset of the pESC plasmid series (Agilent, USA). Specifically, the multiple cloning sites and 
GAL1/GLA10 promoters were were replaced by uracil excision based cloning cassette, 
AsiSI/Nb.BsmI [27], hence, making it USER cloning and USER fusion compatible, see Figure 3.1 [17], 
[21]. The integrative vector set, which we named EasyClone, is based on the integrative plasmids 
from [18]. Specifically, we chose the vectors in the set, where matching integration sites were 
shown to accept foreign DNA without affecting fitness of the strain and where gene expression was 
high [18].For these vectors For these vectors the K. lactis URA3 selection cassette was substituted 
for one of five different selective markers (see Figure 3.2). In order to be able to reuse the 
introduced selection markers the different markers are all flanked by LoxP sites, whereby the 
selection marker can be looped out by Cre recombinase mediated recombination [19]. 
Both episomal and integrative plasmids contain two terminator sequences in opposite directions 
flanking the USER cloning cassette. This facilitates incorporation of two genes and a bi-directional 
promoter, while the option of incorporating only one single gene with one-directional promoter 
remains (Figure 3.1). The design of the cloning cassette ensures directional cloning. It also provides 
flexibility for the combination of different genes with different promoters using the same gene PCR 
fragment for any combination as long as the position of the gene is maintained, i.e. Gene1 or Gene2. 
The different promoter fragments can be combined with any genes having the specified eight-
nucleotide overhang, which allows for high-throughput cloning in a combinatorial setup. 
In order to create a proof-of-concept for the plasmid set, an experiment was set up where the 
expression of three genes encoding three different fluorescent proteins from either episomal 
plasmids or from three integration sites in the genome was tested and compared (Figure 3.3). CFP, 
YFP and RFP were cloned into pESC-USER and three integration- plasmids, whereby six plasmids 
were constructed: pESC-CFP-URA, pESC-RFP-LEU, pESC-YFP-HIS, pX-2-CFP-LoxP-URA, pX-3-RFP-
LoxP-LEU, and pX-4-YFP-LoxP-HIS. Strains were constructed harbouring either the three pESC-xFP 
plasmids or the three integration xFP expression fragments. 
Rapid pathways assembly in yeast 
44 
 
 
Figure 3.2. Plasmid construction. A, Episomal vectors are based on the pESC vector (Agilent, USA), 
where the multiple cloning sites and galactose-induced promoters were replaced by uracil excision 
based cloning cassette. B, Integrative vectors are based on the vectors described in Mikkelsen et al 
(2012). The URA3 selection cassette flanked by direct repeats was exchanged with one of five different 
selective markers as indicated. The five markers are all flanked by LoxP sites allowing Cre mediated 
marker loop out. C, integration sites are organized in clusters on chromosomes X, XI and XII as 
presented by Mikkelsen at al. All integration sites (yellow boxes) are separated by either genetic 
elements which are essential for growth or by genes essential for maintaining wild type growth rates 
(red boxes). Numbers encircled in red represent Integration sites that are covered by the vector set 
presented here. 
 
The three integration fragments carrying the three fluorescent protein encoding genes were 
transformed into yeast in one single transformation event. From this triple transformation 16 
clones were tested for correct insertion by PCR. For seven clones all the expected bands were seen 
on DNA electrophoresis and all of these exhibited triple fluorescence from CFP, RFP and YFP (results 
not shown). This showed that it is indeed possible to do triple integration in a targeted fashion with 
a relatively high success rate (44 %). 
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Figure 3.3. Experimental setup. CFP, YFP, and RFP were cloned into either episomal or integration 
vectors under control of the strong TEF1 promoter. S. cerevisiae was transformed with either three 
episomal or three integration vectors followed by flow cytometric analysis for presence of the three 
fluorescent proteins. 
 
In order to test the individual production of the three fluorescent proteins in the two different 
strains containing the genes either on episomal 2µ plasmids or as a triple genomic integration, the 
fluorescence levels of single cells were analyzed by flow cytometry (Figure 3.4). Triple fluorescent 
protein production in strains containing the relevant genes as genomic integrations was much more 
uniform as compared to strains were they were harbored on episomal plasmids. The mean levels 
of fluorescence were in the same range for the two expression systems, whereas the standard 
deviations for cells expressing the three fluorescent proteins from episomal plasmids were 4-5 
times larger than for cells expressing from triple integrations (Table 3.3). 
 
Table 3.3. Log10 mean values with standard deviations for each fluorescence signal for cells expressing 
CFP, RFP, and YFP. 
 Integration Episomal plasmids 
CFP 3. 11 ± 0.21 3.4 ± 0.83 
RFP 3.1 ± 0.2 3.3 ± 0.98 
YFP 3.38 ± 0.22 3.41 ± 0.94 
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Figure 3.4. Flow cytometry on S. cerevisiae strains co-expressing YFP, RFP and CFP from either three 
episomal plasmids (top panel) or from triple integrations on the genome (bottom panel). The Log10 
mean value ± 15% for each color is indicated with a deep red vertical line and a light red shading, 
respectively. 
 
Next, we determined the levels of simultaneous production of the three fluorescent proteins in 
individual cells and plotted the data into three dimensional plot (representing levels of YFP, CFP, 
and RFP), see Figure 3.5. This analysis convincingly demonstrated that cells expressing the three 
genes from episomal plasmids are much more scattered throughout the whole three-dimensional 
space, whereas the cells with genomic integrations are in a much more defined space. As a measure 
for uniformity of protein production in the two systems we defined that cells containing a 
fluorescent signal deviating from Log10 mean ± 15% for each color are identical for all three colors 
(highlighted in red on Figure 3.5). Based on this definition, only 6% of the cells harboring the 
episomal expression system contained identical levels of fluorescent proteins. In contrast, more 
than 95 % of the cells were identical when the genes were integrated into the genome. This clearly 
demonstrates the advantage of the EasyClone plasmid set for the construction of complex 
pathways in yeast, as it is important to have stable and concomitant expression of all genes 
introduced in each cell in order to draw sensible conclusions. 
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Figure 3.5. 3D plot of the fluorescence levels of cells expressing CFP, RFP and YFP from either triple 
genomic integrations (left box) or from episomal plasmids (right box). Red dots represent cells having 
fluorescence intensities for all three fluorophores being within Log10 mean ± 15% for each color and black 
dots represent cells with one or several fluorescence levels being outside of mentioned interval. 
 
For construction of large pathways or for repeated cycles of metabolic engineering it is important 
that all markers used in a multiple integration experiment can be recycled. We therefore tested 
whether it would be possible to eliminate all three selection markers used for the integration of the 
genes encoding CFP, RFP, and YFP simultaneously. A strain expressing all three fluorescent proteins 
was transformed with a cre-containing plasmid and cre was subsequently induced by growing the 
transformants on galactose to allow for production of Cre recombinase. 96 clones generated in this 
manner were tested for successful selection marker loop out and eight of these showed a histidine, 
leucine and uracil auxotrophy. All eight strains were re-tested for fluorescence and all showed 
fluorescence patterns, which were indistinguishable from the pattern produced by the parent strain 
(Figure S 3.2). The low level of ura his leu clones was most likely due to the proximity of the 
integration sites. The three integration sites were all on the same chromosome, which meant that 
there were 6 LoxP sites introduced within a fairly small genomic region of 42 kb. Hence, there was 
a risk of recombination between LoxP sites in two different integration sites with a lethal loss of an 
essential gene element to follow. Indeed we obtained efficiencies above 90% for removal of 
selection markers integrated on different chromosomes (unpublished results). 
  
95 % 6 %
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Conclusions  
In conclusion, we have shown that using our vector set it is possible to introduce up to three 
integration cassettes in S. cerevisiae genome simultaneously. Each integration cassette can be 
constructed to carry 1-2 genes. The selection markers used for the integration can be looped-out 
simultaneously without the loss of the integrated genes. We also show that expression of multiple 
genes from integrative cassettes leads to more homogeneous expression within the yeast 
population than expression from multiple episomal vectors. Combined with the fact that vector 
construction is based on highly efficient USER cloning, our system is well-suited for the construction 
of cell factories containing multiple genetic modifications, even in a high throughput manner, see 
Figure 3.6. The plasmids are freely available on request. 
 
 
Figure 3.6. Illustration of how our method can be integrated into efficient strain construction in 
metabolic engineering. M1, M2 and M3 represent selective markers associated with genetic elements 
used for yeast transformation. 
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Figure S 3.1. USER cloning protocol 
Digestion
Nicking
Preparation of a batch of USER vector
20 μg of purified USER VECTOR
16 μL FastDigest AsiSI (ThermoScientific)
37⁰C, 1h
Purification on column
(Typically use a Gel and PCR Clean up kit)
The whole eluate
1 μL Nb.BsmI (New England Biolabs) / μg digested vector
65⁰C, 1h
Purification of linear, nicked vector from 
agarose gel (Typically use a Gel and PCR Clean up kit)
Quantification (ng DNA.μL-1)
Evaluation of background and 
positive control*
Storage (-20⁰C)
~30 ng of prepared USER VECTOR**
x ng of prepared PROMOTER fragment**
Preparation of the inserts
PROMOTER Fragment*** GENE Fragment***
PCR using PfuX7 (Nørholm, 2010)
Purification of products on agarose gel (Typically use 
a Gel and PCR Clean up kit)
Quantification (ng DNA.μL-1)
Storage (-20⁰C)
y ng of prepared GENE fragment**
1 unit USER™ enzyme (New England Biolabs)
Overview of the USER cloning procedure
37⁰C, 15minUSER cloning
25⁰C, 15min
For details on primer design, see Fig. 2.
*, For details, see Mat erials & Methods section
**: For x and y:  tipically use ratio vector :insert of 1:3 but this may require optimization (general guidelines in Nour Eldin, 2010)
***: different combinations are possible , see Fig. 2.
Collection of 
Ready to use
prepared 
USER 
VECTORS
Collection  of 
Ready to use
PROMOTER 
fragments 
and GENE 
fragments
USER cloning
Transform E. coli chemically competent cells
Spread transformed cells on selective medium
Reaction volume 200 μL
20 μL 10x FastDigest buffer (ThermoScientific)
Appropriate volume of Buffer 3.1 (New England Biolabs)
2 μL of PCR Buffer 10x
Reaction volume 20 μL
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Figure S 3.2. FACS analysis of the cell before and after the triple selection marker loop-out. A, Single 
color overlay histogram, for cyan (CFP), red (RFP) and yellow (YFP) fluorescent proteins signals before 
(blue) and after (red) marker loop-out. B, 3D plots of CFP, RFP and YFP before (left) and after (right) 
marker loop-out. 
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Chapter 4 
4. Gene amplification in Saccharomyces cerevisiae 
 
 
Title3 
Controlled gene amplification for high, tunable, selection-free gene expression in the yeast 
Saccharomyces cerevisiae 
 
 
Abstract 
Introduction of multi enzyme pathways in to yeast requires precise control over the heterologous 
gene expression levels. Current methods (i.e., episomal multicopy plasmids also known as 2μ 
plasmids) allow high gene expression levels to be reached, but do not ensure genetic stability if a 
proper selection pressure is not applied. The following chapter describes the design and validation 
of a gene amplification system that enables stable and selection-free gene expression in the yeast 
Saccharomyces cerevisiae. Here, the collection of special yeast strains have been developed with 
the capability of autonomous gene amplification up to ten copies. As a proof of concept two genes 
encoding red and cyan fluorescent proteins were amplified using the developed method and the 
fluorescence intensities were compared to the ones obtained by a plasmid based system.  
Most notably, the gene amplification method was successfully applied in the subsequent study 
described in the Chapter 5, where it was used for alleviation of metabolic bottlenecks in the 
heterologous pathway for vanillin-glucoside production in S. cerevisiae. 
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Introduction 
A major challenge when engineering cell factories for industrial production is to achieve high-gene 
expression levels without compromising genetic stability. In the popular expression hosts 
Saccharomyces cerevisiae and Escherichia coli, high copy numbers are readily achieved by 
expressing genes from multi copy plasmids. But plasmids are gradually lost when the cell divides 
because plasmids are not as stably inherited as chromosomes [2]. The instability associated with 
plasmid based expression is a major cause of productivity loss in long-term cultivations [3]–[6]. On 
the other hand genomic integration provides ordered genetic inheritance and thereby increases 
the genetic stability of heterologous genes. However, to meet plasmid based expression levels, it is 
necessary to integrate multiple copies of each gene. This can be achieved by the time consuming 
process of repetitive rounds of genetic transformation. To solve the problems of combining high 
copy numbers with fast strain construction, different methods that allow multi-copy strains to be 
constructed in a few steps have been developed. Generally such methods involve either targeting 
of natural repeats whereby multiple gene copies can be integrated at once or it involves integration 
of a single gene copy followed by gene amplification. By targeting natural repeats such as ribosomal 
DNA [7] or δ-sequences [8] in S. cerevisiae, strains estimated to contain up to 300-400 gene copies 
were obtained and expression levels equaled those that can be achieved by multi copy plasmids at 
least in some cases [7]. But strains were generally unstable, because the method results in tandem 
arrangement of the gene copies even when the targeted repeats are dispersed throughout the 
genome [9]–[11]. In general, the copy number of DNA repeats positioned in close proximity is 
unstable, because repeated elements are easily lost through direct repeat recombination. 
Alternatively, high copy strains can be achieved through gene amplification. In E. coli, strains that 
yielded up to 40 integrated gene copies were achieved by coupling gene amplification to antibiotic 
resistance [12]. This was achieved by placing the genes to be amplified and an antibiotic resistance 
gene in between repetitive sequences. When the cells divide, recombination errors will in some 
cases result in a duplication of the repeat flanked region. As duplication always results in an extra 
copy of the gene(s) of interest as well as an extra copy of the resistance gene, duplications can be 
selected for by growing strains in media with increasing concentrations of the relevant antibiotic. 
When the operons responsible for lycopene and poly-hydroxybutyrate production were amplified 
using this method, the yield exceeded that of strains which expressed the same operons from multi 
copy plasmids by 1.6-4 fold [12]. But similarly to the methods that target repeats, the method 
results in strains where the amplified genes are arranged in tandem and according to the authors 
it was necessary to knock out the recombination protein recA to stabilize strains after amplification. 
If the strain is to be used as a cell factory, the knock-out of enzymes essential for recombination is 
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disadvantageous  because such deletions generally results in strains that are less robust and grow 
slower [12]. Interestingly, a gene amplification method where genes were not arranged in tandem 
has also been developed. By exploiting the natural mechanism of transposon migration Boeke and 
co-workers successfully amplified three genes and obtained strains with up to ten integrated gene 
copies [13].  Strains generated by transposon mediated gene amplification are presumably stable, 
as gene copies are dispersed throughout the genome, but the amplification process occurs through 
the error prone reverse transcriptase which means that the amplified gene copies are likely to 
contain mutations.  Moreover there is limitation associated with the method, as it was observed 
that the amplification rate and copy number decreased substantially when the size of the DNA to 
be amplified was increased from 1kb to 4.6kb [14]. 
Here we describe an inducible, plasmid free gene expression system that enables fast construction 
of stable strains with high copy numbers in the yeast S. cerevisiae. Using our gene amplification 
system, genes are copied and integrated at well-defined positions in the genome. More specifically, 
genes are inserted in non-coding intergenic regions where it has previously been shown that 
integration does not influence fitness of the strain by adversely affecting neighboring genes [15]. 
Moreover, these integrations sites are separated by essential genes which prevent the loss of 
amplified genes through direct repeat recombination. This should ensure long-term strain stability 
and provide selection free gene expression. Gene amplification is achieved through double strand 
break stimulated gene conversion. Copy numbers can be precisely controlled and are determined 
by the number of gene amplification cassettes present in the pre-engineered strain. We 
demonstrate that strains with up to ten integrated copies can be constructed and that strains 
generated using our system remain stable in long-term cultivations. 
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Results 
Design and construction of the gene amplification system 
To develop a plasmid free gene expression system that enables construction of stable strains with 
high copy numbers, we set out to develop a gene amplification system where gene copies are 
integrated at well-defined positions in the genome. The system utilizes an endonuclease to 
stimulate homologous recombination at specific loci. Gene amplification is carried out in a strain 
that has been pre-engineered to contain a number of gene amplification cassettes. Each gene 
amplification cassette contains an I-SceI cleavage site [16] where specific double strand breaks can 
be made. Moreover, each cassette contains a counter-selectable marker, which in our system was 
the URA3 gene of Kluyveromyces lactis flanked by two recombination sequences denoted A and B. 
The recombination sequences A and B enable gene amplification by homologous recombination 
upon I-SceI expression (see Figure 4.1 A for a schematic representation of the process). In this case 
the recombination sequences A and B where approximately 500 and 1000 base pairs in length, 
respectively, and were derived from genomic DNA of Neurospora crassa to avoid any similarity to 
the genomic DNA of S.cerevisiae.  
To set up the gene amplification system in S. cerevisiae we constructed strains with one to ten 
amplification cassettes integrated on chromosome X, XI and XII at specific sites that were previously 
characterized by Mikkelsen et al [15] (Figure 4.1B). Integrations were made sequentially in three 
strains in parallel. This resulted in three types of GA strains; two with three amplification cassettes 
integrated on either chromosome X or XI and one with four amplification cassettes integrated on 
chromosome XII. Subsequently, strains with more than four amplification cassettes were generated 
by crossing the strains containing three or four gene GA cassettes with each other (e.g. a strain with 
seven amplification cassettes was constructed by crossing the strain with three cassettes on 
chromosome X with a strain with four cassettes on chromosome XII). For the general notion gene 
amplification strains were named GAx followed by number, e.g. GAx10 is the strain with ten 
amplification cassettes. All strains were made in minimum two variants of which one had mating 
type “a” and the other had mating “α”. This allows construction of diploid strains with up to 20 
gene copies by mating. In order to easily integrate and amplify any gene or pathway of interest in 
the GAX strains, a USER cloning vector (pCSN) was constructed.  pCSN contains a uracil excision 
based cloning cassette AsiSI/Nb.BsmI cassette [17], flanked by two yeast terminators of ADH1 and 
TRP1, a selective marker and the recombination sequences A and B targeting integration into an 
amplification cassette (Figure 4.5 A). 
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Figure 4.1. The gene amplification (GA) system. A) General scheme of the amplification process. Step 
1: A strain which has been pre-engineered to contain a number of amplification cassettes is 
transformed with a substrate containing “your favorite gene/s” (YFG) to be amplified, a counter 
selectable marker flanked by direct repeats (R-TRP1-R) and the recombination sequences A and B. 
Step 2: The TRP1 marker is recycled by plating cells on counter-selective media (SC-5-FAA). Steps 3 
and 4: I-SceI is introduced to the cell on a plasmid and its expression is induced by transferring cells to 
induction media (SCgal-trp). Expression of I-SceI results in double strand breaks in all amplification 
cassettes except the one where YFG has integrated. After induction, the breaks are repaired by 
homologous recombination which results in the displacement of URA3 with YFG. Step 5: Cells where 
all amplification cassettes have been successfully replaced by YFG are identified by plating cells on 
URA3 counter selective media (SC-5-FOA). B) Simplified representation of integration platform used 
for construction of the GA strains. Three rows represent defined chromosomes (X, XI and XII) and five 
columns correspond to the integration site number (1 to 5) for each chromosome [15]. Yellow box 
depicts the location of the GA cassette. This panel represents only a fraction of all available strains 
developed in this study. 
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A Proof-of-concept  
For a proof of concept the GA system was employed for controlled overexpression of the genes 
encoding the two model proteins – cyan fluorescence protein (CFP) and red fluorescence protein 
(RFP). These two proteins were chosen as model proteins because their fluorescence intensity can 
easily be quantified using flow cytometry. Gene targeting fragment for integrating CFP and RFP in 
the GA strains were prepared by digesting the pCSN-CFP-RFP plasmid with NotI endonuclease. To 
construct strains with different copy numbers of CFP and RFP, the gene targeting substrate was 
transformed into strains containing one, two, four, seven and ten cassettes. Subsequently, gene 
amplification was achieved by transformation with the I-sceI encoding plasmid, pWJ1320-TRP, 
followed by a series of replica plating and selection events as described in the Materials and 
Methods section. In order to construct strains with higher than ten gene copies (up to 20) we 
constructed diploid cells by mating haploids of opposite mating type containing different copies of 
amplified reporter protein genes (SI Table S 4.4). 
To demonstrate an application of the developed gene amplification system and to compare this 
approach to existing plasmid based systems (particularly, multi-copy 2μ plasmids), it was chosen to 
amplify two fluorescent proteins simultaneously in order to mimic a two-step biosynthetic 
pathway. For a two-step pathway, the successful production of the end-product requires the 
presence of both enzymes. From the results in Figure 4.2 it is evident that the GA system developed 
in this work is more advantageous compared to the plasmid based system in terms of simultaneous 
co-expression of two genes. This was true for all GA strains with different copy numbers of CFP and 
RFP genes. In all cases more than 90% of GA cells were fluorescing in both red and cyan colors. 
When these two proteins were expressed from two plasmids only 54% of the cells were fluorescing 
in both colors (Table 4.1). Moreover, fluorescence intensities of the strains expressing reporter 
genes from 2μ plasmids were scattered compared to the ones of the GA strains. This observation 
indicated that concentrations of CFP and RFP in the individual cells of 2μ strain varied significantly, 
i.e. a cell displaying high signal for RFP could have low or no signal for CFP and vice versa. To visualize 
the efficiency of co-production of two reporter proteins the RFP/CFP ratios have been plotted for 
each cell (see Figure 4.2C). 
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Figure 4.2. Scatter plots of CFP and RFP fluorescence levels observed in A) GAx10 based strains and B) 
in strains harboring two 2μ plasmids. C) The RFP/CFP fluorescence ratio in each individual cell 
represented for all analyzed strain population; (•) GAx10 and (•) 2μ plasmid strains. In all graphs CFP 
and RFP are plotted in Log10 scale. 
 
 
Table 4.1. Average percentage of the cell population expressing reporter proteins. (S) – Cultivations 
were done in selective medium and (NS) – non selective medium. 
Copies 
% of all population 
None CFP RFP Both 
0 93.6 1.7 3.5 1.2 
1 17.8 10.9 9.4 61.9 
2 3.0 4.1 2.9 90.0 
4 0.2 0.4 0.7 98.7 
7 0.1 0.1 2.2 97.6 
10 0.1 0.0 0.7 99.2 
2μ (S) 7.4 3.2 35.4 54.0 
2μ (NS) 61.0 2.9 29.1 7.0 
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Next, it was investigated how the gene copy number reflects on the levels of produced fluorescent 
proteins and compared to the levels where the genes were expressed from 2μ plasmids. For this 
reason, mean fluorescence intensities (MFI) for two different colors (cyan and red) were measured 
in the two settings (i.e., GA and plasmid based). This analysis convincingly demonstrated that the 
fluorescence intensity for both colors increased linearly with the increasing gene copy number in 
the GA strains (see Figure 4.3). Not surprisingly, the same trend was also observed in the GA diploid 
strains. In addition, CFP production from the seven-copy GA strains exceeded the plasmid based 
expression system judging on MFI values. That was not true for RFP, where fluorescence levels were 
more than 60 times higher in the plasmid based strains compared to the highest levels obtained in 
the GA based diploid strain with 20 copies of RFP genes (Figure 4.3). 
 
Figure 4.3. Mean fluorescence intensities (MFI) of CFP (•) and RFP (•) in GA and 2μ strains. MFIs 
observed in the haploid strains harboring up to ten copies of the integrated reporter genes (A) and in 
the strains where CFP and RFP were co-expressed on two independent 2μ plasmids (B). 
Correspondingly, MFIs in diploids strains with up to 20 copies (C) and plasmid based expression (D). 
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Genetic stability of the GA strains 
One of the most important requirements of an industrial strain used as cell factories is the genetic 
stability in a long-term cultivations. To check this, the GAx10 and 2μ strains expressing CFP and RFP 
genes were cultivated for approx. 40 generations and samples for flow cytometry were taken at 
regular intervals. Two factors considering the stability of reporter genes were assessed; first, 
fluorescence levels of independent fluorophores throughout the cultivations and, second, the 
percentage of the cells that displayed fluorescence for both CFP and RFP. From the Figure 4.4A it 
can be seen that the GA strain with ten copies of CFP and RFP genes retained its initial fluorescence 
levels after 40 duplications, that was also true for the plasmid based strain. However, significant 
differences between the two strains were found when co-expression of the CFP and RFP genes was 
evaluated (see Figure 4.4B). Close to 100% of cells in all analyzed populations of GAx10 strain 
maintained fluorescence for both cyan and red colors throughout all experiment. Accordingly, only 
approx. 60 % of the cells expressing reporter genes from the 2μ based plasmids were found to 
produce both fluorescence proteins. 
 
 
Figure 4.4. Genetic stability of the GA strains compared to the multi-copy plasmid based expression 
systems. A) Log10 MFI of the cells expressing CFP or RFP in two systems. B) Percentage of the cells that 
displayed fluorescence for both colors. 
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Discussion 
In this work, a new method for gene amplification (GA) in yeast S. cerevisiae have been developed 
and validated. The GA system is conceptually different from the previously reported methods for 
construction of strains containing multi-copies of chromosomally integrated genes of interest [7], 
[8], [13]. Here, the amplification relies on a set of special made strains with a predefined number 
and location of GA cassettes located on three different chromosomes X, XI and XII. The increase in 
gene copy number occurs by the gene conversion mechanism [18] which is triggered by I-SceI 
induced DNA double strand breaks  at the designated GA loci (see Figure 4.1).  
Results of this study provide compelling evidence that the GA system enables amplification of DNA 
fragments of interest to a precise copy number (up to ten copies). This was confirmed when the 
system was used for overexpression of the two reporter proteins CFP and RFP. Mean fluorescence 
intensity increased linearly increased with the copy number of the CFP and RFP genes (Figure 
4.3).To check if the higher gene copy number will result in adequate increase in protein production, 
diploid trains with various copy numbers (up to 20) of integrated CFP and RFP were constructed. 
Diploid data, however, must be treated with caution even though MFI values had increased with 
the similar trend as in haploids, the flow cytometry readings do not account for the increased mass 
and volume of a diploid cell. On the other hand, this indicated that it is possible to further improve 
protein production in haploids if GA strains with higher number of amplification cassettes were 
constructed. 
One of the most important points of this work was the benchmarking of the GA based expression 
system to the 2μ plasmid based expression system. Several important criteria of these systems 
(based on the MFI of reporter proteins) were assessed; i.e., gene expression/protein production 
levels, production stability and homogeneity. These are key parameters of a successful industrially 
applicable cell factory. When MFI was compared for independent fluorophores, the levels of 
produced RFP in a strain harboring a 2μ based plasmid were orders of magnitude higher than in the 
GAx10 strain. In contrast, the CFP production of the GA strains was superior compared to plasmid 
based counterparts when the copy exceeded seven copies (Figure 4.3). The significantly different 
performance of the two plasmids was possibly caused by the uneven copy number of these 
plasmids. This can be explained by previously reported findings, where it was demonstrated that  
copy numbers of the 2μ plasmid can vary depending on the selection marker and the strength of 
the promoter used to express the gene of interest [19], [20]. Predominantly, beneficial properties 
of the GA system became evident when co-expression levels of the two reporter genes CFP and RFP 
in GA strains were compared to plasmid based counterparts (Figure 4.2 and Table 4.1). The ability 
to homogenously overexpress two genes in the GA strains is particularly advantageous in cases 
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where production of the compound of interest is depending on more than one enzyme. Lastly, the 
GA strains were demonstrated to be genetically stable in long-term cultivations for at least 40 
generations (Figure 4.4). Strains with 10 copies of CFP and RFP retained initial fluorescence 
intensities as well as homogeneity after 40 generations in a synthetic complete medium without 
any selective pressure. The aptitude to maintain a stable number of genes is a result of an in-build 
“fail safe” system in GA strains which prevents the further cell propagation if any of amplified gene 
was lost through a direct repeat recombination [15]. Even though a selection pressure was 
constantly applied throughout the cultivation, only 60% of the cells that expressed CFP and RFP 
from plasmids produced both proteins at detectable levels. If the presence of three plasmids is 
required in order for all proteins to be co-expressed in a cell, the proportion of cells that co-
produces all three proteins drops dramatically. In the previous (Chapter 3) it was shown that only 
6% of all analyzed yeast population are capable to co-produce three (CFP, RFP and YFP) proteins in 
the same cell [21]. 
All aforementioned advantages of the GA system are worthless if strain construction is time 
consuming. Fortunately, the procedure of GA was optimized to be as short as ten days (not 
including the time for DNA substrate construction and transformation).  Moreover, due to smart 
design of the GA cassette no intensive screening efforts are required to identify correct clones as 
all strains where gene amplification was unsuccessful or incomplete are automatically selected 
against in the screening system depicted in the Figure 4.5. In fact, routinely three out of four 
plausible strains with amplified genes appear to be correct after checking with analytical PCR (no 
data).  
To this end, the GA system was shown to be suitable for achieving high gene expression levels which 
is a prerequisite when constructing a microbial production host. In addition, the precise control of 
copy number and genomic location of amplified genes in combination with fast strain construction 
makes the GA system suitable for metabolic engineering of heterologous pathways in yeast. In fact, 
the next Chapter (5) of this thesis demonstrates the successful application of GA system for 
identification and elimination of metabolic bottlenecks in the de novo biosynthetic pathway for 
production of vanillin glucoside. 
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Conclusion  
In summary, the gene amplification developed in this study was proven to be robust and easy to 
manipulate, and successful amplification of the reporter CFP and RFP genes in up to ten copies in 
haploid strains and in up to 20 in diploid strains was demonstrated. In some cases, protein 
production levels obtained in GA strains were found to be higher than the ones obtained in the 
strains expressing the same genes from an episomal multicopy plasmids. It was also shown that 
overexpression of two genes via the gene amplification system leads to a more homogeneous 
expression within the yeast population compared to plasmid based expression from 2μ plasmids. 
Moreover, the GA strains were shown to be able to sustain stable expression of amplified genes in 
long term cultivations. To this end, the platform developed in this work can be well-suited for the 
construction of genetically stable cell factories where single or multiple genes have to be 
overexpressed; in addition, the GA can be applied for metabolic engineering purposes where 
precise control of gene expression levels are needed.  
Future perspectives 
This chapter describes only a fraction of all the work being done for this particular project. An 
ongoing research also involves studies of two additional model systems for further validation and 
characterization of the GA method. Firstly, in order to precisely evaluate protein production in GA 
strains, the lacZ gene will be amplified to various copy numbers in the same way as it was described 
above for the fluorescent proteins. By using conventional methods β-galactosidase concentration 
can be easily determined and more importantly normalized to the cell dry-weight. The latter is 
especially important when comparing protein production in haploid and diploid cells since their size 
and volume are different. The β-galactosidase production in GA strains will also be compared to 
plasmid based systems. Next, a simple heterologous two component biosynthetic pathway for 
production of the polyketide 6-methylsalicylic acid (6-MSA) will be studied in GA strains. 6-MSA was 
previously produced in yeast by expressing the genes npga and 6-MSAS  from multi copy plasmids 
[22]. In this study, the two genes will be amplified in GA strains and 6-MSA production will be 
compared to the plasmid based platform. Moreover, 6-MSA pathway titration experiment will be 
done by amplifying independent parts of the pathway in order to investigate whether any (or which) 
of the two enzymes represent a bottleneck in the synthesis of 6-MSA. 
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Materials and Methods 
Media, plasmids and yeast strains  
Cultivation media: Genetic manipulations and cultivations of the yeast strains were done in a 
synthetic complete (SC) medium (Sherman et al. [23]) with minor modifications where the leucine 
concentration was doubled to 60 mg/L. All yeast transformants with gene integrations or plasmids 
were selected on SC media missing the appropriate auxotrophic marker (denoted as SC-aux, e.g. 
SC-trp if tryptophan is missing). In order to select against the TRP1 or URA3 markers, yeast strains 
were grown on SC medium plates supplemented with 500 mg/L 5-fluoroanthranilic acid (SC-5-FAA) 
or 740 mg/L 5-fluororotic acid (SC-5-FOA), respectively. For gene amplification purposes (induction 
of I-SceI plasmid) SC medium was modified by using 2% galactose instead of glucose as a carbon 
source and denoted as SCgal. Yeast Extract Peptone Dextrose (YPD) medium plates were used for 
storage and propagation of the constructed yeast strains as well as for sexual crossing purposes. 
Plasmid construction: The I-SceI expression plasmid pWJ1320 was obtained from Michael Lisby 
[16]. Plasmids used in this study were assembled by USER™ cloning technique previously described 
in [24], [25]. The DNA fragments for cloning were amplified by PCR from the appropriate vector 
templates or genomic DNA of S. cerevisiae using PfuX7 polymerase developed by Nørholm et al. 
[26] with specially designed primer pairs (SI Table S 4.1). A detailed list of all plasmids used and 
constructed in this work is depicted in SI Table S 4.2. 
Strain construction: The Saccharomyces cerevisiae strains CEN.PK110-4C and CEN.PK113-6B were 
used as starter strains for construction of all GA strains. For plasmid comparison experiments 
CEN.PK113-1C and CEN.PK111-61A were used. All CEN.PK strains were obtained from Peter Kötter 
[27]. The GA strains were constructed by sequential transformation with specifically designed GA 
cassettes targeting unique locations on three chromosomes X, XI and XII. Later, several rounds of 
crosses were performed to build strains containing up to ten GA cassettes (see SI Figure S 4.1 and 
Figure S 4.2). For the proof of concept experiments, the strains with different copy numbers of CFP 
and RFP were constructed by applying the GA technology (see below for description); or by 
transforming WT CEN.PK strains with episomal multi-copy plasmids harboring the CFP or RFP genes. 
The GA strains expressing up to 20 copies of CFP and RFP were generated by mating opposite 
mating type haploids with different copy numbers of the reporter genes (see SI Table S 4.4), the 
diploids were constructed using the method described in [28]. 
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Gene amplification protocol 
For a schematic illustration of the gene amplification protocol see Figure 4.5.  
Preparation of gene targeting fragments: Genes of interest (G1 and/or G2) are first assembled 
by USER cloning into the backbone of amplification plasmid pCSN. The final DNA construct 
containing the gene/s of interest, the selection marker TRP1 (flanked by the direct repeats) and 
the recombination sequences A and B are prepared by digesting the pCSN based vector with the 
relevant insert using NotI restriction endonuclease. Lastly, the relevant DNA fragment is purified 
from an agarose gel. 
Transformation 1: A strain with a selected number of GA cassettes is transformed with the gene 
targeting substrate containing the gene(s) to be amplified. Transformants are selected and 
streak-purified on plates with SC-trp medium. Next, the TRP1 marker is recycled by purify 
streaking transformants on plates with SC-5-FAA medium. 
Transformation 2: The resulting strain from transformation 1 is transformed with the plasmid 
pWJ1320-TRP, which encodes the I-SceI endonuclease under the control of the galactose 
inducible GAL1 promoter. The resulting transformants are selected on SC-trp medium. In this 
step it is important to adjust the concentration of pWJ1320-TRP plasmid in order to get the right 
amount of colonies on the plates (preferably 50 – 200 well separated colonies). 
Induction: SC-trp plates with 50-200 single colonies are replicated onto induction media (SCgal-
trp) containing plates.  The plates are incubated at 30°C were for 2-4 days, the time of incubation 
can vary depending on the product properties of the amplified gene. 
Selection: To identify the clones where gene amplification was successful, the SCgal-trp plates 
are replicated twice. Firstly, the SCgal-trp plate is replicated onto SC-5-FOA and incubated for 2-
3 days at 30°C. Secondly, the SC-5FOA plate is replica plated onto YPD and SC-ura (lacking uracil) 
both plates are incubated overnight at 30°C. Colonies growing on YPD plates but not on SC-ura 
are plausible candidates with successfully amplified genes of interest. A reasonable number of 
colonies is streak-purified on plates with SC-5-FOA medium.  
Verification: Finally, the successful amplification is validated by PCR on genomic DNA with the 
primers pairs (see SI Table S 4.1) targeting for the specific amplification sites. 
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Figure 4.5.Generalized illustration of the gene amplification method. A) Assembly of the DNA fragment 
to be amplified and its transformation into GA strain with N-copies of amplification cassettes. B) 
Induction of the gene amplification and subsequent selection of the strains with successfully amplified 
genes. T1 – ADH1 terminator, T2 – TRP1 terminator, A and B – recombination sequences targeting GA 
cassette, P1, P2 – any promoter and G1, G2 – any gene of interest. 
 
Flow cytometry analysis 
Sample preparation: Pre-cultures of the plasmid containing and the GA strains were grown O/N in 
3 mL SC medium (for plasmid SC-his-ura). 50 µL of pre-culture were used to inoculate 15 mL of fresh 
medium in 50 mL falcon tubes, where the cells were grown at 30oC with 150 rpm agitation at 30oC. 
After the cultures had reached mid-exponential phase they were harvested and fixed with 
paraformaldehyde according to the following protocol. 2 mL samples were taken, cooled on ice and 
subsequently centrifuged at 4oC, 3000 x g for 2 min. Supernatant was removed and pellet was 
resuspended in 200 µL of 2 % paraformaldehyde. The mix was incubated on ice for 1 hour and 
subsequently centrifuged at 4oC, 3000 x g for 2 min. Finally, the paraformaldehyde was removed 
A B 
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and pellet was resuspended in 200 µL PBS buffer. The fixed cells were stored at 4oC until FACS 
analysis. 
Sample analysis: The cell samples were analyzed on a BD FACSAria equipped with three solid state 
diode lasers: air-cooled CoherentTM SapphireTM solid-state diode laser (488 nm, 100 mW), air-cooled 
CoherentTM Yellow Green laser (561 nm, 100 mW), and an air-cooled CoherentTM Deep Blue laser 
(445 nm, 50 mW). The following filters were used: mCFP-A and PE-Cy5-A for analysis of emission 
from CFP and RFP, respectively. Signal compensation was performed according to manufacturer’s 
protocol (BD FACSAria II User’s Guide). For a control samples, strains without fluorescent proteins 
and two strains producing each fluorescent protein independently were used. Flow cytometry data 
sets were analyzed and interpreted by open source software (Flowing Software v2.5.0) developed 
by Perttu Terho. 
Genetic stability assay 
Triplicates of multi-copy plasmid strain and 10 copy strain (GAx10) expressing CFP and RFP were 
grown sequentially in 500 mL shake flasks containing 100 mL of SC (for plasmid strains SC-ura-his) 
medium. Cultures were incubated at 30oC with 150 rpm agitation, 2 mL samples for FACS analysis 
were collected once a day during mid-exponential growth phase and processed for storage using 
paraformaldehyde fixation method described above. Simultaneously, small volume of the each 
culture was inoculated to the new shake flask (starting OD600=0.01) with the fresh media. The cycle 
was repeated for five days, all accumulated samples were analyzed in flow cytometer at the same 
day using the settings described above. 
  
PhD Thesis, Tomas Strucko 
71 
 
References 
[1] G. Liti, D. M. Carter, A. M. Moses, J. Warringer, L. Parts, S. a James, R. P. Davey, I. N. Roberts, A. Burt, 
V. Koufopanou, I. J. Tsai, C. M. Bergman, D. Bensasson, M. J. T. O’Kelly, A. van Oudenaarden, D. B. H. 
Barton, E. Bailes, A. N. Nguyen, M. Jones, M. a Quail, I. Goodhead, S. Sims, F. Smith, A. Blomberg, R. 
Durbin, and E. J. Louis, “Population genomics of domestic and wild yeasts.,” Nature, vol. 458, no. 
7236, pp. 337–41, Mar. 2009. 
[2] T.-M. Lo, T. W. Suong, H. Ling, B. Chen, A. Kang, and M. W. Chang, “Microbial engineering strategies 
to improve cell viability for biochemical production.,” Biotechnol. Adv., pp. 1–12, Feb. 2013. 
[3] A. H. Kachroo, M. Jayaram, and P. a Rowley, “Metabolic engineering without plasmids.,” Nat. 
Biotechnol., vol. 27, no. 8, pp. 729–31, Aug. 2009. 
[4] P. M. Kilonzo, A. Margaritis, and M. a Bergougnou, “Plasmid stability and kinetics of continuous 
production of glucoamylase by recombinant Saccharomyces cerevisiae in an airlift bioreactor.,” J. Ind. 
Microbiol. Biotechnol., vol. 36, no. 9, pp. 1157–69, Sep. 2009. 
[5] Z. Zhang, M. Moo-Young, and Y. Chisti, “Plasmid stability in recombinant Saccharomyces cerevisiae.,” 
Biotechnol. Adv., vol. 14, no. 4, pp. 401–35, Jan. 1996. 
[6] P. Caunt, A. Impoolsup, and P. F. Greenfield, “Stability of recombinant plasmids in yeast,” J. 
Biotechnol., vol. 8, no. 3, pp. 173–192, Jul. 1988. 
[7] T. S. Lopes, J. Klootwijk, A. E. Veenstra, P. C. Van Der Aarb, H. Van, H. A. Rauc, and R. J. Planta, “High-
copy-number integration into the ribosomal DNA of Saccharomyces cerevisiae : a new vector,” Gene, 
vol. 79, pp. 199–206, 1989. 
[8] A. Sakai, Y. Shimizu, and F. Hishinuma, “Integration of heterologous genes into the chromosome of 
Saccharomyces cerevisiae using a delta sequence of yeast retrotransposon Ty,” Appl. Microbiol. …, 
pp. 302–306, 1990. 
[9] T. S. Lopes, I. J. de Wijs, S. I. Steenhauer, J. Verbakel, and R. J. Planta, “Factors affecting the mitotic 
stability of high-copy-number integration into the ribosomal DNA of Saccharomyces cerevisiae.,” 
Yeast, vol. 12, no. 5, pp. 467–77, Apr. 1996. 
[10] X. Wang, Z. Wang, and N. a Da Silva, “G418 Selection and stability of cloned genes integrated at 
chromosomal delta sequences of Saccharomyces cerevisiae.,” Biotechnol. Bioeng., vol. 49, no. 1, pp. 
45–51, Jan. 1996. 
[11] R. Parekh, M. Shaw, and K. Wittrup, “An integrating vector for tunable, high copy, stable integration 
into the dispersed Ty δ sites of Saccharomyces cerevisiae,” Biotechnol. Prog., 1996. 
[12] K. E. J. Tyo, P. K. Ajikumar, and G. Stephanopoulos, “Stabilized gene duplication enables long-term 
selection-free heterologous pathway expression.,” Nat. Biotechnol., vol. 27, no. 8, pp. 760–5, Aug. 
2009. 
[13] J. D. Boeke, H. Xu, and G. R. Fink, “A general method for the chromosomal amplification of genes in 
yeast.,” Science, vol. 239, no. 4837, pp. 280–2, Jan. 1988. 
[14] F. W. Lee and N. a Da Silva, “Ty1-mediated integration of expression cassettes: host strain effects, 
stability, and product synthesis.,” Biotechnol. Prog., vol. 12, no. 4, pp. 548–54, 1996. 
Gene amplification in Saccharomyces cerevisiae 
72 
 
[15] M. D. Mikkelsen, L. D. Buron, B. Salomonsen, C. E. Olsen, B. G. Hansen, U. H. Mortensen, and B. A. 
Halkier, “Microbial production of indolylglucosinolate through engineering of a multi-gene pathway 
in a versatile yeast expression platform.,” Metab. Eng., vol. 14, no. 2, pp. 104–11, Mar. 2012. 
[16] M. Lisby, U. H. Mortensen, and R. Rothstein, “Colocalization of multiple DNA double-strand breaks at 
a single Rad52 repair centre.,” Nat. Cell Biol., vol. 5, no. 6, pp. 572–7, Jun. 2003. 
[17] B. G. Hansen, B. Salomonsen, M. T. Nielsen, J. B. Nielsen, N. B. Hansen, K. F. Nielsen, T. B. Regueira, J. 
Nielsen, K. R. Patil, and U. H. Mortensen, “Versatile enzyme expression and characterization system 
for Aspergillus nidulans, with the Penicillium brevicompactum polyketide synthase gene from the 
mycophenolic acid gene cluster as a test case.,” Appl. Environ. Microbiol., vol. 77, no. 9, pp. 3044–51, 
May 2011. 
[18] J. Haber, “Partners and pathways: repairing a double-strand break,” Trends Genet., vol. 16, no. 6, pp. 
259–264, 2000. 
[19] F. Fang, K. Salmon, M. W. Y. Shen, K. A. Aeling, E. Ito, B. Irwin, U. P. C. Tran, G. W. Hatfield, N. A. Da 
Silva, and S. Sandmeyer, “A vector set for systematic metabolic engineering in Saccharomyces 
cerevisiae,” Yeast, vol. 3, no. October 2010, pp. 123–136, 2011. 
[20] A. S. Karim, K. a Curran, and H. S. Alper, “Characterization of plasmid burden and copy number in 
Saccharomyces cerevisiae for optimization of metabolic engineering applications.,” FEMS Yeast Res., 
vol. 13, no. 1, pp. 107–16, Feb. 2013. 
[21] N. B. Jensen, T. Strucko, K. R. Kildegaard, F. David, J. Maury, U. H. Mortensen, J. Förster, J. B. Nielsen, 
and I. Borodina, “EasyClone: method for iterative chromosomal integration of multiple genes in 
Saccharomyces cerevisiae,” FEMS Yeast Res., pp. DOI:10.1111/1567–1364.12118, 2013. 
[22] S. Wattanachaisaereekul, A. E. Lantz, M. L. Nielsen, O. S. Andresson, and J. Nielsen, “Optimization of 
heterologous production of the polyketide 6-MSA in Saccharomyces cerevisiae,” Biotechnol. Bioeng., 
vol. 97, no. 4, pp. 893–900, 2007. 
[23] F. Sherman, G. R. Fink, and J. B. Hicks, Laboratory course manual for methods in yeast genetics. Cold 
Spring Harbor Laboratory, 1986. 
[24] F. Geu-Flores, H. H. Nour-Eldin, M. T. Nielsen, and B. a Halkier, “USER fusion: a rapid and efficient 
method for simultaneous fusion and cloning of multiple PCR products.,” Nucleic Acids Res., vol. 35, 
no. 7, p. e55, Jan. 2007. 
[25] H. H. Nour-Eldin, B. G. Hansen, M. H. H. Nørholm, J. K. Jensen, and B. a Halkier, “Advancing uracil-
excision based cloning towards an ideal technique for cloning PCR fragments.,” Nucleic Acids Res., 
vol. 34, no. 18, p. e122, Jan. 2006. 
[26] M. H. H. Nørholm, “A mutant Pfu DNA polymerase designed for advanced uracil-excision DNA 
engineering.,” BMC Biotechnol., vol. 10, p. 21, Jan. 2010. 
[27] K. Entian and P. Kötter, “Yeast genetic strain and plasmid collections,” Methods Microbiol., vol. 36, 
no. 06, pp. 629–666, 2007. 
[28] D. a Treco and F. Winston, “Growth and manipulation of yeast.,” Curr. Protoc. Mol. Biol., vol. Chapter 
13, no. April, p. Unit 13.2, Apr. 2008. 
[29] R. J. D. R. Reid, M. Lisby, and R. Rothstein, “Cloning-free genome alterations in saccharomyces 
cereuisiae using adaptamer-mediated PCR,” Methods Enzymol., vol. 350, no. 1983, pp. 258–277, 
2002.  
PhD Thesis, Tomas Strucko 
73 
 
Supplementary Information 
Contents 
List of Supplementary Figures 
 
Figure S 4.1. Simplified representation of gene amplification (GA) cassette introductions into yeast 
genome. ........................................................................................................................................... 74 
Figure S 4.2. Construction of the GA strain collection. .................................................................... 75 
 
List of Supplementary Tables 
Table S 4.1. Primers for construction of GA cassette targeting vectors .......................................... 75 
Table S 4.2. List of the plasmids used and created in this study. .................................................... 77 
Table S 4.3. List of the strains used and constructed in this work................................................... 78 
Table S 4.4. The diploid strain construction containing various copy number of amplified CFP and 
RFP genes. ........................................................................................................................................ 79 
 
  
Gene amplification in Saccharomyces cerevisiae 
74 
 
Supplementary methods 
Gene amplification strains were constructed as shown in Figure S 4.1 and Figure S 4.2. 
 
 
Figure S 4.1. Simplified representation of gene amplification (GA) cassette introductions into yeast 
genome. Targeting substrates named “AUTUB” were generated by USER cloning, all required 
fragments (A, B – 500 bp sequences from Neurospora crassa, Ics – homing endonuclease (IsceI) 
recognition sequence, URA and RA3 – 3’ and 5’ truncated sequences (containing overlapping regions) 
of URA3 gene from Kluyveromyces lactis, respectively, and selection marker TRP1 were assembled into 
ten backbone vectors with specific targeting regions (UP and DW) into S. cerevisiae genome [15]. The 
GA cassettes are integrated by sequential transformations with AUTUB fragments and selecting the 
resulting strains on SC-trp medium. Subsequently, TRP1 marker is counter selected on SC-5-FAA 
medium where resulting strain harbors GA cassette with the functional URA3 gene. Once, the first GA 
cassette is integrated, the following transformation involves the integration of next AUTUB substrate. 
Cycle is repeated until required number of the GA cassettes is achieved. Red arrow shaped boxes 
represent essential genetic elements separating the integration sites [15]. 
 
TRP1IcsA RA3URAUP1 B DW1
IcsA URA3 B TRP1IcsA RA3URAUP2 B DW2
1. Selecting TRP transformants
2. Counter-selecting for trp on 5-FAA
3. Transforming with a new (AUTUB) 
cassette
Restored 
GA cassette
Substrate for GA cassette (AUTUB)
Continue building GA strain
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Figure S 4.2. Construction of the GA strain collection. The GA cassettes were integrated as previously 
described in Figure S 4.1. Three traits of strains were built simultaneously where evolution of 
amplification cassettes was done on three separate chromosomes X, XI and XII represented by rows 
of light grey boxes. The dark grey box depicts location where the GA cassette is integrated (the number 
of the column corresponds to the number of the integration site describe by Mikkelsen [15]). The blue 
box represents integration site characterized in this study. Next, opposite mating type strains 
undergone the series of crosses which resulted in construction of strains with up to ten GA cassettes. 
(*) represent a collection of strains with different mating types and selection markers. For the list of 
the strains refer to the Table S 4.3. 
 
Table S 4.1. Primers used in this study. 
Name Sequence 
A-fwd-U1A-adap CGTGCGAUAGGTGTAAAAGTAGGGAGCG 
A-rv TCACTGTCCGCTTGCAGAGT 
TADH1-fwd-A-adap ACTCTGCAAGCGGACAGTGAAGGGAAGAAAGCGAAAGGAG 
TADH1-Rv-U2-adap ATGCACGCGAUCGCACGCATTCGGGTCAAATCGTTGGTAGATACG 
C-fwd-U2-adap ATCGCGTGCAUTCCTATCTTATGCCTTCATTTC 
Ny-C-rv-B-adap CAGGAGTAGCGTACATAGGACAAAGCCCATTTCAATGAGC 
B-fwd TCCTATGTACGCTACTCCTG 
B-rv-U1B-adap CACGCGAUGAGGAGAGTGGATGGATAGTC 
Trp-L1-fwd AGTCAGTUTGGCTTAACTATGCGGCATC 
Trp-U3-rv CACGCGAUCCTTTGACGTTGGAGTCCAC 
Trp-U3-AsiSI-repeat-fwd CGTGCGAUGAATGCGTGCGATCGCGTGCATTCGTTTGTGCACTTGCCTA
TGC 
Trp-L1-repeat-rv AACTGACUCCTTTGACGTTGGAGTCCAC 
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
XI
X
XII
CEN.PK113-6B
Mata
CEN.PK110-4C CEN.PK110-4C
Matα Matα
*
*
*
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Name Sequence 
A-fwd-AsiSI/Bsm-adap cgtgcgaUAGGTGTAAAAGTAGGGAGCG 
A-fwd-AsiSI/Bsm-adap cgtgcgaUAGGTGTAAAAGTAGGGAGCG 
3-int-U1-adap acgaatgcUGAGCAATGAACCCAATAACGAAATC 
Trp1-up-fwd-U1-adap agcattcgUTGGCTTAACTATGCGGCATC 
Trp1-down-Rv-U2-adap agtagcatUCCTTTGACGTTGGAGTCCAC 
5-int-U2-adap aatgctacUCTTGACGTTCGTTCGACTGATGAGC 
B-rv-AsiSI/Bsm-cass-adap cacgcgaUGAGGAGAGTGGATGGATAGTC  
A-fwd-U3-adap agctacgUAGGTGTAAAAGTAGGGAGCG 
B-Rv-U4-adap agcaaggUGAGGAGAGTGGATGGATAGTC 
X-2-UP-rv-U3-adap acgtagcUACGTGACCACTTCGAGAGCA 
X-2-DW-fwd-U4-adap accttgcUCCTGCATAATCGGCCTCACA 
X-3-UP-rv-U3-adap acgtagcUAGTCTCGTATGTCGGCTCTC 
X-3-DW-fwd-U4-adap  accttgcUTGTGTCCGCGTTTCTAAGGC 
X-4-UP-rv-U3-adap acgtagcUCTGCTCTTGAATGGCGACAG 
X-4-DW-fwd-U4-adap  accttgcUAACAGGCATGGGAAGATTCGC 
XI-1-UP-rv-U3-adap acgtagcUGGCTGCAAAGAATCCTCCGAG 
XI-1-DW-fwd-U4-adap  accttgcUCTTCCACGGAATACCAAGCCC 
XI-2-UP-rv-U3-adap acgtagcUTGTGGAAGTTCATGGCAAACG 
XI-2-DW-fwd-U4-adap  accttgcUCACACGACTAGCGCTTTCAG 
XI-3-UP-rv-U3-adap acgtagcUAATCAGACGCACGCTTGGCG 
XI-3-DW-fwd-U4-adap  accttgcUTACGTGGATTGAGCCAGCAATAC 
XII-1-UP-rv-U3-adap acgtagcUGAAAGAACCGAACCGATGCCA 
XII-1-DW-fwd-U4-adap  accttgcUCTTCCCGTGAATCAACTGCAC 
XII-2-UP-rv-U3-adap acgtagcUCATAACGCGTTACACGGAAGG 
XII-2-DW-fwd-U4-adap  accttgcUCTACTATCGGCGACTCTCTC 
XII-3-UP-rv-U3-adap acgtagcUGTAATGCGAATGAGCAGGTAC 
XII-3-DW-fwd-U4-adap  accttgcUGGAAGTTTTGCAGATGAAGTGC 
XII-4-UP-rv-U3-adap acgtagcUCTATCGCTGAACAGGAACTTAAG 
XII-4-DW-fwd-U4-adap  accttgcUCCAACTTTGTACTATTCCTTCCC 
XII-5-UP-rv-U3-adap acgtagcUGCTGATGTGACACTGTGACAA 
XII-5-DW-fwd-U4-adap  accttgcUGCAACTCAGAAGTTTGACAGCAAG  
Verification primers 
XI-4A_UF GGGTTTAAUGTGAATACTGCACAAAATGAATAC 
XI-4A_UR GGACTTAAUCTTGAATCTTTTAAGCAGCCA 
XI-4A_GA_UR AcgtagcUCTTGAATCTTTTAAGCAGCCA 
XI-4_DF GGCATTAAUATCAAGAGAAACATTACAAGGC 
XI-4_GA_DF accttgcUATCAAGAGAAACATTACAAGGC 
XI-4A_DR GGTCTTAAUCTGTGGCAAGATTGGCAAG 
XI-4A_out_DR CAGCAACCAGAATATCTATGATG 
X-2-up-out-sq TGCGACAGAAGAAAGGGAAG 
X-3-up-out-sq TGACGAATCGTTAGGCACAG 
X-4-up-out-sq CTCACAAAGGGACGAATCCT 
Ny-XI-1-up-sq CTTAATGGGTAGTGCTTGACACG 
XI-2-up-out-sq CAATATCAGTGTGGTGAAC 
XI-4A_out_UF AAGCCCTATTATTGCTGACTTG 
XII-1-up-out-sq CTGGCAAGAGAACCACCAAT 
XII-2-up-out-sq CGAAGAAGGCCTCCAATTC 
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Name Sequence 
XII-3-up-out-sq TGGGCAGCCTTGAGTAAATC 
XII-4-up-out-sq GAACTGACGTCGAAGGCTCT 
C1_TADH1_F CTTGAGTAACTCTTTCCTGTAGGTC 
 
Table S 4.2. List of the plasmids used and created in this study. 
Name Description Reference 
Template plasmids   
pX-2 Backbone for targeting to X2 [15] 
pX-3 Backbone for targeting to X3 [15] 
pX-4 Backbone for targeting to X4 [15] 
pXI-1 Backbone for targeting to XI1 [15] 
pXI-2 Backbone for targeting to XI2 [15] 
pXI-4A Backbone for targeting to XI4A This study 
pXII-1 Backbone for targeting to XII1 [15] 
pXII-2 Backbone for targeting to XII2 [15] 
pXII-3 Backbone for targeting to XII3 [15] 
pXII-4 Backbone for targeting to XII4 [15] 
pWJ1042 TRP1 [29] 
pWJ1163 CFP [29] 
pWJ1350 RFP [16] 
Plasmids for GA cassette introduction 
pX2-AUTUB Targets GA cassette to X2 This study 
pX3-AUTUB Targets GA cassette to X3 This study 
pX4-AUTUB Targets GA cassette to X4 This study 
pXI1-AUTUB Targets GA cassette to XI1 This study 
pXI2-AUTUB Targets GA cassette to XI2 This study 
pXI4A-AUTUB Targets GA cassette to XI4 This study 
pXII1-AUTUB Targets GA cassette to XII1 This study 
pXII2-AUTUB Targets GA cassette to XII2 This study 
pXII3-AUTUB Targets GA cassette to XII3 This study 
pXII4-AUTUB Targets GA cassette to XII4 This study 
Plasmids targeting GA cassette 
pCSN AsiSI/Nb.BsmI cassette This study 
pCSN-CFP-RFP pTPI::CFP, pACT::RFP  This study 
Muticopy episomal plasmids 
pESC-HIS 2μ, HIS3 Agilent 
pESC-URA 2μ, URA3 Agilent 
pESC-his-RFP  pACT::RFP, 2μ This study 
pESC-ura-CFP pTPI::CFP, 2μ This study 
IsceI inductive plasmids 
pWJ1320 pGAL1:IsceI [16] 
pWJ1320-TRP1 pGAL1:IsceI This study 
pWJ1320-HIS3 pGAL1:IsceI This study 
pWJ1320-LEU2 pGAL1:IsceI This study 
pWJ1320-KanMX pGAL1:IsceI This study 
pWJ1320-HghMx pGAL1:IsceI This study 
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Table S 4.3. List of the strains used and constructed in this work. All strains are CEN.PK based, the 
genotype of all strains is MAL2-8C SUC2 + (definition in the table). The colored square in the grey 3X5 
array represents the location of the amplification cassette or amplified genes of interest, each column 
of the array corresponds to the number of the integration site described earlier by Mikkelsen et al. 
(2012). 
NAME 
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Copy 
No. 
Cassette 
location 
Description or 
Reference 
Starting strains 
CEN.PK110-4C  • •  • • ―  Peter Kötter [27] 
CEN.PK113-6B •   • • • ―  
Peter Kötter [27] 
CEN.PK113-1C  •  •  • • ―  
Peter Kötter [27] 
CEN.PK113-7A •  •    ―  
Peter Kötter [27] 
CEN.PK113-7B  •  • • • ―  
Peter Kötter [27] 
CEN.PK111-61A  • • •  • ―  
Peter Kötter [27] 
Gene amplification  strains 
GA-X-3  • •  •  1  Constr. by transformation 
GA-XI-1  • •  •  1  Constr. by transformation 
GA-XII-1 •   • •  1  Constr. by transformation 
GA-X-3+4  • •  •  2  Constr. by transformation 
GA-XI-1+2  • •  •  2  Constr. by transformation 
GA-XII-1+4 •   • •  2  Constr. by transformation 
CSN-9C  • •  •  2  Constructed by cross 
GA-X-3+4+2  • •  •  3  Constr. by transformation 
GA-XI-1+2+4a  • •  •  3  Constr. by transformation 
GA-XII-1+4+2 •   • •  3  Constr. by transformation 
GA-XII-1+4+2+3 •   • •  4  Constr. by transformation 
GAX4-2B; 3A  •  • •  4  Constructed by cross 
GAX4-2D •  •  •  4  Constructed by cross 
GAX4-3D  •   •  4  Constructed by cross 
GAX7-5C; 34D; 43C  •  • •  7  Constructed by cross 
GAX7-23A  • •  •  7  Constructed by cross 
GAX7-12B; 34C •  •  •  7  Constructed by cross 
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Copy 
No. 
Cassette 
location 
Description or 
Reference 
GAX7-5D •  • • •  7  Constructed by cross 
GAX10-1C; 4A; 9A •  •  •  10  Constructed by cross 
GAX10-2B; 4B; 9D  •  • •  10  Constructed by cross 
GAX10-7A  • •  •  10  Constructed by cross 
GAX10-4D •  • • •  10  Constructed by cross 
A proof of concept strains with amplified CFP and RFP genes 
H0+FP (113-1C) •  •  • • ―  Negative control 
H1+CFP •  •  • • 1  One color control CFP 
H1+RFP •  •  • • 1  One color control RFP 
GAX7-34C+FP unamp. •  •  • • 1  Not amplified 7 copy strain 
CSN-9C+FP; 1A; 2A •  •  • • 2  A proof-of-concept strain 
GAX4-1A-FP •  •  • • 4  A proof-of-concept strain 
GAX7-5C+FP; 1D; 2C  •  • • • 7  A proof-of-concept strain 
GAX7-34C+FP; 1A; 4A •  •  • • 7  A proof-of-concept strain 
GAX10-1C+FP;1A; 2B •  •  • • 10  A proof-of-concept strain 
GAX10-2B+FP; 2; 5  •  • • • 10  A proof-of-concept strain 
H2u-FP (113-1C) •    •  ? Plasmids 
Multi copy plasmid expression 
(pESC-his-RFP, pESC-ura-CFP) 
 
Table S 4.4. The diploid strain construction containing various copy number of amplified CFP and RFP 
genes. 
Name Mat a strain Mat alpha strain Copies Comments 
D0-FP CEN.PK113-7A CenPK113-7B 0 Non fluorescence control 
D4-FP GAx4-FP-1A CEN.PK113-7B 4  X  
D10-FP GAX10-1C+FP CEN.PK113-7B 10  X  
D14-FP GAX7-34C+FP GAX7-5C+FP 14  X  
D20-FP-A GAX10-1C+FP, 1A GAX10-2B+FP, 2 20  X  
D20-FP-B GAX10-1C+FP, 2B GAX10-2B+FP, 5 20  X  
D2u-FP CEN.PK113-1C CenPK111-61A 2μ 
Harbors two plasmids pESC-his-
RFP and pESC-ura-CFP 
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Chapter 5 
5. Balancing vanillin production in yeast 
 
 
Title4 
Balancing the heterologous biosynthetic pathway for improved production of Vanillin-β-
glucoside in Saccharomyces cerevisiae 
 
 
Abstract 
It was previously demonstrated that one of the most important aroma compounds – vanillin can be 
produced in baker’s yeast in its glycosylated form – vanillin β-D-glucoside. Nevertheless, the 
amount of vanillin-β-glucoside obtained by the engineered cell factory was insufficient for 
commercial production. Metabolic engineering efforts to enhance the production were limited by 
the inherent capacity of the heterologous pathway to accommodate efficient conversion towards 
vanillin-β-glucoside. To identify the rate limiting steps of the vanillin-β-glucoside biosynthesis, we 
have systematically increased the dosage of each gene of the integrated pathway. Based on the 
experimental observation, subsequent overexpression of the gene combinations was performed. 
The most productive strain, combining the amplification of last two steps of the integrated 
biosynthetic pathway, conferred an approximately 6-fold increase in vanillin-β-glucoside levels. 
Moreover the accumulation of several intermediates was substantially decreased. Lastly, the data 
obtained in this study will enable further development of the improved vanillin-β-glucoside 
production in S. cerevisiae. 
 
Keywords: Yeast; Gene Amplification; Vanillin-β-glucoside; Pathway optimization 
  
                                                          
4 Manuscript in preparation 
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Introduction 
Vanillin is one of the most popular aromatic flavor and fragrance compounds, primarily used in food 
and perfumes and to some extent also for animal feed, tobacco and as precursor in the 
pharmaceutical industry. Originally, vanillin was extracted from the cured pods of the vanilla orchid, 
Vanilla planifolia, however, nowadays only about 0.25 % of the global annual market of 
approximately 16000 tons comes from the vanilla orchid. The remaining portion is mainly produced 
by chemical synthesis from lignin or fossil hydrocarbons such as guaiacol [1], [2]. As fossil based 
natural resources are decreasing rapidly and the need for “natural” vanillin is increasing, 
biosustainable and more environmentally friendly biotechnological routes were implemented. 
Those are mainly based on bioconversion of plant secondary metabolites (e.g. eugenol and ferulic 
acid) by various bacteria and fungi, and are summarized in reviews [3] and [4]. As an attractive 
alternative, Hansen and co-workers have assembled the de novo metabolic pathway for vanillin-β-
glucoside (VG) production in yeast using glucose as a substrate [1]. VG is less toxic and more soluble 
than vanillin and is the form which naturally accumulates in the vanilla pod [2]. The engineered 
pathway involves the incorporation of five heterologous genes from several different and 
evolutionary distant organisms (see Figure 5.1). However, the amount of VG produced in the S. 
cerevisiae strain was insufficient for commercial production.  In addition to that, subsequent studies 
on the VG biosynthetic pathway revealed significant accumulation of several intermediates, which, 
in fact, decreased the possible final yields of VG dramatically [5], [6]. Moreover, some 
intermediates, especially aromatic aldehydes, produced by the unbalanced heterologous pathway 
are toxic and can most likely compromise cell growth [1], [7]. 
Metabolic engineering has shown to be a successful tool in development and improvement of 
microbial cell factories for production of heterologous secondary metabolites [8]–[10]. Several 
approaches involving global and local metabolic engineering strategies have been considered in 
order to increase the VG production in S. cerevisiae. In the first case, the yeast central metabolism 
was reengineered to boost the supply of cofactors (in particular, ATP and NADPH) used by enzymes 
of the VG pathway, which led to fivefold improvement in production [5]. Subsequently, the de novo 
VG pathway was engineered by integrating an additional copy of either ACAR or HsOMT genes. 
While overexpressed ACAR had no effect on the VG metabolic profile, the additional copy of HsOMT 
resulted in slightly improved VG production by 30 % [6]. However, the problem of the accumulation 
of intermediates remained, indicating the presence of unsolved metabolic bottlenecks in the VG 
biosynthesis. Therefore, further improvements of the VG production in a yeast cell factory had to 
be considered. 
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The aim of this work was to systematically overexpress each VG pathway gene and several gene 
pair combinations in order to pinpoint metabolic bottlenecks in the biosynthesis of the VG. To 
achieve stable and controlled overexpression of the gene/s of interest, we have implemented a 
recently developed gene amplification (GA) system described in Chapter 4. Here, overexpression 
was assured by eight copies of the chromosomally integrated gene/s of interest. In addition, data 
obtained in this experiment provided a better understanding of the VG pathway dynamics which 
may give clues for further development of a yeast cell factory for VG production. Nonetheless, in 
this paper we have also demonstrated the first successful application of the GA for overexpression 
and manipulation of a complex heterologous pathway in yeast. 
 
 
 
Figure 5.1. Simplified representation of the vanillin-β-glucoside (VG) production in S. cerevisiae. 3-DHS 
– 3-dehydroshikimic acid, PAC – protocatechuic acid, PAL – protocatechuic aldehyde, VAC – vanillic 
acid, VAN – vanillin, VG – vanillin-β-glucoside. Black thick arrows with numbered circles represent 
enzymatic reactions by heterologous enzymes: 1) 3DSD – 3-dehydroshikimate dehydratase 
(Podospora anserina), 2) ACAR – aromatic carboxylic acid reductase (Neurospora sp.), 3) PPTase (EntD) 
– phosphopantetheine transferase (Escherichia coli), 4) HsOMT – O-methyltransferase (Homo sapiens) 
and 5) UGT (UGT72E2) – UDP-glycosyltransferase (Arabidopsis thaliana). 
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Materials and Methods 
Molecular cloning procedures 
All molecular cloning procedures were done by applying the uracil-speciﬁc excision reagent 
(USER™) as previously described in [11], [12]. The genes constituting the de novo VG pathway and 
the promoters were amplified by PCR from the appropriate vector templates using PfuX7 
polymerase developed by Nørholm et al. [13]. The pathway genes and promoters were assembled 
into the vector pCSN specially designed for the gene amplification system (GA) [Chapter 4]. A 
number of plasmids carrying single ORFs or their combinations were generated (see Table 5.1). 
Finally, all plasmids were validated by DNA sequencing (StarSEQ® GmbH, Germany).The full list of 
the plasmids used and constructed in this study is shown in the Table 5.1. The schematic plasmid 
cloning procedure is explained in SI Figure S 5.3. 
Table 5.1. List of plasmids used in this study. 
Name Description Reference 
pCSN-01 For amplification of 3DSD  This study 
pCSN-20 For amplification of ACAR This study 
pCSN-03 For amplification of EntD This study 
pCSN-04 For amplification of HsOMT This study 
pCSN-50 For amplification of UGT72E2 This study 
pCSN-23 For amplification of ACAR and EntD This study 
pCSN-24 For amplification of ACAR and HsOMT This study 
pCSN-25 For amplification of ACAR and UGT72E2 This study 
pCSN-54 For amplification of UGT72E2 and HsOMT This study 
pCSN Backbone vector for amplification purposes Chapter 4 
pWJ1320-TRP Inductive plasmid with Isce-I endonuclease Chapter 4 
pSP-G2 Template for bidirectional pPGK1/pTEF1 promoter Partow et al. [14] 
pJH500 Template for 3DSD gene Hansen et al. [1] 
pJH674 Template for ACAR gene Hansen et al. [1] 
pJH589 Template for EntD gene Hansen et al. [1] 
pJH543 Template for HsOMT gene Hansen et al. [1] 
pJH665 Template for UGT72E2 gene Hansen et al. [1] 
pUG6 Template for KanMX Güldener et al [15] 
pSH47 Plasmid containing Cre recombinase Güldener et al [15] 
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Table 5.2. List of primers used in this study. All sequences are presented in 5’ to 3’ direction, 
standard capital letter are gene specific sequences,  standard underline letters represent USER 
specific tails, italics underlined letters show targeting sequences for the  appropriate gene 
deletions, and standard bold letters represents translational enhancer sequence [16], [17]. 
Name Sequence 
PGK_R- ACCCGTTGAUGCCGCTTGTTTTATATTTGTTG 
TEF_F+ CGTGCGAUGCCGCACACACCATAGCTTC 
TEF_R+ ACGTATCGCUGTGAGTCGTATTACGGATCCTTG 
DSD_F+ AGCGATACGUAAAAATGCCTTCCAAACTCGCC 
DSD_R+ CACGCGAUTTACAAAGCCGCTGACAGC 
ACAR_F- ATCAACGGGUAAAAATGGCTGTTGATTCACCAGATG 
ACAR_R- CGTGCGAUCTTATAACAATTGTAACAATTCCAAATC 
OMT_F+ AGCGATACGUAAAAATGGGTGACACTAAGGAGCAA 
OMT_R+ CACGCGAUCTTATGGACCAGCTTCAGAACC 
PPT1_F+ AGCGATACGUAAAAATGGTCGATATGAAAACTACGC 
PPT1_R+ CACGCGAUTTAATCGTGTTGGCACAGC 
UGT1_F- ATCAACGGGUAAAAATGCATATCACAAAACCACACG 
UGT1_R- CGTGCGAUACTAGGCACCACGTGACAAGTC 
BGL1_del_F ATTTTTTGTTTACTTTCTTTTTCTAGTTAATTACCAACTAAACTTCGTACGCTGCAGGTC 
BGL1_del_R CATTAGAAAATTCAGCTAAAATGAGCGGACTGAGGGCGACTAGTGGATCTGATATCACCTA 
ADH6_del_F GAGGAAGAAATTCAACACAACAACAAGAAAAGCCAAAATCCTTCGTACGCTGCAGGTC 
ADH6_del_R GTTAAAAAGAAAGGAGCTACATTTATCAAGAGCTTGACAACTAGTGGATCTGATATCACCTA 
 
Strain construction 
The genotype and source of the strains used in this study is given Table 5.3. The yeast constructs 
used in this study were generated by three different techniques; first, by using a high efficiency 
genetic transformation method described by Gietz et al. [18],second, implementing a novel GA 
technique described by in Chapter 4, and third, by sexual mating following the protocol explained 
in [19]. 
Prior to construction of the strains with increased VG pathway gene copy number, several 
additional yeast strains had to be developed. The strain TS086 with double gene deletion (Δadh6 
and Δbgl1) was generated using a method described by Güldener et al [15]. For this reason, the 
strain CEN.PK110-7C was consecutively transformed with PCR fragments carrying the loxP-KanMX-
loxP cassette amplified form plasmid pUG6 with the primers containing 40 nt long targeting 
sequences. The transformants were selected on YPD medium supplemented with G418 (sigma). In 
between the transformations, the KanMX marker was removed by expressing the Cre recombinase 
from the vector pSH47 [15]. 
Haploid strains (TS152 and TS155) containing the full VG biosynthetic pathway were obtained in a 
previous study by sexual cross  of two CEN.PK110-16D and C-VG-aux strains, followed by 
sporulation and tetrad dissection (Chapter 6). 
Balancing vanillin production in yeast 
86 
 
In this study the GA strain GAX7-34C (with integration capacity for seven copies) was used for 
overexpression purposes. In order for the GA to be compatible with the de novo VG pathway, a 
double gene deletion (Δadh6 and Δbgl1) had to be introduced, which was done by crossing the 
strain GAX7-34C with TS086. The resulted diploid was then sporulated and after tetrad dissection 
the strain TS160 was selected for further genetic manipulations. 
The haploid strains containing seven copies of the integrated gene of interest (GOI) were 
constructed in an identical manner for all combinations used in this study. The TS160 strain was 
transformed with a linear fragment obtained by digesting pCSN-## with NotI endonuclease 
(Fermentas-Thermo Fischer Scientific). Resulting transformants were selected and streak purified 
on SC-trp plates. Next, the TRP1 marker was eliminated by counter-selective plating on SC-5-FAA 
medium. Afterwards, these strains were transformed with the plasmid pWJ1320-TRP and 
subsequently selected on SC-trp plates. In order to induce the gene amplification process, strains 
with the pWJ1320-TRP plasmid were replica-plated on SCgal-trp. Finally, strains carrying seven 
copies of the GOI were selected by several consecutive replica-plating events using different 
selective media (the detailed gene amplification method is described in Chapter 4).  
To analyze the effect of increased dosage of the VG pathway genes, diploid strains were 
constructed. This was done by mating haploid strains with the amplified GOIs with the haploid strain 
with the full VG biosynthetic pathway (Table 5.4). Diploid cells were selected and streak purified on 
SC-his-ura plates. 
Finally, all gene targeting and gene amplification events were validated by diagnostic PCR using 
specially designed primer pairs (SI Table S 5.2)  
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Table 5.3. List of the haploid yeast strains used in this study. 
Name Genotype Reference 
CEN.PK110-7C MATα MAL2-8C SUC2 trp1-289 ura3-52 Peter Kötter5 
CEN.PK110-16D MATα MAL2-8C SUC2 trp1-289 Peter Kötter1 
GAX7-34C 
MATa MAL2-8C SUC2 his3Δ1 trp1-289 ura3-52 (X-2; 
X-3; X-4; XII-1; XII-2; XII-3; XII-4::(A-Ics-URA3-B)) 
Chapter 4 
C-VG-aux 
MATa SUC2 gal2 mal mel ura3-52 XII2(pTEF1-
HsOMT, pPGK1-UGT) XII1(pTEF1-PPT, pPGK1-ACAR) 
XII5(pTEF1-3DSD) Δbgl1::loxP Δadh6::KanMX 
Chapter 6 
TS152 
MATa MAL2-8C SUC2 ura3-52 his3Δ XII2(pTEF1-
HsOMT, pPGK1-UGT) XII1(pTEF1-PPT, pPGK1-ACAR) 
XII5(pTEF1-3DSD) Δbgl1::loxP Δadh6::KanMX 
Chapter 6 
TS155 
MATα MAL2-8C SUC2 ura3-52 his3Δ XII2(pTEF1-
HsOMT, pPGK1-UGT) XII1(pTEF1-PPT, pPGK1-ACAR) 
XII5(pTEF1-3DSD) Δbgl1::loxP Δadh6::KanMX 
Chapter 6 
TS086 
MATα MAL2-8C SUC2  trp1-289 ura3-52 Δbgl1::loxP 
Δadh6::KanMX 
This study 
TS160 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-Ics-URA3-B)) Δbgl1::loxP 
Δadh6::KanMX 
This study 
TS192,TS193 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-pTEF1-3DSD-B)) 
Δbgl1::loxP Δadh6::KanMX 
This study 
TS199, TS201 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-pPGK1-ACAR-B)) 
Δbgl1::loxP Δadh6::KanMX 
This study 
TS188, TS189 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-pTEF1-PPT-B)) 
Δbgl1::loxP Δadh6::KanMX 
This study 
TS182, TS183 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-pTEF1-HsOMT-B)) 
Δbgl1::loxP Δadh6::KanMX 
This study 
TS185, TS186 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-pPGK1-UGT-B)) 
Δbgl1::loxP Δadh6::KanMX 
This study 
TS186, TS187 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-pPGK1-ACAR,pTEF1-
PPT-B)) Δbgl1::loxP Δadh6::KanMX 
This study 
TS250, TS251 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::( A-pPGK1-ACAR,pTEF1-
HsOMT-B)) Δbgl1::loxP Δadh6::KanMX 
This study 
TS252, TS253 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::( A-pPGK1-ACAR,pTEF1-
UGT-B)) Δbgl1::loxP Δadh6::KanMX 
This study 
TS238, TS239 
MATα MAL2-8C SUC2 trp1-289 ura3-52 (X-2; X-3; X-
4; XII-1; XII-2; XII-3; XII-4::(A-pPGK1-UGT,pTEF1-
HsOMT-B)) Δbgl1::loxP Δadh6::KanMX 
This study 
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Table 5.4. Construction of diploid strains with amplified VG pathway genes. 
Diploid* Description Haploid 1 Haploid 2 
D-VG-00 Reference strain, one copy of VG pathway TS086 TS152 
D-VG-01 VG pathway with o/e 3DSD TS192, TS193 TS152 
D-VG-20 VG pathway with o/e ACAR TS199, TS200 TS152 
D-VG-03 VG pathway with o/e EntD TS188, TS189 TS152 
D-VG-04 VG pathway with o/e HsOMT TS182, TS183 TS152 
D-VG-50 VG pathway with o/e UGT72E2 TS185, TS186 TS152 
D-VG-23 VG pathway with o/e ACAR and EntD TS186, TS187 TS152 
D-VG-24 VG pathway with o/e ACAR and HsOMT TS250, TS251 TS152 
D-VG-25 VG pathway with o/e ACAR and UGT72E2 TS252, TS253 TS152 
D-VG-54 VG pathway with o/e UGT72E2 and HsOMT TS238, TS239 TS152 
D-VG-VG Two copies of VG pathway TS155 TS152 
* – represents two diploid strains as a results of two variants of haploid 1, which were used as a biological replicas in 
this experiment. 
 
Media  
To propagate Escherichia coli DH5α strains harboring the cloned plasmids, lysogeny broth (LB) [20] 
supplemented with 100 mg/L of ampicillin (Sigma) was used. 
For genetic manipulations of yeast all media were prepared as previously described by Sherman et 
al. [21], with minor modifications of the synthetic complete (SC) medium where the leucine 
concentration was doubled to 60mg/L. All yeast transformants with gene integrations or plasmids 
were selected on synthetic complete media missing tryptophan (SC-trp). In order to remove the 
TRP1 marker, yeast strains were grown on SC medium plates supplemented with 500 mg/L 5-
fluoroanthranilic acid (5-FAA). 
For gene amplification purposes SC-trp medium was modified by using 2% galactose instead of 
glucose as a carbon source (SCgal-trp). Strains with amplified VG pathway genes were selected on 
SC medium containing 30 mg/L uracil and 740mg/L 5-fluoroorotic acid (5-FOA) (Sigma), while SC 
medium lacking uracil SC-ura was used as a negative control. 
Yeast Extract Peptone Dextrose (YPD) medium plates were used for storage and propagation of the 
constructed yeast strains as well as for sexual crossing purposes. The medium composition was as 
follows: 10 g/L of yeast extract, 20 g/L of peptone and 20 g/L of glucose and 20 g/L of agar. For 
selection and propagation of engineered diploid strains with different combinations of amplified 
the VG pathway genes synthetic medium lacking histidine and uracil (SC-his-ura) was used. 
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For shake flask experiments a defined minimal medium previously described by Verduyn et al. [22] 
with 20 g/L glucose as a carbon source was used. The medium is composed of: 7.5 g/L (NH4)2SO4, 3 
g/L KH2PO4, 0.75 g/L Mg2SO4, 1.5 mL/L trace metal solution, 1.5 mL/L vitamins solution, 0.05 mL/L 
antifoam 204 (Sigma- Aldrich A-8311). The trace metal solution contains 3 g/L FeSO4∙7H2O, 4.5 g/L 
ZnSO4∙7H2O, 4.5 g/L CaCl2∙6H2O, 0.84 g/L MnCl2∙2H2O, 0.3 g/L CoCl2∙6H2O, 0.3 g/L CuSO4∙5H2O, 0.4 
g/L NaMoO4∙2H2O, 1 g/L H3BO3, 0.1 g/L KI and 15 g/L Na2EDTA∙2H2O. The vitamin solution includes 
50 mg/L d-biotin, 200 mg/L para-amino benzoic acid, 1.0 g/L nicotinic acid, 1.0 g/L Ca-pantothenate, 
1.0 g/L pyridoxine HCL, 1.0 g/L thiamine HCl and 25 mg/L minositol. To maintain a constant pH of 
around 5.6 the medium was buffered by adding 10 g/L succinic acid and 6 g/L NaOH. Glucose was 
autoclaved separately and the vitamin solutions was sterile filtered (pore size 0.2 μm Ministart®-
Plus, Sartorius AG, Germany) and both added after autoclavation. 
Shake flask cultivations 
Pre-inocula of the engineered yeast diploid strains were incubated O/N in 3 mL of SC-his-ura 
medium with constant agitation of 150 rpm at 30°C. The shake-flask cultivations were performed 
in 500 mL flasks containing 50 mL of buffered mineral medium (pH=5.6), which were incubated at 
30°C on an orbital shaker set to 150 rpm. The flasks were inoculated with an initial OD600 =0.01 and 
sampled at two time points of 48h and 60h. For comparison purposes only the final time point 
samples were considered. 
Cell dry weight measurements 
The biomass concentration was determined by cell dry-weight (DW) measurements using 
polyethersulfone (PES) filters with a pore size of 0.45 μm Montamil® (Membrane Solutions, LLC). 
The filters were pre-dried in a microwave oven at 150 W and weighed. 5 mL of cultivation broth 
was filtered and then washed with three volumes of distilled water. Finally, the filters with biomass 
were dried in the microwave oven at 150 W for 20 min and cooled down in a desiccator for a 
minimum of 2 hours. Finally, the filters with biomass were weighed and the cell DW was determined 
[23]. 
Extracellular metabolite measurements 
Samples for the quantification of VG and its pathway catabolites were prepared as follows: 500 μL 
of fermentation broth and 500 μL of 96% EtOH were carefully mixed by vortexing and centrifuged 
at 12000xg for 2 min, the supernatant was transferred to a new tube and stored at -20 oC until 
further analysis. Extracellular vanillin β-D-glucoside (VG), vanillin (VAN), protocatechuic acid (PAC), 
protocatechuic aldehyde (PAL) and vanillic acid (VAC) were quantified using Agilent 1100 series 
equipment with a Synergi Polar-RP 150*2 mm 4u column (Phenomenex). A gradient of acetonitrile 
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(ACN) with 1% tetra-fluoroacetic acid (TFA) and water with 1% TFA at a constant flow rate of 0.5 
mL/min was used as mobile phase. The elution profile was as follows: 5% ACN for 1 min, 5% ACN 
to 30% ACN for 8 min, 30% ACN to 100% ACN for 1 min, 100% ACN for 1 minute, 100% ACN to 5% 
ACN for 3 min. The column was kept at 40 oC and metabolite detection was performed using a UV 
diode-array detector set to 230 and 280 nm. 
 
 
Results 
Gene overexpression strategy  
In this work, we decided to manipulate the dosage of the heterologous VG pathway genes by 
implementing the gene amplification (GA) system described in Chapter 4. The system relies on the 
use of specially designed yeast strains with predefined overexpression capacity, where gene 
amplification occurs in controlled manner by genomic integration into well characterized loci. As a 
starting point we have chosen the GA strain with an amplification capacity of seven copies, with 
three integration sites on chromosome X and four sites on XII [24].  
To shorten the strain construction time, we have setup a fast and combinatorial method based on 
the use of yeast diploid cells (see Figure 5.2). First, the library of haploid strains carrying different 
parts of the amplified VG pathway was created (Table 5.3). Later, each of these haploids was 
independently crossed to the haploid of opposite mating type with the fully functional VG pathway 
resulting in the collection of prototrophic diploids carrying the VG pathway and seven additional 
copies of gene/s of the interest (GOI) (see Materials and Methods). In total more than 9x2 unique 
diploid strains were constructed for the VG pathway titration analysis (see Table 5.4).  
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Figure 5.2. Schematic representation of the strategy used for overexpression of vanillin-β-glucoside 
pathway genes; GOI – gene/s of interest, VG – vanillin-β-glucoside. 
 
Metabolic profile of the reference strain for VG production 
All previous studies involving VG production in yeast were performed in haploid cells [5], [6]. 
However, diploid yeast are known to a have larger cell volume and the double amount of genetic 
material which might result in different VG production profile compared to the one obtained in 
haploid cells. Hence, to evaluate the effects of increased gene dosage of VG pathway genes, a 
proper diploid reference strain had to be developed. This was done by mating two specially 
constructed haploid strains (carrying double deletion of adh6 and exg1), where only one of the 
mates had the VG pathway resulting in the heterozygous diploid strain D-VG-00 (see Materials and 
Methods and Table 5.4). The metabolic profile of the reference strain is shown in Figure 5.3, which 
is based on C-mol(metabolite)/C-mol(biomass) and the sum of all metabolites is normalized to  1 
(arbitrary unit). The most pronounced metabolite appeared to be PAC (≈40 % of total metabolites), 
which is in line with previous observations by Brochado [5], [6]. The distribution of other VG 
pathway metabolites was somewhat correlated to the results obtained in Chapter 6 and was as 
follows: PAL ≈2 %, VAC ≈24 %, VAL ≈5 % and VG ≈ 18 %. In addition to that, small quantities of 
isovanillin (IVAN) and isovanillic acid (IVAC) were detected (see SI Table S 5.5). To reduce the 
complexity of data interpretation, the side products IVAN and IVAC, representing less than 10% of 
the total metabolites, were neglected. 
Overexpressing ACAR and its activating PPTase 
Accumulation of the intermediates PAC and VAC in the reference strain D-VG-00 seems to be 
caused by limited activity of the ACAR. It is well known that ACARs as well as the related fatty acid 
synthetases, polyketide synthetases and non-ribosomal peptide synthetases require specific 
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activation by phosphopantetheinylation by PPTase enzymes [25], [26]. In this study, ACAR was 
activated by heterologous expression of bacterial PPTase EntD, which was found to perform the 
best compared to other PPTases tested [27]. Both, ACAR and EntD originate from different host 
organisms, and nothing is known about efficiency and interaction of those enzymes in S. cerevisiae. 
Thus, to investigate if the bottlenecks (PAC reduction to PAL and/or VAC reduction to VAN) are 
caused by low activity of ACAR or inefficient ACAR activation by PPTase, we constructed three 
different strains D-VG-20, D-VG-23 and D-VG-03 with overexpressed ACAR, ACAR+PPTase and 
PPTase, respectively. The distribution of the VG pathway metabolites produced by both D-VG-20 
and D-VG-23 strains appeared to be very similar. In both strains, elevated ACAR activity resulted in 
10 fold increased production of PAL and absent or significantly decreased accumulation (2.3 fold) 
of VAC (Figure 5.3). The VG production also improved by 2.1 fold in D-VG-20 and 2.7 fold in D-VG-
23. As expected, experimental results of the PPTase overexpression, did not show significant 
changes in PAL and VAC levels. 
Independent overexpression of OMT or UGT leads to a minor increase in VG production 
A previous study had suggested OMT as a limiting step in VG production [6]. To confirm this, we 
have decided to check the effect of overexpressed OMT in the diploid cell based system. To our 
surprise, increased OMT dosage was not reflected in the metabolic profile of the D-VG-04 strain 
and minor improvement (1.6 fold) in VG production was detected (Figure 5.3). The distribution of 
the rest of the intermediates of the VG pathway were found to be similar to the ones found in the 
reference strain D-VG-00 (see also Table S 5.5). 
The absence of VAN in the cultivation broth of the reference strain indicates that the UGT enzyme 
is capable to efficiently glycosylate VAN. However, we decided to test if overexpressed UGT would 
improve the flux towards VG production by creating metabolic “sink” by fast turnover of VAN to 
VG. The strain D-VG-50 indeed showed a 1.7 fold improvement in VG production (Figure 5.3). It can 
also be seen, that efficient VAN glycosylation made the VAC reduction by ACAR and PAL methylation 
by OMT more favorable, as the accumulated VAC and PAL were approximately 2 fold decreased. In 
addition to that, VAN reduction by the remaining activities of native yeast AHDs was outcompeted 
by overexpressed UGT, and therefore VAL was present in barely detectable quantities (Table S 5.5).  
Coupled gene overexpression displays the highest impact on VG production 
In addition to independent ACAR, OMT and UGT overexpression, we investigated the effect of 
combined overexpression of those genes. For this we constructed the strains D-VG-24, D-VG-25 and 
D-VG-54 harboring eight copies of ACAR+OMT, ACAR+UGT and UGT+OMT, respectively (Table 5.4). 
Notable changes in metabolic profiles of all three strains were observed (Figure 5.3). The strain D-
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VG-54 displayed remarkably higher (4.1 fold compared to the reference) amount of produced VG, 
however no changes were observed for the remaining VG catabolites.  On the other hand, the 
strains D-VG-24 and D-VG-25 had very similar PAL and VAC production profiles compared to the 
ones with overexpressed ACAR (D-VG-20 and D-VG-23). In both cases increased amount of PAL and 
decreased amount of VAC was observed see Figure 5.3. However, simultaneous overexpression of 
VG pathway steps 2 and 3 (Figure 5.1) in the strain D-VG-24 resulted in significant accumulation of 
VAN which in fact was a reason for increased amounts of VAL. The latter problem (accumulation of 
VAN) was absent in the strain D-VG-25 where amplified UGT helped to efficiently glycosylate VAN. 
Lastly, the production of VG was improved by four-fold in the D-VG-24 strain and as high as six-fold 
in the D-VG-25 strain. 
Overexpressed 3DSD leads to increased flux towards VG pathway 
In the VG pathway, PAC is formed by dehydration of the native precursor 3-DHS in a reaction 
catalyzed by 3DSD. Despite the fact that PAC is the most abundant intermediate, we decided to 
check if increased activity of the 3DSD would increase the carbon flux towards the heterologous 
pathway. Indeed, the strain D-VG-01 carrying eight copies of the 3DSD gene produced 4.5 fold larger 
amount of PAC compared to the reference D-VG-00 (Figure 5.3). As expected, due to the basal 
activity of the remaining VG pathway enzymes no significant improvement was detected for the 
final product VG. However, overproduced PAC resulted in a slight increase of the products VAC and 
PAL of the following enzymatic steps carried by OMT and ACAR. Most importantly, the total amount 
of carbon redirected towards the de novo pathway increased by a factor of 2.7 (Figure 5.3), 
indicating highly improved potential for de novo production of VG.  
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Figure 5.3 Results from the VG pathway gene overexpression. A) Represents the fold change of VG 
pathway metabolites in the strains with overexpressed gene/s (represented by black squares) with 
respect to the reference strain D-VG-00. *-for VAN metabolite, D-VG-20 was used as a reference. B) 
Metabolite distribution of the strains with overexpressed VG pathway genes, represented as c-
mol(metabolite)/c-mol(biomass) and normalized to 1 according to the reference strain D-VG-00. 
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Discussion 
Metabolic engineering of the de novo VG pathway was previously done by Brochado et al [6]. 
However, only two proteins of the pathway ACAR and OMT were overexpressed by genomic 
integration of an additional copy of either gene. In this study we have systematically overexpressed 
all VG pathway genes and several gene combinations by eight chromosomally integrated copies. 
We have demonstrated that by the increased dosage of different VG pathway genes it was possible 
to significantly improve the biosynthesis of VG and in some cases to reduce or eliminate the 
accumulation of unwanted intermediates (see Figure 5.3). It is worth to mention that, this study 
was based on an assumption that necessary cofactors (ATP, NADPH, SAM and UDP-Glucose) 
associated with the VG pathway enzymes are present/available in sufficient amounts and, 
therefore, previously described global metabolic engineering targets for increasing of the cofactor 
pools [5] were not pursued.  
It appears that the de novo biosynthesis of VG in yeast is hampered by the wide substrate specificity 
of the heterologous pathway enzymes [1], creating two possible biosynthetic routes represented 
in steps 2 and 3 in Figure 5.1, which was confirmed by the metabolic profile of the reference strain 
D-VG-00. In fact, a significant percentage of accumulated PAC and VAC suggested that ACAR might 
be the primary bottleneck in the synthesis of VG. As mentioned earlier in this text, the ACAR in yeast 
is being expressed in the form of an apo-protein which requires posttranslational activation by 
PPTase [26]. In this work we have experimentally demonstrated that the ACAR protein was 
efficiently activated by phosphopantetheinylation, as the overexpressed PPTase did not affect the 
metabolite distribution of the VG pathway in the strain D-VG-03. However, when PPTase was 
overexpressed together with ACAR (D-VG-23), a slight improvement in VAC turnover to VAN and 
overall production of VG was observed, compared to when only ACAR was amplified (D-VG-20). 
This suggests that in case of further overexpression of ACAR an additional copy (or another, more 
efficient version [28]) of PPTase should be considered.  Nonetheless, in both cases increased ACAR 
activity resulted in a buildup of the toxic intermediate PAL. Thus, overexpression of the O-
methyltransferase encoded by OMT was also pursued to increase the metabolic flux from PAL to 
VAN. The additional dosage of OMT on top of the overexpressed ACAR (D-VG-24) did not affect the 
PAL dynamics, nevertheless, the flux through the pathway steps 2 and 3 was noticeably improved, 
represented by the accumulation of VAN and a fourfold increased amount of VG (Figure 5.3). 
In previous optimization studies for VG production [5], [6] only one of the two possible biosynthetic 
routes (PACPALVANVG) was considered. However, based on the results presented above, we 
hypothesize that the VG biosynthesis might go primarily via VAC, rather than PAL, i.e. via the upper 
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route in steps 2 and 3 in Figure 5.3. Despite that the enzymatic properties of heterologous ACAR 
and OMT expressed in S. cerevisiae are not known, metabolic profiles of D-VG-20, D-VG-23, D-VG-
24 and D-VG-04 suggest that ACAR might exhibit higher affinity towards VAC compared to PAC. The 
latter is also supported by the results of the in vitro characterization studies of ACAR from Nocardia 
sp. (the same isolate as used in this study), which demonstrated that out of a broad substrate range 
[26], vanillic acid (VAC) was found to be the most preferable substrate for ACAR [28]. On the other 
hand, it seems that the enzyme OMT preferably methylated PAC but not PAL as the overexpression 
of ACAR+OMT increased the flux through the PACVACVAN route, while PAL turnover remained 
intact Figure 5.3. In addition to the undefined substrate preferences of OMT, we speculate that the 
limited activity of overexpressed OMT might be a result of its cellular mislocalization or protein 
misfolding (SI Supplementary note 1). Furthermore, it was also found that the OMT enzyme also 
synthesized several unwanted isoforms of intermediates (SI Figure S 5.2 and Table S 5.5), by 
methylation of the para-hydroxyl group of VAN and VAC. This side activity makes the OMT enzyme 
a troublesome point in the VG biosynthesis. 
The intermediate VAN is known to be toxic for yeast [7] and it has been demonstrated that its 
presence in fermentation media in concentration as low as 3 mM causes growth inhibition [1]. In S. 
cerevisiae, VAN is mainly detoxified by its reduction to vanillyl alcohol (VAL) by the natural alcohol 
dehydrogenases (ADHs), in particular ADH6 [1]. The gene coding for ADH6 is deleted in the VG 
producing strain. However, accumulation of VAL indicates the presence of another minor enzymatic 
activity of the remaining ADHs (SI Figure S 5.2).This appears more evident in case of D-VG-24, were 
the increased flux towards VG is being constrained by insufficient activity of UGT leading to 
accumulation of VAN and consequently VAL. Thus, it is obvious that the native ADHs enzymes and 
heterologous UGT are competing for their substrate – VAN. Overexpression of the UGT (D-VG-50) 
eliminated VAL and also reduced the accumulation of VAC (see Figure 5.3). We speculate that 
increased activity of UGT generates some kind of “metabolic sink” around VAN which 
thermodynamically favors reactions catalyzed by enzymes upstream in the VG pathway. In the 
original study by Hansen et al. it was also reported that the accumulation of several upstream 
metabolites decreased after the glucosylation step was introduced into the vanillin producing strain 
[1]. In this study, the advantage of UGT overexpression appeared to be even more prominent when 
it was combined with the increased gene dosage of either OMT or ACAR (D-VG-54 and D-VG-25, 
respectively) which resulted in the best metabolic distribution observed, with significantly 
improved VG production as well (Figure 5.3 and SI Table S 5.5). 
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We found that in all overexpression variants the accumulation of PAC was not reduced, which 
indicates that the activity of the following enzymes ACAR and OMT has to be enhanced even 
further. The production of PAC is predefined by the availability of the precursor 3-dehydroshikimic 
acid (3-DHS) and the efficiency of the enzyme 3DSD. Since, there are no cofactors associated with 
reaction of 3-DHS to PAC, it was hypothesized that the PAC dynamics are directly linked to the 
aromatic amino acid biosynthesis and, therefore, yeast growth. Indeed, two independent studies 
have demonstrated a very good correlation between biomass yield and PAC production during 
batch fermentation experiments [5] and Chapter 6. In this study, however, we were able to 
demonstrate that the amount of PAC can be significantly increased by overexpression of 3DSD as 
can be seen in the metabolic profile of D-VG-01 (Figure 5.3 and SI Table S 5.5). This also noticeably 
in the improved metabolic flux towards the VG pathway which, in fact, increased the theoretical 
potential for VG production by 270%. One needs to add that in case of the balanced de novo 
pathway, further improvements could be achieved by increasing the metabolic flux through the S. 
cerevisiae aromatic amino acid biosynthesis pathway. This was successfully demonstrated by the 
deregulation of key nodes  of the shikimate pathway (in particular ARO3 and ARO4 [29]), which 
resulted in more than 200-fold increased extracellular concentration of shikimate (the metabolite 
of 3-DHS) [30]. 
 
Concluding remarks and Future perspectives 
The present study aimed at pinpointing the rate limiting steps in the vanillin-β-glucoside 
biosynthetic pathway by overexpressing each step of the heterologous pathway. The results of this 
work suggested that there is more than one bottleneck in the pathway and that a combined gene 
overexpression is needed. We demonstrated that the enzymes ACAR and HsOMT are the primary 
rate-limiting steps in the VG production. Nevertheless, an overexpressed ACAR or OMT had to be 
further complemented by an increased activity of UGT, which is the last step in the VG biosynthesis. 
In this study the best result was a 6-fold improvement in VG production, which was obtained by 
overexpressing the combination of ACAR+UGT. Moreover, based on observations, we have 
proposed that the VG biosynthesis predominantly follows the PACVACVANVG route rather 
than PACPALVANVG. In conclusion, this study showed that the existing de novo VG pathway 
in the yeast S. cerevisiae has a high potential for successful VG production, however, there is still 
room for improvement. 
Future work on the development of the yeast cell factory for VG production should focus on finding 
the right ratios of ACAR, OMT and UGT, which can be easily done by implementing our existing GA 
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platform (SI Figure S 5.4). It is also of high importance to focus on improving the heterologous 
enzyme specificities and catalytic activities, which could be done both by using alternative genes or 
by targeted protein engineering [31] as recently demonstrated[32]. Finding or engineering an ACAR 
enzyme with exceptional specificity towards VAC and not PAC would eliminate the accumulation of 
the toxic intermediate PAL and presumably improve the flux towards the production of VG. 
Alternatively, it was shown that protein fusion can improve the flux through desired nods of a 
heterologous pathway [33]. Following our proposed VG biosynthetic route the overexpressed 
protein fusions of 3DSD-OMT and ACAR-UGT might solve the existing accumulation of the 
intermediates and increase the flux towards VG production. Lastly, the fact that heterologous 
enzymes are dependent on various cofactors must not be ignored and additional metabolic 
engineering strategies for increased cofactor supply might also be pursued [5], [6]. 
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Supplementary note 1 
GFP tagging reveals plausible cellular localization of O-methyltransferase – one 
of the limiting steps in the VG biosynthesis 
When expressing heterologous metabolic pathways in yeast, it is important that all enzymes are 
properly folded and localized in the same cellular compartment, most commonly the cytoplasm. 
The de novo Vanillin-β-glucoside (VG) pathway is assembled from enzymes originating from several 
evolutionary distant organisms, though, little is known about the actual expression of these 
proteins in S. cerevisiae. Misfolding, co-localization and aggregate formation of any protein from 
the VG pathway might lead to inefficient production and intermediate accumulation, which was 
observed by several studies [5], [6]. One way of checking the location of the protein in the cell is by 
means of fusing with a fluorescent reporter protein [34]. 
The aim of this experiment was to investigate whether all VG pathway enzymes are localized in the 
same cellular compartment, preferably the cytosol. In addition, fluorescence levels could indicate 
the relative expression levels of the VG pathway enzymes. To do that, we have C-terminally tagged 
all five heterologous proteins with either red (RFP) or cyan fluorescent proteins (CFP).  
In this study, three strains with tagged VG pathway proteins were constructed see Table S 5.1. This 
was done by transforming the VG producing strain TS155 (one of the intermediate strains from the 
study described in Chapter 6) with DNA substrates shown in Figure S 5.1A. The tagged ORFs were 
integrated into defined location on the chromosome XI at position 2 [24]. Fluorescence microscopy 
of the generated strains revealed plausible localization of the OMT protein, while the remaining 
four were found in the cytoplasm (Figure S 5.1B). Moreover, the fluorescence signal of the 
OMT_RFP was relatively low compared to e.g. the one of the PPT_RFP fusion. The pattern of tagged 
OMT in the cell closely resembles the one of the proteins localized in the vacuole [34]. However, to 
determine the exact cellular location of the OMT, additional experiments need to be done. Firstly, 
to rule out if the localization is not an artifact of the tagging by RFP, the OMT should be also tagged 
N-terminally. Secondly, to confirm the exact cellular location of OMT, the proteins with known 
localization should be tagged simultaneously in the same strain. Alternatively, chemical staining of 
cell organelles can be done. 
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Figure S 5.1 Tagging proteins of vanillin-β-glucoside pathway proteins. A) Schematic representation of 
protein tagging. Molecular cloning was done using the methods as described in Chapter 6. B) 
Fluorescent microscopy results. To analyze the localization of the VG pathway proteins, strains 1) 
TS155-3R, 2) TS155-CAPR and 3) TS155-CUOR were incubated overnight in 20 mL of SC media with 
constant shaking 150 rpm and temperature set to 30°C. 
 
Table S 5.1 List of the yeast strains used for the enzyme tagging experiment. 
Strains Relevant genotype Reference 
TS155 MATα MAL2-8C SUC2 ura3-52 XII2(pTEF1-HsOMT, pPGK1-UGT) XII1(pTEF1-PPT, pPGK1-ACAR) 
XII5(pTEF1-3DSD), ΔEXG1::loxP ΔADH6::KanMX 
Chapter 6 
TS155-3R MATα MAL2-8C SUC2 ura3-52 XII2(pTEF1-HsOMT, pPGK1-UGT) XII1(pTEF1-PPT, pPGK1-ACAR) 
XII5(pTEF1-3DSD), XI2(pTEF1-3DSD_RFP), ΔEXG1::loxP ΔADH6::KanMX  
This study 
TS155-CAPR MATα MAL2-8C SUC2 ura3-52 XII2(pTEF1-HsOMT, pPGK1-UGT) XII1(pTEF1-PPT, pPGK1-ACAR) 
XII5(pTEF1-3DSD), XI2(pTEF1-PPT_RFP, pPGK1-ACAR_CFP), ΔEXG1::loxP ΔADH6::KanMX  
This study 
TS155-CUOR MATα MAL2-8C SUC2 ura3-52 XII2(pTEF1-HsOMT, pPGK1-UGT) XII1(pTEF1-PPT, pPGK1-ACAR) 
XII5(pTEF1-3DSD), (pTEF1-HsOMT_RFP, pPGK1-UGT_CFP), ΔEXG1::loxP ΔADH6::KanMX  
This study 
 
pTEF1T1 T2pPGK1ACAR PPTCFPXI2 UP XI2 DWRFP Kl.URA3Strain 2
pTEF1T1 T2pPGK1UGT OMTCFPXI2 UP XI2 DWRFP Kl.URA3Strain 3
pTEF1 T23DSD XI2 DWRFP Kl.URA3T1XI2 UPStrain 1
 
A 
B 
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Table S 5.2 list of verification primer pairs used for the validation of gene targeting events. Appearance 
of the correct size band on the gel verifies targeted integration of your favorite fragment (XII-1, XII-2 
and XII-5). In case of deletions, the band size confirms your favorite gene deletion. *In case of ADH6 
the band size also includes the KanMX cassette. 
Site Name Sequence Fragment size, bp 
XII-1 XII-1-up-out-sq  CTGGCAAGAGAACCACCAAT 729 
XII-2 XII-2-up-out-sq  CGAAGAAGGCCTGCAATTC 739 
XII-5 XII-5-up-out-sq  CCACCGAAGTTGATTTGCTT 688 
— C1_TADH1_F CTTGAGTAACTCTTTCCTGTAGGTC  
For  Deletion  Verification   
BGL1 BGL1_VF TCATCCTCCCTGTGTTTACA 1044 
 BGL1_VR AGTTGAAACAGAGGATAAGGTG  
ADH6* ADH6_VF GTTTTGCTTTTTTCTCTGGG 2773 
 ADH6_VR GGAGTATCAACCACTAAAGCG  
 
 
Table S 5.3 list of verification primers pairs used for checking if the gene amplification has appeared. 
*Band sizes obtained when the reverse primer is C1_TADH1_F (Table S 5.2). 
Site Name Sequence Size, bp* 
X-2 X-2-up-out-sq TGCGACAGAAGAAAGGGAAG 1395 
X-3 X-3-up-out-sq TGACGAATCGTTAGGCACAG 1581 
X-4 X-4-up-out-sq CTCACAAAGGGACGAATCCT 1505 
XII-1 XII-1-up-out-sq  CTGGCAAGAGAACCACCAAT 1374 
XII-2 XII-2-up-out-sq  CGAAGAAGGCCTGCAATTC 1384 
XII-3 XII-3-up-out-sq TGGGCAGCCTTGAGTAAATC 1484 
XII-4 XII-4-up-out-sq GAACTGACGTCGAAGGCTCT 1350 
 
 
Table S 5.4 the list of the additional primers used for sequencing purposes of the plasmids 
Name Sequence 
S1_TEF_F CGGTCTTCAATTTCTCAAGTTTC 
S1_PGK_F CAAGGGGGTGGTTTAGTTTAGT 
S1_ACAR_F CATTGTTCGTTCCAGACACTGAC 
S2_ACAR_F GAAATTGTCTCAAGGTGAGTTCG 
S3_ACAR_F TTTGGGTAGATTCTTGTGTTTGG 
YF19 AAAAAATAAATAGGGACCTAGACTTCA 
YF21 GACCTACAGGAAAGAGTTACTCAAGAAT 
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Table S 5.5 Concentration of the VG pathway metabolites, mg (g DW)-1. 
 
 
 
 
Figure S 5.2 Simplified heterologous pathway of vanillin-β-glucoside (VG) with side reactions shown. 
3-DHS – 3-dehydroshikimic acid, PAC – protocatechuic acid, PAL – protocatechuic aldehyde, VAC – 
vanillic acid, VAN – vanillin, VG – vanillin-β-glucoside. Black thick arrows with numbered circles 
represent enzymatic reactions by heterologous enzymes: 1) 3DSD – 3-dehydroshikimate dehydratase 
(Podospora pauciseta), 2) ACAR – aromatic carboxylic acid reductase (Neurospora sp.), 3) EntD – 
phosphopantetheine transferase (Escherichia coli), 4) HsOMT – O-methyltransferase (Homo sapiens) 
and 5) UGT72E2 – UDP-glycosyltransferase (Arabidopsis thaliana). Grey arrows and boxes show 
unwanted side reactions; VAL – vanillyl alcohol, IVAC – isovanillic acid, IVAN – isovanillin and IVG 
isovanillin-β-glucoside. Cofactors: SAM – S-adenosyl methionine, ATP – adenosine triphosphate, 
NADPH – nicotinamide adenine dinucleotide phosphate. 
 
Strain
D-VG-00 43.49 ± 2.20 1.19 ± 0.18 23.86 ± 0.87 16.4 ± 2.9 5.2 ± 1.3 14.36 ± 0.17 0.11 ± 0.11
D-VG-VG 101 ± 21 8.26 ± 0.63 26.4 ± 5.8 6.87 ± 1.35 72.4 ± 5.8 15.98 ± 1.10 10.91 ± 3.57 3.09 ± 0.10
D-VG-01 193.42 ± 0.04 5.15 ± 0.91 40.8 ± 0.2 29.1 ± 8.8 5.02 ± 0.63 15.89 ± 1.45 0.53 ± 0.53
D-VG-20
D-VG-03 44.3 ± 6.9 2.19 ± 0.03 27.8 ± 12.1 38.8 ± 6.7 9.75 ± 1.99 14.09 ± 4.40 0.43 ± 0.09
D-VG-04 37.4 ± 2.3 2.37 ± 0.09 22.9 ± 2.0 31.0 ± 2.0 10.11 ± 0.47 10.45 ± 0.07 0.62 ± 0.01
D-VG-50 68.21 ± 2.41 0.63 ± 0.12 11.4 ± 0.6 33.1 ± 2.7 0.88 ± 0.11 5.19 ± 5.19
D-VG-23 76.3 ± 24.2 16.0 ± 2.2 3.71 ± 2.10 52 ± 22 7.03 ± 2.02 4.58 ± 0.04 2.41 ± 0.70
D-VG-54 53.2 ± 4.2 1.91 ± 0.75 16.56 ± 1.68 1.82 ± 1.82 80 ± 25 6.25 ± 2.25 10.87 ± 1.06 0.84 ± 0.84
D-VG-00 27.64 ± 4.22 1.16 ± 0.09 15.39 ± 2.71 13.85 ± 1.57 3.00 ± 0.34 5.50 ± 0.59
D-VG-20
D-VG-24 48.05 ± 4.50 8.25 ± 1.85 3.45 ± 0.07 9.07 ± 0.40 47.81 ± 9.07 11.01 ± 0.97 2.78 ± 0.23 2.66 ± 0.20
D-VG-25 44.30 ± 5.54 8.98 ± 5.01 1.98 ± 0.21 2.39 ± 1.08 73.31 ± 6.05 2.84 ± 0.28 3.06 ± 0.24 0.91 ± 0.46
1.37
PAC PAL VAC VAN VG VAL IVAC IVAN
n/a
38.6 8.47 6.66 4.45
10.18 4.98 2.76 27.76 5.20 4.65
n/a
n/a
40.70
77.53 18.5 13.0
n/an/a
n/a
n/a
n/a
n/a
n/a
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Figure S 5.3 Schematic representation of vector cloning for gene amplification purposes. The pCSN 
vector is linearized with AsiSI and Nb.BsmI enzymes. The yellow boxes A and B are targeting sequences 
homologous to the gene amplification cassette. T1 and T2 are terminator sequences Tadh1 and Tcyc1, 
respectively. The black arrow indicates the counter-selectable auxotrophic marker TRP1.   White, grey 
and black boxes represent the USER cloning compatible tails.  
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Figure S 5.4 Schematic representation of the VG pathway titration by implementing GAS strains. Each 
colorful box represents an integrated GOI as well as the location of the integration described by 
Mikkelsen (2012). By several rounds of genetic cross it is possible to generate a huge library with 
different combinations of amplified genes coding for VG pathway enzymes. 
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Chapter 6 
6. Comparison of yeast strains for vanillin production 
 
 
Title6 
Benchmarking two commonly used Saccharomyces cerevisiae strains for heterologous 
vanillin-β-glucoside production 
 
Abstract  
The yeast Saccharomyces cerevisiae is a widely used eukaryotic model organism and a key cell 
factory for production of biofuels and wide range of chemicals. From the several available yeast 
strains, the most popular are the ones derived from laboratory strain S288c and the industrially 
relevant CEN.PK strain series. In recent years these strains have been subjected for comparison 
studies where genotypic and phenotypic differences were outlined. Based on high quality 
quantitative data obtained by multi-laboratory efforts it is hypothesized that strains S288c and 
CEN.PK might exhibit different biosynthetic capacity towards heterologous production. To test this, 
we have reconstructed previously published de novo vanillin-β-glucoside pathway, which uses an 
intermediate of aromatic amino acid biosynthesis (3-dehydroshikimate) as a precursor, in both 
S288c and CEN.PK strains in an identical manner. Characterization of the two producer strains 
revealed that the S288c background strain produced significantly higher amounts of vanillin-β-
glucoside compared to CEN.PK in two standard growth conditions. This study demonstrated that 
yeast strain background may play a major role in the outcome of newly developed cell factories for 
production of a given product. 
Keywords: Yeast; Cell factory, Strain choice; S288c, CEN.PK; Heterologous production; Vanillin-
glucoside; Shikimate pathway.  
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Introduction 
With the recent achievements in the field of systems biology in combination with constantly 
advancing metabolic engineering and molecular biology tools, the yeast Saccharomyces cerevisiae 
is becoming a key cell factory for heterologous production of scientifically and industrially relevant 
products. The latter comprise a large variety of products ranging from low-value bulk chemicals and 
biofuels (e.g., ethanol) to food additives (e.g., flavors and colorants) and high value pharmaceuticals 
(e.g., recombinant proteins) [1], [2]. Today, a range of different S. cerevisiae strain backgrounds are 
available for the yeast community of which BY (S288c), W303 and CEN.PK are the most frequently 
used [3]. The variety of strains has been developed by different laboratories to suit a range of 
diverse research goals within different disciplines such as genetics, physiology and biochemistry. 
For example, CEN.PK strain, is a popular platform for physiological as well as metabolic engineering 
studies [3] whereas   S288c, the first eukaryote to be sequenced, is mainly used for genetic studies, 
but has in recent years been increasingly used as an alternative platform for metabolic engineering 
experiments [4]. Specifically, recent surveys show that over the past ten years the two strains were 
used in more than 50% of the analyses with CEN.PK series being the most popular (approx. 37% - 
CEN.PK vs. 24% - S288c and its derivatives) [1], [2]. The importance of the two strains as cell 
factories is further substantiated by an extensive multi-laboratory efforts were made for systematic 
comparisons of S288c and CEN.PK [5]–[7]. Genetic differences of these strains were revealed first 
by microarray studies [8] and more recently genotype to phenotype relation was investigated after 
whole-genome sequencing of the CEN.PK113-7D strain [9], [10]. These sequencing studies revealed 
more than 13,000 single nucleotide polymorphisms (SNPs) in CEN. 113-7D compared to S288c, 
where 35% of those resulted in amino acid substitutions that affected 1406 proteins, moreover, 83 
genes were absent in CEN.PK relative to S288C [10]. Considering only metabolic genes the highest 
SNPs enrichment was detected in the genes involved in the carboxylic acid, organic acid, and 
carbohydrate metabolism, as well as, nitrogen, amino acid, lipid and aromatic compound 
metabolism [9]. Several phenotypic differences were assigned to these mutations, e.g., differences 
in galactose uptake and ergosterol biosynthesis etc. in two strains. 
The fact that the two main S. cerevisiae backgrounds for construction of cell factories are 
genetically/phenotypically quite different raises the possibilities that production yields also may be 
significantly different in CEN.PK and in S288c. To examine this possibility we have therefore 
constructed comparable cell factories for vanillin-β-glucoside (VG) production in S288c and CEN.PK 
backgrounds. Importantly, all five relevant genes for VG production in S. cerevisiae, (see Hansen et 
al. [12]) were integrated at phenotypically neutral and well defined locations in the yeast 
chromosome using a recently published integration platform [11]. Moreover, in order for the 
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engineered strains to be directly comparable, auxotrophies were eliminated by a sexual backcross 
to the corresponding wild-type strains. Remarkably, the physiological characterizations of both VG 
cell factories in two different cultivation modes revealed major differences in the VG production. 
Next, we examined the comprehensive –“omics” datasets for S288c and CEN.PK strains [6] to look 
for plausible reasons for the different VG production profiles in the two genetic backgrounds. 
Together our analyses serve as a step towards a scenario where the optimal genetic background 
for cell factory construction can be successfully selected based on a systems biology model for yeast 
cell factories. 
 
 
Figure 6.1. De novo vanillin-β-glucoside pathway in S. cerevisiae assembled by Hansen and co-workers 
[12]. Colored boxes represent metabolites of the pathway: PAC – protocatechuic acid, PAL – 
protocatechuic aldehyde, VAC – vanillic acid, VAN – vanillin, VG – vanillin-glucoside. Black thick arrows 
show enzymatic reactions by heterologous enzymes: 3DSD – 3-dehydroshikimate dehydratase 
(Podospora pauciseta), ACAR – aromatic carboxylic acid reductase (Neurospora sp.), EntD – 
phosphopantetheine transferase (Escherichia coli), HsOMT – O-methyltransferase (Homo sapiens) and 
UGT72E2 – UDP-glycosyltransferase (Arabidopsis thaliana). Grey arrows and boxes (left side of the 
picture) represent simplified shikimate biosynthetic pathway and native parts of yeast metabolism: 
PPP – pentose phosphate pathway, DAHP – 3-deoxy-D-arabinoheptulosonate 7-phosphate, 3-DHS – 
3-dehydroshikimic acid, Trp – tryptophan, Phe – phenylalanine, Tyr – tyrosine. Key enzymes of the 
shikimate pathway:  ARO3 and ARO4 – DAHP synthase isoenzymes and ARO1 – pentafunctional 
enzyme catalyzing DAHP conversion to chorismate.  
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Materials and Methods 
DNA cloning procedures 
The DNA fragments used for vector construction were amplified by PCR with PfuX7 polymerase 
developed by Nørholm et al. [13] using the primers listed in the Table 5.2. Molecular coning was 
done by uracil-speciﬁc excision reagent (USER™) as previously described in [14], [15].Final 
constructs were validated by sequencing (StarSEQ® GmbH, Germany). The genes constituting the 
de novo VG pathway (1-3DSD, 2- ACAR, 3-EntD, 4-HsOMT, and 5-UGT72E2) and a set of bidirectional 
promoters (pPGK1/pTEF1) were amplified by PCR from the appropriate vector templates (see Table 
5.1). The pathway genes and promoters were assembled into vectors designed to integrate on 
chromosome XII [11]. A total of three plasmids were produced: pXII1-23 (pPGK1::ACAR; 
pTEF1::EntD), pXII2-54 (pPGK1::UGT72E2; pTEF1::HsOMT) and pXII5-01 (pTEF1::3DSD).  For a full 
list of plasmids used or constructed in this work see Table 5.1; and for a schematic representation 
of plasmid cloning procedure refer to the SI Figure S 6.1. 
 
Table 6.1. List of the plasmids used in this study. 
Name Genetic element Reference 
pXII1-23 pPGK1::ACAR, pTEF1::EntD  This study 
pXII2-54 pPGK1::UGT72E2, pTEF1::HsOMT This study 
pXII5-01 pTEF1::3DSD This study 
pXII1 ― Mikkelsen et al. [11] 
pXII2 ― Mikkelsen et al. [11] 
pXII5 ― Mikkelsen et al. [11] 
pSP-G2 pPGK1;pTEF1 Partow et al. [16] 
pJH500 3DSD Hansen et al. [12] 
pJH674 ACAR Hansen et al. [12] 
pJH589 EntD Hansen et al. [12] 
pJH543 HsOMT Hansen et al. [12] 
pJH665 UGT72E2 Hansen et al. [12] 
pUG6 KanMX Güldener et al [17] 
pSH47 Cre recombinase Güldener et al [17] 
 
  
PhD Thesis, Tomas Strucko 
113 
 
 
Table 6.2. List of the primers used in this study. All sequences are presented in 5’ to 3’ direction, 
standard capital letter are gene specific sequences, bold underline letters represent USER specific tails, 
standard underline letters represent targeting sequences for appropriate gene deletions. Italic letters 
represents translational enhancer sequence [18], [19]. 
Name Sequence 
PGK_R- ACCCGTTGAUGCCGCTTGTTTTATATTTGTTG 
TEF_F+ CGTGCGAUGCCGCACACACCATAGCTTC 
TEF_R+ ACGTATCGCUGTGAGTCGTATTACGGATCCTTG 
DSD_F+ AGCGATACGUAAAAATGCCTTCCAAACTCGCC 
DSD_R+ CACGCGAUTTACAAAGCCGCTGACAGC 
ACAR_F- ATCAACGGGUAAAAATGGCTGTTGATTCACCAGATG 
ACAR_R- CGTGCGAUCTTATAACAATTGTAACAATTCCAAATC 
hOMT_F+ AGCGATACGUAAAAATGGGTGACACTAAGGAGCAA 
hOMT_R+ CACGCGAUCTTATGGACCAGCTTCAGAACC 
PPT1_F+ AGCGATACGUAAAAATGGTCGATATGAAAACTACGC 
PPT1_R+ CACGCGAUTTAATCGTGTTGGCACAGC 
UGT1_F- ATCAACGGGUAAAAATGCATATCACAAAACCACACG 
UGT1_R- CGTGCGAUACTAGGCACCACGTGACAAGTC 
BGL1_del_F ATTTTTTGTTTACTTTCTTTTTCTAGTTAATTACCAACTAAACT
TCGTACGCTGCAGGTC 
BGL1_del_R CATTAGAAAATTCAGCTAAAATGAGCGGACTGAGGGCGAC
TAGTGGATCTGATATCACCTA 
ADH6_del_F GAGGAAGAAATTCAACACAACAACAAGAAAAGCCAAAATC
CTTCGTACGCTGCAGGTC 
ADH6_del_R GTTAAAAAGAAAGGAGCTACATTTATCAAGAGCTTGACAAC
TAGTGGATCTGATATCACCTA 
 
Strain construction 
The genotype and source of the strains used in this study is given the Table 5.3. Two different 
background strains CEN.PK113-11C and X2180-1A (isogenic to S288c) were used as hosts for 
reconstruction of the de novo vanillin-β-glucoside (VG) pathway. All yeast constructs were 
generated by high efficiency transformation method (lithium acetate/polyethylene glycol/single 
carrier DNA) previously described by Gietz et al. [20]. 
To construct two yeast strains containing the VG pathway, vectors pXII1-23, pXII2-54 and pXII5-01 
harboring the following genes (ACAR and EntD), (UGT72E2 and HsOMT) and (3DSD), respectively, 
were digested with NotI restriction enzyme (Fermentas-Thermo Fisher Scientific) and gel-purified 
using illustra GFX PCR DNA and Gel Band Purification Kit (GE Lifesciences). The individual gene 
targeting substrates were transformed iteratively into both yeast strain backgrounds in three 
consecutive transformations. To prevent undesired production of toxic intermediates especially 
protocatechuic aldehyde (PAL), the 3DSD gene was cloned at the latest step. After each round of 
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transformation the URA3 marker was eliminated by direct repeat recombination and counter-
selection on 5-FOA [21] allowing the URA3 marker to be recycled. 
Complete gene deletions of BGL1 and ADH6 were achieved using method described by Güldener et 
al [17]. PCR fragment carrying loxP-KanMX-loxP flanked by 40 nt long segment homologous to 
sequences of Up- and Down-stream of the appropriate open reading frame (ORF) to be deleted 
were amplified form plasmid pUG6. The KanMX marker was excised by expressing Cre recombinase 
from the vector pSH47 [17]. All gene targeting events were validated by diagnostic PCR using 
specially designed primer pairs (see SI Table S 5.2) 
To eliminate any auxotrophies, two engineered strains S-VG-aux and C-VG-aux were sexually 
crossed to S288c and CEN.PK110-16D, respectively. The latter resulted in two final prototrophic 
vanillin-β-glucoside producing yeast strains S-VG (s288c based) and C-VG (CEN.PK based). Genetic 
cross and selection procedures were performed as described in [22]. 
Schematic flowchart representing the strain construction is depicted in Figure S 6.2. 
Table 6.3. List of the yeast strains used in this study. 
Name Genotype Reference 
X2180-1A (ura3) MATa SUC2 mal mel gal2 CUP1 ura3-52 Public domain [23] 
S288c MATα SUC2 gal2 mal mel flo1 flo8-1 hap1 ho bio1 bio6 ATCC 204508 
CEN.PK113-11C MATa MAL2-8C SUC2 ura3-52 his3Δ Peter Kötter7 
CEN.PK110-16D MATα MAL2-8C SUC2 trp1-289 Peter Kötter1 
S-VG-aux MATa MAL2-8C SUC2 ura3-52 his3Δ XII2(pTEF1-HsOMT, pPGK1-
UGT) XII1(pTEF1-PPT, pPGK1-ACAR) XII5(pTEF1-3DSD) Δbgl1::loxP 
Δadh6::KanMX 
This study 
C-VG-aux MATa SUC2 gal2 mal mel ura3-52 XII2(pTEF1-HsOMT, pPGK1-UGT) 
XII1(pTEF1-PPT, pPGK1-ACAR) XII5(pTEF1-3DSD) Δbgl1::loxP 
Δadh6::KanMX 
This study 
S-VG MATα MAL2-8C SUC2 XII2(pTEF1-HsOMT, pPGK1-UGT) XII1(pTEF1-
PPT, pPGK1-ACAR) XII5(pTEF1-3DSD) Δbgl1::loxP Δadh6::KanMX 
This study 
C-VG MATα SUC2 gal2 mal mel XII2(pTEF1-HsOMT, pPGK1-UGT) 
XII1(pTEF1-PPT, pPGK1-ACAR) XII5(pTEF1-3DSD) Δbgl1::loxP 
Δadh6::KanMX 
This study 
 
Media  
For cloning purposes lysogeny broth (LB) [24] supplemented with 100 mg/L of ampicillin was used 
for growing of Escherichia coli DH5α. 
All media used for genetic manipulations of yeast were prepared as previously described by 
Sherman et al. [25], with minor modifications of synthetic medium where leucine concentration 
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was doubled to 60mg/L. All yeast transformants with gene integrations were selected on synthetic 
complete media without uracil. For subsequent rounds of transformations, the URA3 marker was 
recycled through direct repeat recombination and selected on synthetic complete media containing 
30 mg/L uracil and 740mg/L 5-fluoroorotic acid (5-FOA) (Sigma-Aldrich).  
Yeast transformants with necessary gene deletions were selected on Yeast Extract Peptone 
Dextrose (YPD) plates supplemented with 200 mg/L of G418 (Sigma) [17]. The medium composition 
was as follows: 10 g/L of yeast extract, 20 g/L of peptone and 20 g/L of glucose and 20 g/L of agar. 
A defined minimal medium previously described by Verduyn [26] with 7.5 g/L glucose as a carbon 
source was used for S. cerevisiae cultivations in batch and chemostat cultures. Prior inoculation of 
fermenters, the medium was supplemented with 30 g/L of glucose [6]. The medium is composed 
of: 7.5 g/L (NH4)2SO4, 3 g/L KH2PO4, 0.75 g/L Mg2SO4, 1.5 mL/L trace metal solution, 1.5 mL/L vitamin 
solution, 0.05 mL/L antifoam 204 (Sigma-Aldrich). Trace metal solution contained 3 g/L FeSO4∙7H2O, 
4.5 g/L ZnSO4∙7H2O, 4.5 g/L CaCl2∙6H2O, 0.84 g/L MnCl2∙2H2O, 0.3 g/L CoCl2∙6H2O, 0.3 g/L 
CuSO4∙5H2O, 0.4 g/L NaMoO4∙2H2O, 1 g/L H3BO3, 0.1 g/L KI and 15 g/L Na2EDTA∙2H2O. Vitamin 
solution included 50 mg/L d-biotin, 200 mg/L para-amino benzoic acid, 1.0 g/L nicotinic acid, 1.0 g/L 
Ca-pantothenate, 1.0 g/L pyridoxine HCL, 1.0 g/L thiamine HCl and 25 mg/L minositol. Glucose was 
autoclaved separately and the vitamin solution was sterile filtered (pore size 0.2 μm Ministart®-
Plus, Sartorius AG, Germany) and added after autoclavation. 
Batch and chemostat cultivations 
For each biological replicate, separate colonies of engineered yeast strains from YPD plate were 
inoculated to 0.5 L shake flasks with 50 mL of the previously described minimal medium (pH 6.5). 
Pre-cultures were incubated in an orbital shaker set to 150 rpm at 30°C until mid-exponential phase 
OD600 ≈ 5 and directly used for inoculation. In this work, batch cultivations were performed in 
duplicates and continuous cultures – in triplicates. 
Batch cultivations were performed under aerobic conditions in 1L fermenters equipped with 
continuous data acquisition (Sartorius, B. Braun Biotech International, GmbH, Melsungen, 
Germany) with a working volume of 1L. Fermenters were inoculated with initial O.D.600 =0.05. To 
ensure adequate mixing and aeration a stirrer speed was set to 600 r.p.m and airflow rate to 1.0 
v.v.m. (60 L/h). The temperature was maintained at 30°C during the cultivation and pH=5.0 level 
was controlled by automatic addition of 2M NaOH or 2M H2SO4. The batch cultures were sampled 
at regular intervals through both glucose and ethanol growth phases. Glucose-limited chemostat 
cultures were grown in the same conditions as previously described for batch cultivations. 
Chemostats were initiated as batch cultivations with starting glucose concentration of 15 g/L and 
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OD600 =0.05 and switched to continuous mode in early exponential phase. Minimal medium was fed 
at a constant dilution rate of 0.1 h–1 [6].The working volume of 1 L was kept constant by a level 
based outlet. Samples were taken overr at least five residence times (50 hours) of constant biomass 
and carbon dioxide concentration readings. 
In both cultivation experiments exhaust gas composition was constantly monitored by an off gas 
analyzer (1311 Fast response triple gas, Innova) combined with Mass Spectrometer (Prima Pro 
Process MS, Thermo Fisher Scientific, Winsford UK). 
The biomass concentration was monitored by measuring both optical density at 600nm wavelength 
(OD600) and cell dry weight (DW) in the cultivation broth. OD600 was estimated using a UV mini 1240 
spectrophotometer (Shimadzu, Kyoto, Japan), biomass samples were diluted with distilled water to 
achieve OD600 reading within 0.1 to 0.4 range. DW measurements were performed using 
polyethersulfone (PES) filters with a pore size of 0.45 μm Montamil® (Membrane Solutions, LLC). 
The filters were pre-dried in a microwave oven at 150 W and weighed. A known volume of 
cultivation broth (5 mL) was filtered and then washed with approx. 15 mL of distilled water. Finally, 
the filters with biomass were dried in the microwave oven at 150 W and cell DW was determined 
[27].  
Extracellular metabolite measurements 
External metabolites were determined by high performance liquid chromatography (HPLC) analysis. 
Two distinct HPLC methods were applied for analysis of different groups of extracellular 
compounds. 
The submerged cultivation samples for yeast primary metabolites were centrifuged at 12000xg for 
2 min, supernatant was transferred to a new tube and stored at -20 oC until further analysis. 
Glucose, ethanol, glycerol, pyruvate, succinate and acetate were determined by high performance 
liquid chromatography (HPLC) analysis using an Aminex HPX-87H ion-exclusion column (Bio-Rad 
Laboratories, Hercules, CA). The column temperature was kept at 60 oC and the elution was 
performed using 5 mM H2SO4 with constant flow rate of 0.6 mL min-1. Metabolite detection was 
performed by a RI-101differential refractometer detector (Shodex) and an UVD340U absorbance 
detector (Dionex) set at 210 nm.  
Samples for quantification of VG and its pathway metabolites were prepared as follows: 1mL of 
fermentation broth and 1mL of 96% EtOH was carefully mixed by vortex and centrifuged at 12000xg 
for 2 min, supernatant was transferred to a new tube and stored at -20 oC until further analysis. 
Extracellular vanillin-β-glucoside (VG), vanillin (VAN), protocatechuic acid (PAC), protocatechuic 
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aldehyde (PAL) and vanillic acid (VAC) were quantified using Agilent 1100 series equipment with a 
Synergi Polar-RP 150*2 mm 4u column (Phenomenex). A gradient of acetonitrile (ACN) with 1% 
tetra-fluoroacetic acid (TFA) and water with 1% TFA at a constant flow rate of 0.5 mL/min was used 
as mobile phase. The elution profile was as follows: 5% ACN for 1 min, 5% ACN to 30% ACN for 8 
min, 30% ACN to 100% ACN for 1 min, 100% ACN for 1 minute, 100% ACN to 5% ACN for 3 min. The 
column was kept at 40 oC and metabolite detection was performed using a UV diode-array detector 
set to 230 and 280 nm. 
Intracellular metabolite measurements 
Quenching and extraction: Samples for intracellular metabolites were taken in the end of 
continuous cultivation (during steady state conditions). The samples were quenched and extracted 
as previously described by Villas-Boas et al; 5 mL of culture broth was sprayed into pre-cooled (-
40°C) falcon tube containing 20 mL of 60% methanol, spun down for 2 min at 5000xg in precooled 
centrifuge (-10°C) and extracted using boiling ethanol method [28] with addition of internal 
standards described below. 
Stock solutions: Single stock solutions with concentration of 1 mg/ml of ATP, ADP, AMP, NADPH, 
NADP, NADH, NAD, UDP, UDP-glucose and shikimic acid were prepared in water and stored under 
–20°C until use. Aliquots of the stock solutions were used to prepare the daily working solutions by 
further dilution in 10 mM TBA and 10 mM acetic acid solution. Stock solutions (1 and/or 0.2 mg/ml) 
of labeled internal standards of [U-13C]ATP,  [U-15N]AMP  and  [U-15N]UTP were prepared in water 
and kept under –20 °C until use. Mixture containing 30 µg/ml of [U-13C]ATP and 10 µg/ml of both 
[U-15N]AMP and [U-15N]UTP was used for spiking the calibration standards and the extracts. 
Ion-pair UHPLC-MS/MS analysis of C-di-GMP. The analysis was carried out on an Agilent 1290 binary 
UHPLC system coupled with an Agilent 6460 triple quadrupole mass spectrometer (Torrance, CA, 
USA). The MS was operated in negative ion and multiple reactions monitoring mode. Separation of 
0.5 µL samples was performed by ion-pair chromatography, as described in details in [29] using 10 
mM tributylamine as ion pair reagent. The gradient used was 0-12 min 0-50% B, 12-12.5 min 50-
100% B, 12.5-14 min 100% B, 14-14.5 min 100-0% B, 14.5-19.5 min 0% B. Calibration curves were 
constructed by preparing calibration solutions ranging from 1 to 100 µg/ml for ATP, NAD and UTP 
and 0.3 to 25 µg/ml for NADPH, NADP, NADH, NAD, UDP, UDP-glucose and shikimic acid. Both the 
extracts after the quenching and the calibration solutions were spiked with 60 µl of isotope labeled 
standard mixture. The calibration curves, for the compounds for which isotope-labeled analog was 
added, were constructed by plotting the peak area ratios of the unlabeled nucleotide standard to 
the corresponding labeled one versus the concentrations of the nucleotide standard added. For the 
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compounds where no IS was added, the calibration curves were constructed by plotting the peak 
area of the compound versus the concentration. The quantification was carried out using Mass 
Hunter Quantitative analysis software (version B.06.00). 
 
Results 
De novo pathway reconstruction in CEN.PK and S288c backgrounds 
To compare CEN.PK and S288c for their ability to produce VG in a fair manner, it is important that 
all genes are inserted identically in both strain backgrounds. In the original VG producing strain the 
individual genes of the pathway were inserted by repeated integrations into the TPI1 promoter 
region in an S288c based strain [12] and the gene order is consequently ill defined and therefore 
not easy to reconstruct in CEN.PK. We therefore introduced the VG pathway in the two strain 
backgrounds, S288c (isogenic isolate X2180-1A [23]) and CEN.PK113-11C [4], in a different manner. 
Specifically, the five genes used by Hansen et al.[12] for VG production were integrated into three 
sites located on chromosome XII, which are part of a defined gene expression platform we have 
previously established [11]. Importantly, prior to integration, we compared the up- and 
downstream sequences at these integration sites in CEN.PK and S288c and found that they differ 
by only a single SNP, a C (CEN.PK) to G (S288c) substitution in the upstream targeting sequence of 
XII-5 in genome (SI Table S 6.3). The five genes are therefore inserted into a genetic context, which 
is essentially identical. Finally, for both genetic backgrounds, auxotrophic markers were eliminated 
by sexual back crossing to wild-type variants of the two strain backgrounds to produce two 
prototrophic VG producing strains, C-VG (CEN.PK based) and S-VG (s288c based), which we used 
for further analysis.  
 
 
Figure 6.2. Schematic representation of VG pathway reconstruction in two different S. cerevisiae 
background strains. T1, T2 – terminators of ADH1 and CYC1, respectively; P1, P2 – promoters of PGK1 
and TEF1, respectively. Red arrows represent essential genetic elements of S. cerevisiae and yellow 
boxes represent integration sites on chromosome XII characterized by Mikkelsen et al [11]. 
 
XII-2 XII-3 XII-5XII-4XII-1
P2T1 T2P1ACAR EntD P2T1 T23DSDP2T1 T2P1UGT72E2 HsOMT
Chr. XII
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Physiological characterization of vanillin glucoside producing strains 
Before evaluating the VG production ability of the two strain backgrounds, we first assessed 
whether VG production affected the overall physiology of the C-VG and S-VG strains. Hence, they 
were grown in batch and as continuous cultures in well-controlled bioreactors under standard 
cultivation conditions. Like for wild-type strains, the overall growth profiles exhibited by the S-VG 
and C-VG strains in batch reactors were composed by two growth phases. One initial growth phase 
where all glucose was fermented; followed, after the diauxic shift, by a second growth phase where 
all accumulated ethanol was respiro-fermented, see Figure 1.3. The main physiological parameters 
derived from these two experiments are summarized in Table 6.4.  
Using identical growth conditions, a specific biomass yields on glucose (Ysx) were found to be slightly 
higher in WT CEN.PK (~0.16 c-mol/c-mol) compared to the WT s288c-(~0.14 c-mol/c-mol) in 
previous studies [3], [6]. The same trend was found to be similar to what we find for C-VG and S-
VG, respectively, in this experiment. Further analysis of the cultivation broth showed that the 
production profiles of five primary metabolites in the central carbon metabolism of S-VG and C-VG 
did not show any abnormalities (see SI Figure S 6.4). It has previously been observed that CEN.PK 
grows faster than S288c at these conditions, μmax ≈ 0.4 h-1 vs. μmax ≈ 0.3 h-1, respectively [3], [6], [9]. 
Importantly, we find that both VG producers displayed decreased and identical growth rates on 
glucose (μmax ≈ 0.2 h-1) compared to the corresponding wild-type strains. Finally, we note that S-VG 
displayed a growth deficiency during the ethanol respiration phase, which for that reason is much 
longer for S-VG (23 h) than for C-VG (12 h). This deficiency has also been reported for wild-type 
S288c [9]. 
In chemostats, steady-state conditions with constant production of biomass as well as stable 
readings of carbon dioxide and oxygen by the off gas analyzer where obtained for both strain 
backgrounds. For the C-VG strain this was achieved in less than 5 residence times (50 hours) after 
feeding was initiated, whereas for the S-VG strain it took more than 8 residence times (80 hours), 
see SI Figure S 6.3. Importantly, at this dilution rate, both strains propagated exclusively by 
respiratory metabolism [30] as no production of ethanol, glycerol and organic acids was observed 
(see Table 6.4) The two strains produced similar amounts of biomass, and like in the batch 
fermentation experiment, the glucose uptake rate was slightly higher (7 %) in S-VG compared to C-
VG. 
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Figure 6.3. Growth profiles of two strains in the batch cultures: A) S-VG and b) C-VG. Grey areas/zones 
represent ethanol respiration (ER) phase; GF stands for glucose fermentation. qCO2 – carbon dioxide 
production rate, qO2 – oxygen consumption rate; Glc – glucose, Eth – ethanol and DW – dry weight. 
 
Table 6.4. Physiologic parameters of the two engineered strains. Ysx – biomass yield on glucose, r – 
specific metabolite production or consumption rates (C-mmol/g(DW)∙h); Glc –glucose, Eth – ethanol 
and Gly – glycerol. NA – not applicable and ND – not detected. The yield coefficient Ysx for biomass is 
calculated based on a molecular weight for biomass of 26.4 g Cmol-1 [31]. 
 Batch Chemostat 
Strain S-VG C-VG S-VG C-VG 
Glucose μ, h-1 0.21 ± 0.01 0.20 ± 0.00 (0.1)* (0.1)* 
Ethanol μ, h-1  0.05 ± 0.01 0.08 ± 0.00 NA NA 
Ysx (C-mol/C-mol) 0.133 ± 0.014 0.151 ± 0.001 0.56 ± 0.02 0.60 ± 0.02 
-rGlc 60.7 ± 8.00 49.9 ± 0.60 6.81 ± 0.29 6.37 ± 0.20 
rEth 25.9 ± 3.10 20.9 ± 3.00 ND ND 
rGly 4.05 ± 0.05 1.40 ± 0.13 ND ND 
* - the dilution rate used in this study. 
 
Metabolic profiles of S-VG and C-VG reveal significant differences in VG production in 
batch cultures 
To compare VG production in the S-VG and C-VG strains, samples were taken at regular time points 
throughout the entire batch cultivation experiment. Remarkably, HPLC analysis of extracellular 
metabolite levels in the cultivation broth revealed obvious differences between the two VG 
producers. At the end of the experiment (t=45 hours), strain S-VG produced almost twice the 
amount of VG (39 mg/gGlc) as compared to C-VG (20 mg/gGlc). As has been previously observed 
A B 
GF ER ER GF 
Time, (h) Time, (h) 
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before, various levels of VG intermediates PAC, PAL, VAC and VAN were also produced at this time 
point due to inherently unbalanced heterologous VG pathway [12], [32]. Notably, despite that the 
two strain produce VG at very different levels the amounts of these intermediates were almost 
identical in the S-VG and C-VG strains (Figure 6.4A).Specifically, the metabolite PAC was the most 
abundant (close to 40 mg/gGlc in both strains), whereas the amounts of other VG pathway 
metabolites PAL, VAC, and VAN, were significantly lower (ranging from 1.6 to 9 mg/gGlc). 
To account for the metabolic flux towards VG pathway in each strain, we have calculated total 
carbon based on the sum of all produced VG metabolites expressed in C-mmol/gDW .It appeared 
that total carbon produced by VG pathway was 35 % higher in S-VG than in C-VG (Figure 6.4B). The 
final conversion to VG was as high as 43% in S-VG compared to only 27% in C-VG of total metabolites 
produced by integrated pathway. 
Heterologous production of VG and its intermediates depends on yeast growth state in 
the batch cultivation 
By monitoring the evolution of the VG pathway metabolites throughout both growth stages – 
glucose fermentation (GF) and ethanol respiration (ER) phase, differences in production profiles of 
two strains were observed (Figure 6.5c and SI Figure S 6.5). During the GF phase C-VG exhibited 
fairly better performance towards VG production which can be seen in Table 6.5. Here, the VG 
specific yield on glucose during exponential growth phase was approx. 37 % higher for C-VG 
compared to S-VG and was in correlation with the specific production rates (0.50 vs. 0.45 C-
mmol/(gDW∙h), respectively). On the contrary, during ER phase the situation had reversed and the 
strain S-VG produced twofold more of VG compared to C-VG strain (Figure 6.5) in correlation with 
increased time for ethanol respiration by S-VG and slightly different volumetric productivities of (41 
vs. 34 mg/(L∙h), respectively. Nevertheless, other VG metabolites were produced in relatively 
similar manner by both strains. Most importantly, however, the total metabolic flux towards the 
VG pathway was lower in C-VG compared to S-VG in either GF or ER growth phases (Figure 6.5). 
Unlike the other VG pathway intermediates, production of the PAC was not associated with any 
cofactors and was dependent on the availability of the precursor 3-DHS (Figure 6.1). In batch 
cultivation we have observed close correlation between PAC and biomass production in both strains 
during both GF and ER growth phases. However, it is clear from the Figure 6.5A and B that strain C-
VG produced significantly less PAC per biomass compared to S-VG.  
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Figure 6.4.  Final yields of VG and its intermediates produced by S-VG and C-VG during batch 
cultivation; A) based on final samples taken 45 hours after inoculation, B) sum of all detected VG 
metabolites normalized to dry-weight.  
 
Table 6.5. Yields - YS Met (mg/g(Glc)) and production rates of VG and its intermediates - rMet (C-
mmol/g(DW)∙h). 
 Batch A Chemostat 
Strain S-VG C-VG S-VG C-VG 
YS PAC 19.0 ± 1.8 15.2 ± 0.2 3.57 ± 0.62 0.26 ± 0.04 
YS PAL 1.9 ± 0.2 2.0 ± 0.2 ND  0.09 ± 0.01 
YS VAC 1.5 ± 0.2 4.3 ± 1.5 0.88 ± 0.18 3.65 ± 0.09 
YS VAN 0.1 ± 0.1 0.2 ± 0.1 0.18 ± 0.14 ND  
YS VG 5.4 ± 0.8 7.4 ± 0.3 13.7 ± 1.4 1.06 ± 0.18 
rPAC 1.59 ± 0.35 1.03 ± 0.03 0.64 ± 0.11 0.044 ± 0.008 
rPAL 0.18 ± 0.04 0.15 ± 0.01 ND  0.016 ± 0.002 
rVAC 0.13 ± 0.03 0.31 ± 0.10 0.16 ± 0.03 0.62 ± 0.03 
rVAN 0.01 ± 0.01 0.01 ± 0.01 0.17 ± 0.12 ND 
rVG 0.45 ± 0.12 0.50 ± 0.02 2.47 ± 0.25 0.18 ± 0.03 
Note: A – for the batch experiments calculations were made only for exponential 
growth phase on glucose. 
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Figure 6.5. Distribution of VG and its intermediates in batch cultivation. Production profiles for biomas 
(DW) and metabolites PAC and VG in strains: A) S-VG and B) C-VG. Panel C) represents distribution of 
VG pathway metabolites  at the end of different growth phases – glucose fermentation (GF) and 
ethanol respiration (ER). D) Average of PAC per DW rations calculated throughout all batch cultivation. 
 
Metabolic profiles of VG producing strains in continuous cultures 
In contrast to batch cultivation, HPLC analysis of the samples taken during continuous cultures 
revealed more prominent changes in the VG metabolic profiles of S-VG and C-VG strains (Figure 
6.6A and Table 6.5). The activity of the VG pathway in the C-VG strain was decreased fourfold 
compared to S-VG, which can be seen from the total amount of carbon obtained by heterologous 
pathway (Figure 6.6B). Intermediates PAL and VAN were produced in trace quantities, the VAC 
accumulated to approx. 4 mg/gGlc in both strains, while biosynthesis of the first intermediate PAC 
was pronounced in S-VG strain. Lastly, more than 10 fold higher VG yields based on glucose were 
observed in S-VG compared to C-VG, which well correlated with VG production rates (2.47 and 0.18 
C-mmol/(gDW∙h), respectively). The fraction of the total carbon converted to VG was much higher in 
S-VG (62%) than in C-VG (17%) during chemostat cultivations. 
GF 
ER 
A B 
C 
ER ER 
D 
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Figure 6.6.  Final yields of VG and its intermediates produced by S-VG and C-VG during continuous 
cultivation; A) average of last three samples with more than one retention time in between, B) sum of 
all detected VG metabolites normalized to dry-weight. 
Measuring intracellular cofactors associated with heterologous pathway enzymes 
Since VG production is associated with several cofactors (Figure 6.1) we set out to measure their 
intracellular concentrations in two producing strains S-VG and C-VG. This was done to check if VG 
production differences might be a result of cofactor limitation. To ensure equivalent conditions for 
both strains, samples were taken during chemostat cultivations (see Materials and Methods). In 
particular, cofactors responsible for key enzymes (ACAR and UGT) in VG biosynthesis were 
considered. As displayed in Table 6.6 concentrations of ATP, NADP and UDP-Glc were very similar 
in two VG producing strains and more importantly comparable to the ones obtained in several other 
studies were strains were cultivated under the same conditions [6], [33]. 
 
Table 6.6. Concentrations of internal metabolites during chemostat cultivations (μmol/ g DW). 
Cofactor concentrations 
 S-VG C-VG 
ATP 8.51 ± 0.50 10.56 ± 1.25 
ADP 0.91 ± 0.06 1.10 ± 0.06 
NADP 0.35  ± 0.01 0.30 ± 0.01 
NADPH <0.02 <0.02 
UDP 0.31 ± 0.02 0.32 ± 0.03 
UDP-Glc 0.50 ± 0.02 0.53 ± 0.02 
UTP 1.70 ± 0.20 1.45 ± 0.23 
 
  
A B 
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Discussion 
The importance of the Saccharomyces cerevisiae in development of novel yeast cell factories is 
evident by the increasing number of research projects focusing on heterologous production of wide 
range industrially relevant substances [1], [34]. In the last decade, yeast strains S288c and CEN.PK 
or their derivatives are most frequently studied and used for cell factory development by the yeast 
community [2], [6]. In this study we demonstrated, however, that heterologous production of VG 
was significantly better in S288c based strain compared to CEN.PK based background. Assuming the 
transcription/translation efficiency in two strains is similar we have assured identical “genomic” 
conditions for integrated VG pathway in both strains by using well defined platform [11]. Therefore, 
based on the results of our study we speculate that the major changes in VG production were 
caused by the genotypic (consequently, phenotypic and/or physiologic) differences of S288c and 
CEN.PK strains [3], [6], [9], [10]. 
The heterologous production of VG in yeast is comprised of multi-enzymatic four step conversion 
with two possible biosynthetic routes (Figure 6.1).The existence of the two biosynthetic routes 
indicates wide substrate specificity of the heterologous enzymes, especially ACAR and HsOMT [12] 
as discussed previously [12]. The metabolic flux through the VG biosynthetic pathway is determined 
by 1) the availability the precursor 3-DHS, an intermediate of shikimate pathway, and 2) the activity 
of the heterologous enzymes and availability of cofactors associated with these enzymes. Since 
there are no cofactors associated with biosynthesis of first intermediate (PAC) [12] it was 
hypothesized that flux towards VG pathway should be dependent on the activity of shikimate 
pathway or, in other words, available pools of 3-DHS. The hypothesis was supported by strong 
correlation between PAC production and biomass yield discovered during batch cultivation in both 
S-VG and C-VG strains (Figure 6.5D). Moreover, the same correlation was previously detected by 
Brochado et al. [32] in the original VG producing (S288c based) strain. 
In this experiment the comparison of S-VG and C-VG was troubled by the accumulation of 
intermediates of the VG pathway. The latter is a result of a non-optimally functioning heterologous 
enzyme in yeast cells. Despite the recent pathway optimization efforts [35], accumulation of 
intermediate metabolites remained unsolved. We speculate that unbalanced conversion to VG was 
mainly caused by low activities of heterologous enzymes and not by limitation of associated 
cofactors. In fact, intracellular concentrations of main cofactors such as ATP, NADPH and UDP-Glc 
(Table 6.6) were found to be similar in both S-VG and C-VG strains and moreover comparable to 
wild-type S288c and CEN.PK [6], [33]. Since the intermediate accumulation profiles were slightly 
different in two strains we therefore calculated the total metabolic flux through VG pathway for 
comparison purposes. 
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In batch, the total carbon produced by the heterologous pathway differed by 35% between the two 
strains, however, most of that difference was caused by a nearly twofold higher amount of VG 
produced by the S-VG compared to C-VG. The clear advantage of VG production in S-VG appeared 
only after the strain switched to the ER growth phase. It is evident from Figure 6.5 that S-VG 
accumulated more of VG due to its nearly twice prolonged ethanol growth phase. The particular 
phenotype of S-VG is a result of the inherent deficiency in respiro-fermentative metabolism of 
ethanol found in the wild-type S288c strain [9]. Unfortunately, the reasons for impaired growth on 
ethanol in S288c when compared to CEN.PK could not be explained by neither transcriptional 
profiling nor genome sequencing efforts [9], [10]. The last enzymatic step in biosynthesis of VG (the 
UGT72E2 enzyme) itself is highly unlikely to play a significant role for the VG production difference 
between engineered strains. In this step vanillin is glycosylated by the UGT72E2 glycosyltransferase 
enzyme which uses UDP-Glucose as a donor for glycosylation [12]. Assuming that UGT was 
expressed identically in two strains there were no indications that its activity was restricted by the 
lower availability of UDP-Glc in C-VG strain as the  volumetric productivity rates of VG in both strains 
were similar. In addition, in the previous (Chapter 5) it was shown that overexpression of UGT 
increased VG production in CEN.PK based strain.  
As mentioned before, the role of alcoholic fermentation in VG biosynthesis in S-VG and C-VG strains 
is vague, however, the fact of plausibly different shikimate pathway activity in two strains cannot 
be ignored. In the batch cultivation experiments, metabolic flux through the VG pathway was found 
to be lower in the C-VG strain during both GF and ER growth phases (Figure 6.5). To investigate 
physiology in the absence of ethanol production, we have characterized S-VG and C-VG strains in 
chemostats with a standard cultivation conditions [6]. As we can see in Figure 6.6B metabolic flux 
through the VG pathway is 4-fold higher in S-VG compared to C-VG, and VG production more than 
10-fold different Figure 6.6A and Table 6.5). Here we speculate that VG production is most likely 
restricted by decreased flux through the native shikimate pathway of C-VG and, therefore, less 
available 3-DHS pools. Recalling the correlation of PAC and biomass production observed in the 
batch experiment, the latter assumption is also supported by nearly absent accumulation of its 
direct metabolite PAC in chemostat cultures. Moreover, in a study by Canelas [6], the intracellular 
concentration of shikimic acid (the direct metabolite of 3-DHS) was found to be significantly higher 
in the YSBN (S288c based) strain under similar cultivation conditions in batch and chemostat 
cultivations. The shikimate pathway is a part of aromatic amino acid biosynthesis and is well 
characterized in yeast [36]–[38], furthermore, it is tightly regulated via two 3-deoxy-D-
arabinoheptulosonate 7-phosphate (DAHP) synthase isoenzymes ARO3 and ARO4, which are 
feedback inhibited by phenylalanine and tyrosine, respectively Figure 6.1. Canelas and co-workers 
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have reported that under batch conditions CEN.PK113-7D is able to maintain higher intracellular 
amino-acid pools [6], which was suggested and later explained as a result of increased protein 
turnover rate [39]. However, here we speculate that higher concentrations of intracellular aromatic 
amino acids in C-VG might inhibit ARO3 and ARO4 and lead to decreased flux towards 3-DHS and 
consequently lower the capacity for VG production. Despite the fact that shikimate pathway is well 
understood in S. cerevisiae, there are no reported studies where this pathway is compared in two 
strains S288c and CEN.PK, and the exact cause of difference in shikimate pathway is not known. 
However, genome sequencing of CEN.PK113-7D revealed (considering only metabolic genes) 219 
SNPs where 85 of those resulted in non-synonymous amino acid substitution [9]. The mutations 
were also found in genes encoding for proteins involved in amino acid and aromatic compound 
metabolism. Here, we have compared ORFs sequences of several ARO genes in strains S288c and 
CEN.PK (Table 6.7). For example, the gene of pentafunctional enzyme ARO1 (which is directly 
involved in synthesis of 3-DHS) is enriched with 15 SNPs, seven of those results in non-synonymous 
amino acid substitutions. In addition to that, the gene of the regulatory protein ARO3 was found to 
contain 23 SNPs, where three of those caused amino acid substitutions. However, phenotypic or 
metabolic repercussions of these mutations are unidentified, and need to be further characterized 
by targeted mutagenesis in one of the producing strains. 
Table 6.7. Point mutations of ARO genes found in CEN.PK113-7D compared to S228c. Mutations 
represented by one letter code for amino acid and number denoting the position in the protein. 
Genes 
SNPs 
Amino acid substitution 
Total Non-synonymous 
ARO1 15 7 
T225I, P337S, S517P, N844T,  
M1141K, V1386I, G1576A 
ARO3 23 3 K141R, E214D, S349T 
ARO4 — — — 
ARO7 — — — 
 
Yet another way to test the role of shikimate pathway in VG production is by alleviating feedback 
inhibition of key regulatory points of shikimate pathway in C-VG strain. This can be done by 
expressing inhibition insensitive ARO3 and ARO4 [38]. The improved VG production in C-VG with 
deregulated shikimate pathway would serve as strong evidence supporting the hypothesis of 
different aromatic amino acid metabolism in S288c and CEN.PK strains. One needs to add that 
production differences between strain backgrounds 288c and CEN.PK might be also true for other 
heterologous compounds which are using aromatic amino acids or intermediates of shikimate 
biosynthetic pathway as their precursors, for example indolylglucosinolates [11], flavonoid 
precursor - naringen [40] and other aromatics [41], [42].  
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The genotypic/phenotypic differences between two commonly used yeast strains [5], [6], [9], [10] 
may also be reflected in the production of other non-aromatic related heterologous compounds; 
e.g., antimalarial drug artemisinin precursors – artemisinic acid [43] or amorphadiene [44] are 
derived from ergosterol biosynthetic pathway which was found to be different in strains S288c and 
CEN.PK [9]. Particular differences in ergosterol pathway also led to rational target selection for 
metabolic engineering towards triterpene production in yeast [45]. 
Conclusions 
In conclusion, we have demonstrated that the genetic background of two commonly used yeast 
strains had a significant impact on heterologous production of VG. The S-VG strain (s288c based) 
accumulated double the amount of VG in batch and more than 10 fold in chemostat cultures 
compared to the C-VG (CEN.PK based). The difference in VG production was defined by two major 
factors; first, in batch cultures, the production advantage in S-VG was an indirect result of inherent 
physiology of S288c (prolonged ethanol respiration phase), second, in batch and chemostat cultures 
VG production in the CEN.PK based strain was most probably limited due to reduced flux through 
yeast native shikimate pathway, which was also evident by significantly reduced accumulation of 
the first heterologous intermediate PAC.  To this end, the comparison study for heterologous 
production of VG, an aromatic compound class metabolite, presented here might serve as useful 
information for correct yeast strain choice for future yeast based cell factory design. This study also 
indicated the importance of high quality systems biology datasets available for commonly used 
yeast strains which can be used in strain selection for building a cell factory. 
Future perspectives 
Several follow up studies for the particular project should be done. First, the role of shikimate 
pathway in different VG production in two strains should be tested by introducing point mutations 
in ARO3/4 which would alleviate feedback inhibition by tryptophan and phenylalanine [38]. By 
implementing aforementioned modifications in CEN.PK based strain we could easily check if 
increased flux through shikimate pathway in S-VG strain would result in higher production of VG. 
Secondly, more global approach can be implemented. Regardless of the fact that VG producing 
capacity was shown to be significantly better in S288c based strain, the CEN.PK series strains exhibit 
better physiological characteristic [3] and is more preferable strain for industrial applications. The 
VG production and physiological properties are defined by s288c and CEN.PK strain genetic 
backgrounds. One can speculate that combining these properties of two strains in one could result 
in super producing strain with advantageous physiological properties of CEN.PK. Unfortunately, 
exact gene sets responsible for particular behavior of both strains toward VG production are not 
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yet identified. This can be tested by creating hybrid strains, i.e., crossing S-VG and C-VG strains and 
screening a vast number of spores, which would contain a random set of genes from both strains, 
while the VG biosynthetic pathway would remain intact as it was engineered in an identical manner. 
If improved traits were discovered, the genomes of these mutants should be sequenced and 
analyzed. Obtained genetic set could explain not only the improved properties for the heterologous 
VG production, but give hints and clues for designing better yeasts with improved characteristics 
for cell factory development for production of other chemicals. 
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Table S 6.1. List of verification primer pairs used for validation of gene targeting events. Appearance 
of the correct size band on the gel verifies targeted integration of your favorite fragment (XII-1, XII-2 
and XII-5). In case of deletions, band size confirms your favorite gene deletion. *In case of ADH6 the 
band size also includes KanMX cassette. 
Site Name Sequence 
Fragment 
size, bp 
XII-1 XII-1-up-out-sq  CTGGCAAGAGAACCACCAAT 729 
XII-2 XII-2-up-out-sq  CGAAGAAGGCCTGCAATTC 739 
XII-5 XII-5-up-out-sq  CCACCGAAGTTGATTTGCTT 688 
— C1_TADH1_F CTTGAGTAACTCTTTCCTGTAGGTC  
For  Deletion  Verification   
BGL1 BGL1_VF TCATCCTCCCTGTGTTTACA 1044 
 BGL1_VR AGTTGAAACAGAGGATAAGGTG  
ADH6* ADH6_VF GTTTTGCTTTTTTCTCTGGG 2773 
 ADH6_VR GGAGTATCAACCACTAAAGCG  
 
Table S 6.2. The list of the additional primers used for sequencing purposes. 
Name Sequence 
S1_TEF_F CGGTCTTCAATTTCTCAAGTTTC 
S1_PGK_F CAAGGGGGTGGTTTAGTTTAGT 
S1_ACAR_F CATTGTTCGTTCCAGACACTGAC 
S2_ACAR_F GAAATTGTCTCAAGGTGAGTTCG 
S3_ACAR_F TTTGGGTAGATTCTTGTGTTTGG 
YF19 AAAAAATAAATAGGGACCTAGACTTCA 
YF21 GACCTACAGGAAAGAGTTACTCAAGAAT 
 
 
Table S 6.3. List of the open reading frames (ORF) surrounding the integration sites used for VG 
pathway transfer. 
Site ORF Function (from SGD[46]) 
XII-1 
(upstream) 
RPS25B Protein component of the small (40S) ribosomal subunit; homologous to 
mammalian ribosomal protein S25, no bacterial homolog; RPS25B has a 
paralog, RPS25A, that arose from the whole genome duplication 
XII-1 
(downstream) 
YLR334C Dubious open reading frame unlikely to encode a protein, based on available 
experimental and comparative sequence data; overlaps a stand-alone long 
terminal repeat sequence whose presence indicates a retrotransposition 
event occurred here 
XII-2 
(upstream) 
SPO77 Meiosis-specific protein of unknown function, required for spore wall 
formation during sporulation; dispensable for both nuclear divisions during 
meiosis 
XII-2 
(downstream) 
FKS1 Catalytic subunit of 1,3-beta-D-glucan synthase; functionally redundant with 
alternate catalytic subunit Gsc2p; binds to regulatory subunit Rho1p; involved 
in cell wall synthesis and maintenance; localizes to sites of cell wall 
remodeling; FKS1 has a paralog, GSC2, that arose from the whole genome 
duplication 
XII-5 
(upstream) 
ILV5 Bifunctional acetohydroxyacid reductoisomerase and mtDNA binding protein; 
involved in branched-chain amino acid biosynthesis and maintenance of wild-
type mitochondrial DNA; found in mitochondrial nucleoids 
XII- 5 
(downstream) 
ATG33 Mitochondrial mitophagy-specific protein; required primarily for mitophagy 
induced at post-log phase; not required for other types of selective 
autophagy or macroautophagy; conserved within fungi, but not in higher 
eukaryotes; ATG33 has a paralog, SCM4, that arose from the whole genome 
duplication 
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Figure S 6.1. Schematic representation of cloning procedure for transferring vanillin-β-glucoside 
pathway genes. Targeting vectors pXII1, pXII2 and pXII5 are linearized with AsiSI and Nb.BsmI enzymes. 
Yellow boxes UP and DW are targeting sequences homologous to chromosomal integration sites. T1 
and T2 are terminator sequences Tadh1 and Tcyc1, respectively. Black arrow is counter-selectable 
auxotrophic marker URA3.   White, grey and black boxes represent USER cloning compatible tails.  
 
 
Figure S 6.2 Flowchart representing reconstruction of Vanillin-β-glucoside producing strains. De novo 
biosynthetic pathway was reconstructed in two strains by sequential transformation with 
appropriate DNA fragments depicted in the center of the figure. Native genes were deleted with 
loxP-KanMX-loxP cassette. Prototrophy was restored by genetic cross. 
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Figure S 6.3 Time profiles of online fermentation data of two strains A) S-VG and B) C-VG in chemostat 
cultivation mode. Orange line – volumetric rates of CO2 production; red line – volumetric rates of 
oxygen consumption. Grey vertical lines represent the sampling points and the start of the chemostat 
phase. One residence time is equal to 10 hours. 
 
 
Figure S 6.4 Primary metabolite profiles in strains S-VG (a) and C-VG (b) during batch cultivation. 
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Figure S 6.5 VG metabolite profiles in strains S-VG (A) and C-VG (B) during batch cultivation. 
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Chapter 7 
7. Conclusions and future perspectives 
 
The work presented in my thesis dealt with the development and validation of genetic engineering 
tools that can be useful for yeast cell factory construction and metabolic engineering purposes. Two 
platforms have been successfully developed in this work: i) integrative vector set for rapid assembly 
and integration of large DNA fragments into the yeast S. cerevisiae, and ii) gene amplification 
system for controlled and stable gene overexpression. The latter system was further successfully 
applied for a real problem i.e., titration of unbalance metabolic pathway for vanillin-β-glucoside 
production. Moreover, an important point in yeast cell factory development, i.e., S. cerevisiae strain 
choice for the production of a given product (vanillin-β-glucoside), was addressed. In respect to 
this, it was demonstrated that two commonly used laboratory strains S288c and CEN.PK produced 
significantly different yields of vanillin-β-glucoside. Main conclusions and future perspective for 
each research project were outlined at the end of corresponding chapters (Chapters 4 to 6).This 
chapter provides with overall conclusions and general perspectives of the thesis. 
 
Developed methods described in Chapter 3 and Chapter 4 were validated and proven to be efficient 
by expressing/overexpressing genes encoding for different fluorescent proteins. The EasyClone 
platform (Chapter 3) is an upgraded version of the integrative vector set previously developed at 
our center. It consists of 11 integrative vectors that allow integration of total of 22 genes of interest. 
Moreover, due to built-in safety system, it is possible to introduce repetitive DNA elements (the 
same promoter or gene can be used many times). The most appealing property of the EasyClone 
method is the short time required for gene assembly and integration. It was demonstrated that it 
is possible to introduce up to three integration cassettes (i.e., six genes) into S. cerevisiae genome 
in one transformation step. In this respect, the integration platform will be very useful for the 
construction of cell factories expressing large biosynthetic pathways in a high throughput manner. 
For example vanillin-β-glucoside pathway that consist of five genes could be integrated in one 
transformation step, in contrast, it took three rounds of transformation when using the first 
generation gene integration platform (Chapter 2). 
The gene amplification method (Chapter 4) developed in this work was shown to be capable to 
amplify gene/s of interest up to ten copies. More importantly, it was demonstrated that strains 
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with overexpressed genes of interest were able to sustain stable expression levels in long term 
cultivations, which is a desired property for industrial applications. The fact gene amplification 
system allows overexpression of gene/s to a precise copy number and defined genomic location, 
makes the particular system very attractive for metabolic engineering applications. This was 
successfully demonstrated in Chapter 5, where gene amplification was used for balancing the 
heterologous production of vanillin-β-glucoside. The gene amplification system was designed to be 
expandable, by using specially designed targeting vectors the number of simultaneously amplified 
genes can be expanded from two to eight. In this case, an entire metabolic pathway can be 
overexpressed up to ten copies. Finally, the collection of gene amplification strains exist in various 
genetic markers and mating type combinations, which enables further manipulations via sexual 
cross (e.g., construction of diploid cells that was widely applied in vanillin-β-glucoside pathway 
titration experiments). 
To this end, EasyClone and gene amplification system were designed to be compatible with high-
throughput USER cloning method. Particular cloning method provides flexibility and enables 
combinatorial approaches when constructing expression cassettes. Therefore, genetic engineering 
tools developed in this work can be successfully applied for systemic biological studies to 
understanding production related processes of S. cerevisiae. 
 
Future perspectives 
The tool development for yeast genetic engineering is constantly evolving process. On the other 
hand, more attention has to be addressed to the genetic differences of the available S. cerevisiae 
strains. For example, genetic tools developed in my PhD project are based on CEN.PK background 
strain, which is mostly used for metabolic engineering studies mainly due to its industrially relevant 
phenotypic properties. However, the comparison study (Chapter 6) has indicated that S288c strain 
background is producing significantly higher yields of vanillin-β-glucoside than CEN.PK. This implies 
that the gene amplification system is not optimal for production of vanillin-β-glucoside and, most 
likely, other aromatic molecules. However, it might be opposite for the metabolites that are derived 
from other than shikimate pathway precursors. Moreover, these properties might be possible to 
predict from the available systems biology data sets for S288c and CEN.PK wild type strains. 
Instead of using “pure” strain backgrounds, hybrid S. cerevisiae strains might be implemented. For 
example, to improve the gene amplification system, selected gene amplification strain (CEN.PK) can 
be crossed to a wild-type S288c strain. Subsequently, a vast number of spores would be screened 
to identify hybrid strain exhibiting desired properties, e.g., fast growth rate, high metabolic fluxes 
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through required pathways (e.g., shikimate pathway) and existence of gene amplification cassettes. 
If a haploid with desired traits would be obtained, the full genome sequencing could give hints and 
clues for development of "next generation" cell factories for the production of complex high-value 
natural and unnatural chemicals. 
 
